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20-hydroxyeicosatetraenoic acid (20-HETE) is a vasoconstrictive metabolite of 
arachidonic acid by cytochrome P450 (CYP) 4A11 and 4F2 in humans. Inhibition of 20-HETE 
formation produces neuroprotective effects in cardiac arrest and stroke preclinical models. Clinical 
evidence shows that high CSF 20-HETE level is associated with three-fold increased mortality and 
unfavorable outcomes in subarachnoid hemorrhage patients. These findings suggest that 20-HETE 
synthase inhibition is a potential therapeutic strategy for neuroprotection after brain injury. 
HET0016, a 20-HETE inhibitor, did not enter clinical development due to poor solubility and short 
half-life. Currently, a clinically relevant 20-HETE inhibitor is not available to be evaluated as a 
therapeutic intervention.  
The primary goal of this dissertation is to develop novel 20-HETE formation inhibitors that 
have strong potency and favorable physicochemical, metabolic stability, selectivity, solubility, 
CYP inhibition, and blood-brain barrier (BBB) permeability. We developed analytical methods to 
facilitate metabolic stability, CYP inhibition evaluation, and quantify the novel compound in a 
pharmacokinetic study. After iterations of screening and in vitro evaluation for 143 novel 
compounds, UPMP107 was identified as a preclinical candidate that had strong potency and 
advantage of highly metabolically stable, wide selectivity window, and good brain penetration in 
vitro. Intravenous administration of 107 to postnatal day 17 rats showed that it could penetrate 
 v 
BBB and reduce brain 20-HETE levels. The 20-HETE inhibitory effect was maintained up to 9 
hrs after IV administration at 20 mg/kg. UPMP107 exhibited a biphasic plasma concentration-
time profile after IV administration. It has a low clearance, an intermediate volume of distribution, 
and a relatively short half-life. 
The secondary goal was to optimize marketed CNS therapy, propofol, to improve the 
neurological outcome. The pharmacokinetics of propofol in an ICU population was described 
using a population pharmacokinetic model. A two-compartment, zero-order infusion, first-order 
elimination model best described the profile. This model could be used to explore the relationship 
between propofol exposure and sedative response to optimize the therapy in the ICU population. 
Collectively, the work identified a novel compound that inhibits 20-HETE formation and 
can be used in proof of concept animal studies. Propofol pharmacokinetics was characterized in 
the ICU population, and the model could potentially be used to explore an exposure-response 
relationship in the future. 
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1.0 Introduction  
Cardiac arrest and stroke continue to be major public health issues. Out-of-hospital cardiac 
arrest (OHCA) has an estimated incidence of 356,361 in adults and 7,037 in children (Virani et al. 
2020). The survival to hospital discharge was about 10%. The prevalence of stroke is around 3% 
of the adult population. More than 795,000 people in the United States have a stroke every year, 
and someone dies of a stroke every 4 minutes (Virani et al. 2020). Patients who survived the initial 
insults often suffer from secondary brain injury, which has complex and multifaceted 
pathogenesis. Disturbance of cerebral blood flow and unbalance in vasoconstrictors and 
vasodilators are observed after cardiac arrest and stroke. Several CYP4 enzymes synthesize 20-
hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs) that produce a 
constrictive and dilative effect in regulating cerebral vascular tone. Therefore, modulation of 
CYP4 enzymes is a potential strategy for restoring the balance between constrictive and dilatory 
mediators to improve cerebral blood flow after cerebrovascular injuries. We hypothesize that 20-
HETE synthase inhibitors may reduce brain injury by improving cerebral blood flow and 
attenuating ischemic brain damage. 
The primary objective of the thesis was to develop novel 20-HETE synthase inhibitors. To 
date, no 20-HETE formation inhibitor enters clinical development. Therefore, developing novel 
20-HETE formation inhibitors to enable them to be tested in the clinic is needed. This chapter first 
introduces the pathways of arachidonic acid metabolism with an emphasis on the 20-HETE 
formation pathway. Next, this chapter includes the biological roles of 20-HETE and rationales of 
targeting 20-HETE synthase enzymes as potential new treatments in cardiac arrest and stroke. 
Lastly, the discovery of currently available 20-HETE synthase inhibitors is summarized.   
 2 
1.1 Overview of CYP4 enzymes 
The history of discovering omega-hydroxylases dates back to the early 1930s. Omega-
oxidation was first reported by Verkade et al. when saturated fatty acids or certain C8-C11 
derivatives were fed to dogs or humans, dicarboxylic acids were excreted (Verkade P.E. 1933, 
Robbins 1968). In the early 1960s, ω -hydroxylation was observed in vitro by two separate groups 
of researchers. Wakabayashi and Shimazono showed that sorbic acid amide was oxidized to 
muconic acid amide in guinea pig liver microsomes and supernatant fraction (Wakabayashi et al. 
1961). Robbins demonstrated that incubation of mid-chain monocarboxylic acids in hog, dog, rat 
liver, and dog kidney with cofactors formed corresponding dicarboxylic acids (Robbins 1968). 
Later, Preiss and Bloch added evidence in the field where rat liver microsomes catalyzed ω-1 and 
ω-2 hydroxylation of fatty acids (Preiss et al. 1964). These initial seminal studies were the first to 
report the hydroxylation of fatty acid at the terminal and subterminal position, which led to an 
expansion of the research in this field as data emerged that the oxidation reaction led to bioactive 
eicosanoids.  
One of the pathways for the bioactivation of fatty acids is through the terminal oxidation 
of hydrophobic fatty acid aliphatic chain. Omega-hydroxylation is the reaction where a hydroxy 
group is added to the terminal carbon of a hydrophobic fatty acid aliphatic chain (Baba et al. 1963, 
Hamberg et al. 1971). This reaction is carried out by cytochrome P450 enzymes, specifically the 
CYP4 family (Fer et al. 2008). Although compared to CYP1, 2, 3 families, the CYP4 family 
metabolize xenobiotics to a lesser extent, it is involved in the metabolism of endogenous fatty 
acids, eicosanoids, nutrients, xenobiotics, and carcinogens (Baer et al. 2006, Edson et al. 2013, 
Eun et al. 2018). In the latest human liver CYP450 “pie” updated by S.Michaels and M. Z. Wang, 
CYP4F subfamily accounts for 15% of the total hepatic enzymes (Michaels et al. 2014). The 
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estimated total amount of CYP4F protein in the human liver ranged from 18 to 128 pmol/mg liver 
microsomal protein comparing to 64 pmol/mg liver microsomal protein of CYP3A4. The large 
amount of CYP4F protein levels highlight the important emerging role of these enzymes in 
endogenous and xenobiotics metabolism (Jin et al. 2011, Kawakami et al. 2011). 
CYP4 subfamilies, including CYP4A, CYP4B, CYP4F, CYP4V, CYP4X, CYP4Z, have 
been identified in humans (Kalsotra et al. 2006, Hsu et al. 2007, Hardwick 2008). Among the six 
subfamilies, CYP4A, 4B, and 4F subfamilies exhibit ω-hydroxylation activity (Hardwick 2008). 
In humans, CYP4F subfamily includes seven isoforms CYP4F2, CYP4F3A, CYP4F3B, CYP4F8, 
CYP4F11, CYP4F12, and CYP4F22 (Jarrar et al. 2019). In rats, CYP4F subfamily has four 
isoforms, including CYP4F1, 4, 5, and 6 (Xu et al. 2004). Human CYP4A isoforms include 
CYP4A11 and CYP4A22 (Drolet et al. 2017). The known rat CYP4A isoforms are CYP4A1, 4A2, 
4A3, and 4A8 (Xu et al. 2005).  
Long-chain fatty acids are essential components of cell membranes. Fatty acids such as 
dodecanoic (lauric) acid (C12:0), tetradecanoic acid (C14:0), hexadecenoic acid (C16:0), 
arachidonic acid (C20:4), eicosapentaenoic acid (EPA) (C20:5), and docosahexaenoic acid (DHA) 
(C22:6) are known CYP4 substrates (Hoch et al. 2000, Arnold et al. 2010, Honda Malca et al. 
2012, Scheps et al. 2013). In general, CYP4A metabolizes medium-chain fatty acids (C10 – C16) 
such as lauric acid, and CYP4F metabolizes long-chain fatty acids (C16 – C26) such as arachidonic 
acid. Arachidonic acid is recognized as an essential component of neuronal cell membrane due to 
its role in supporting membrane fluidity and modulating ion channels, receptors, and enzymes. 
Additionally, CYP-mediated arachidonic acid metabolites play an important role in various 
neurological disorders such as stroke and post-cardiac arrest brain injury. The following sections 
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will focus on the CYP-mediated arachidonic acid metabolism and the biological actions of the 
metabolites. 
1.2 Metabolism of arachidonic acid by CYP450  
Arachidonic acid is a polyunsaturated ω-6 fatty acid that can be metabolized by 
cyclooxygenase (COX), lipoxygenase (LOX), and CYP450 enzymes (Fig 1.1). The COX and LOX 
products include prostaglandins, prostacyclin, thromboxanes, and leukotrienes. These eicosanoids 
possess various biological functions such as vasoconstriction, vasodilation, and inflammatory 
responses (Moncada et al. 1979, Ricciotti et al. 2011). A third metabolism pathway was discovered 
in the early 1980s where arachidonic acid can also be metabolized by CYP450 enzymes into 
epoxyeicosatrienoic acids (EETs) and dihydroxyeicosatetraenoic acids (DiHETs) (Capdevila et al. 
1981, Oliw et al. 1981). For metabolizing arachidonic acid, CYP2C19 possesses the highest 
catalytic activity of 32 pmol/pmol of P450/min, followed by CYP1A1, CYP4F3B, CYP4A11, and 
CYP4F2 (El-Sherbeni et al. 2016).  The major metabolites mediated by CYP2C19 pathway mainly 
included 19-HETE, 8,9-EET, and 14,15-EET. CYP1A1 also mainly mediates 19-HETE formation. 
CYP4F3B, 4A11, and 4F2 mainly produce 20-HETE (El-Sherbeni et al. 2016).  
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Figure 1.1 Arachidonic acid metabolism pathways 
The stimulation of cytosolic phospholipid A2 (cPLA2) leads to arachidonic acid release from the 
membrane. Arachidonic acid can be metabolized into prostaglandins (PGG2, PGH2 PGE2, PGF2α), 
prostacyclin (PGI2), and thromboxanes (TXA2 and TXB2) by lipoxygenase (LOX) and 
cyclooxygenase (COX). CYP450-mediated hydroxylation happens at the terminal and subterminal 
positions yield 16-, 17-, 18-, 19-, and 20-HETE. CYP450-mediated oxidation produces four 
regioisomers of cis-epoxyeicosatrienoic acid (EET): 5,6-, 8,9-, 11,12-, and 14,15-EET. They can 
be metabolized by soluble epoxide hydrolase (sEH) to DiHETs.    
 
1.2.1 ω-hydroxylases and 20-HETE formation 
CYP4 family plays a vital role in the ω-hydroxylation of arachidonic acid. 20-HETE is a 
vasoactive eicosanoid that elicits the vasoconstrictive effect in cerebral vasculatures (Poloyac et 
al. 2006). It is the hydroxylated product of arachidonic acid at the omega position (Lasker et al. 
2000). CYP4A and CYP4F subfamilies are well-studied enzymes responsible for 20-HETE 
formation in rat and human species (Powell et al. 1998, Nguyen et al. 1999, Lasker et al. 2000).  
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The isozymes that are responsible for the majority of 20-HETE formation have long been 
a topic of debate. The enzymes that underlie 20-HETE formation rely on the protein level and 
catalytic activity. A summary of different CYP450 enzymes that are involved in 20-HETE 
formation is presented in Table 1.1. In humans, CYP4A11, CYP4F2, CYP4F3B, and CYP4F11 
show catalytic activity to transform arachidonic acid into 20-HETE. These enzymes are mainly 
expressed in the liver, kidney, and small intestine (The Human Protein Atlas). A non-CYP4 
enzyme, CYP2U1, that also catalyzes ω-hydroxylation of arachidonic acid, was found in the 
thymus and cerebellum (Chuang et al. 2004). CYP4F2, 4F3B, and 4F11 share 74% amino acid 
sequence homology. And the only difference between CYP4F3A and CYP4F3B was the amino 
acid at residues 67 – 114 (Hirani et al. 2008). The high homology between these isoforms makes 
it challenging to quantify the amount of each enzyme with antibodies. Immunoquantitation of 
CYP4F2 using anti-CYP4F2 IgG revealed high variability of CYP4F2 expression in the liver and 
kidney with an average amount of 16.4 ± 18.6 and 3.9 ± 3.8 pmol/mg microsomal protein, 
respectively (Hirani et al. 2008). To the best of our knowledge, the protein levels of CYP4F3B and 
CYP4F11 are still unknown. 
The contributing enzymes for 20-HETE formation in human species were first reported in 
1999 by Powell’s group. By applying antibodies of CYP4F2 and CYP4A11, the 20-HETE 
formation was inhibited by 93.4 ± 6% and 13.0 ± 9% in human liver microsomes, respectively 
(Powell et al. 1998). Enzyme kinetics was also reported in the same study. The apparent Km of 
CYP4F2 for arachidonic acid (AA) is 24 µM, which is nearly 10-fold lower than that of CYP4A11 
of 228 µM (Powell et al. 1998). This suggested that CYP4F2 has a high affinity for arachidonic 
acid and requires a lower concentration of arachidonic acid to achieve maximum hydroxylation 
reaction. The predominant role of CYP4F2 was also found in the kidney. Antibodies of CYP4F2 
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and CYP4F11 inhibited by 20-HETE formation by 65.9 ± 17% and 32.5 ± 14%, respectively 
(Lasker et al. 2000). The limitation in these studies is that the antibodies could not distinguish 
CYP4F2 from CYP4F3B, which shares high sequence identity with CYP4F2. CYP4F3B isoform 
also shows a high affinity to arachidonic acid. It has a Km value of 22 µM in the recombinant 
CYP4F3 microsomes (Christmas et al. 2001). Later, Mayde Fer et al. compared the catalytic 
activity of purified CYP4A11, CYP4F2, CYP4F3A, and CYP4F3B in hydroxylating arachidonic 
acid. CYP4F3B exhibited the highest hydroxylation rate, followed by CYP4F3A, CYP4F2, and 
CYP4A11 (Fer et al. 2008). One thing worth noting in this study is that 20-carboxy arachidonic 
acid (20-COOH-AA), a metabolite of 20-HETE, was measured. Therefore, the hydroxylation rate 
should not be generalized to compare the activity in forming 20-HETE. In a recent study of 
identifying selective CYP4 inhibitors, 1,2,3,4,5-13C AA was incubated in human kidney 
microsomes, CYP4A11, CYP4F2, and CYP4FB recombinant enzymes. The intrinsic clearance 
values for 1,2,3,4,5-13C AA were 9.5, 0.02, 0.9 and 10.1 µL/min/pmol, respectively. Together, 
these results, in conjunction with the protein abundance, suggesting that CYP4F2 is more efficient 
in hydroxylating arachidonic acid because of the lower Km (24 µM) value, higher maximum 20-
HETE formation rate, and greater reduction in 20-HETE formation in the immunoinhibition study 
in human liver microsomes. The quantification of enzyme abundance with specific antibodies will 
provide additional insight into the enzymatic pathways in 20-HETE biosynthesis. 
In rats, CYP4A1, 4A2, 4A3, 4F1, and 4F4 can generate 20-HETE. CYP4A1, 4A2, 4A3, 
and 4A8 share 66-98% homology (Uniprot). CYP4A1 is mainly expressed in the liver. The four 
CYP4A isoforms were also expressed in the kidney, but there was a sex-dependent expression 
difference. The mRNA expression level was similar for CYP4A1, 4A3, and 4A8 in females, 
whereas CYP4A2 mRNA was four-fold greater in the kidney of males compared to females 
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(Sundseth et al. 1992). A recent study localized the expression of CYP4A enzymes in hippocampal 
and hypothalamic neurons, pial and penetrating arterioles in the brain (Gonzalez-Fernandez et al. 
2019). CYP4F1 and CYP4F2 were found to express in the kidney and liver in a sex-dependent 
manner in contrast to CYP4A, where the protein expression was higher in females compared to 
males (Kalsotra et al. 2002). The protein levels studied in a western blot analysis showed that 
CYP4A and CYP4F subfamilies had similar protein expression in the liver (El-Sherbeni et al. 
2013). The quantification of the absolute abundance of the isoforms will require specific antibodies. 
In baculovirus-Sf9-expressed CYP4A isoforms, the Km for arachidonic acid was 10 µM, 
19 µM, and 41 µM for CYP4A1, 4A2, and 4A3. The intrinsic clearance was 947, 72, and 22 
nM/min, respectively (Nguyen et al. 1999). This evidence in the purified system suggested that 
CYP4A1 was more 10-times more efficient in generating 20-HETE compared to CYP4A2 and 
4A3. CYP4A2 and 4A3 also act as epoxygenases in forming 11,12-EET. Among the CYP4F 
subfamilies, CYP4F1 and CYP4F2 were the major catalysts of 20-HETE formation. Although 
CYP4F4 has higher hydroxylase activity, the relatively low expression compared to CYP4F1 in 
the kidney precludes its major role in 20-HETE synthesis (Xu et al. 2004).  In an immunoinhibition 
study, anti-CYP4A1/2/3 antibody inhibited arachidonic acid hydroxylation by 71.5% in the liver, 
suggesting the primary role of CYP4A1/2 in 20-HETE formation in the liver.
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Table 1.1 Summary of CYP isoforms that catalyze 20-HETE formation 
Species Isoform Tissues Km (µM) 
Vmax  
(nmol/pmol of P450/min) 
reference 
Rat CYP4A1 K, L, B 10 6.3a  (Nguyen et al. 1999) 
Rat CYP4A2 K, L, B, V 19 1.1 a  
Rat CYP4A3 K, L, B, V 0.92 0.7 a  
Rat CYP4F1 K, L, LG - 9 a (Xu et al. 2004) 
Rat CYP4F4 K, L, LG - 11 a  
Human  CYP4A11 L, K  228 15.6  
Human  
CYP4F2 
CYP4F2 wild type 
CYP4F2 V433M 







(Powell et al. 1998) 
(Yi et al. 2017) 
 
Human  CYP4F3B L, K 22 0.0133 (Christmas et al. 2001) 
Human  
CYP4F11 wild type  
CYP4F11 C276R 
CYP4F11 D315N 
CYP4F11 D374Y  
CYP4F11 D446N 











(Yi et al. 2017) 
Human  CYP2U1 B 2.7 - (Chuang et al. 2004) 
a The turnover rate in rat was expressed in min-1.  
L: liver; B: brain; K: kidney; V: vasculature; LG: lung; SI: small intestine.  
“-”: unknown.
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1.2.2 Epoxygenases and EETs formation 
A variety of CYP enzymes can produce EETs, including CYP1A, 2B, 2C, 2D, 2E, 2J, and 
4A subfamilies. The CYP epoxygenases add an epoxide group to the double bonds in arachidonic 
acid and produce four regioisomeric EETs, including 5,6-, 8,9-, 11,12-, and 14,15-EET (Fig 1.1). 
In humans,  CYP1A2, 2B6, 2C8, 2C9, 2C19, and 2J2 have been reported to catalyze EETs 
formation (Roman 2002). CYP2C8, 2C9, and 2J2 were identified as primary enzymes for EETs 
formation. In the presence of CYP2C9 inhibitor sulfaphenazole, the epoxygenase activity was 
inhibited by 50% compared to a 32% reduction with CYP1A2 inhibitor alpha-naphthoflavone, 
indicating the primary role of CYP2C9 in EETs formation (Rifkind et al. 1995). In an 
immunoinhibition study, CYP2C8 antibody inhibited EETs formation by 85-90% (Zeldin et al. 
1996). Although the expression of CYP2J2 in the liver is low, it has a significant role in catalyzing 
EETs in extrahepatic tissue such as the heart and pancreas (Xu et al. 2011).  
In rats, isoforms including CYP1A2, 2B1, 2B2, 2C11, 2C12, 2C23, 2C24, 2D18, 2J3, 2J4, 
and 2J10 produce EETs (Roman 2002). The predominant epoxygenases showed a tissue-
dependent manner. In an immunoinhibition study, CYP2C11, 2B1, 2C23, and CYP2C11/2C23 
were found to be predominant epoxygenases in the heart, lung, kidney, and liver, respectively (El-
Sherbeni et al. 2013). Specifically, anti-CYP2C11 and anti-CYP2C23 antibodies inhibited the 
epoxygenase activity by 88.5 ± 26.5% and 62.6 ± 28% in the liver microsomes, respectively.   
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1.3 Biological actions of 20-HETE  
 
Many of the biological activities of 20-HETE and EETs are opposite. For example, 20-
HETE inhibits large-conductance K+ channels and activates L-type Ca2+ channels in vascular 
smooth muscle cells to induce intracellular Ca2+ concentration and vasoconstriction. While EETs 
activate large-conductance K+ channels that lead to vasodilation. Through soluble epoxide 
hydrolase (sEH) metabolism, EETs are transformed to less bioactive metabolites DiHETs. 
Pharmacological inhibition of 20-HETE formation elicits beneficial effects in various therapeutic 
areas such as cardiac arrest, ischemic stroke, hemorrhagic stroke, and cancer (Poloyac et al. 2006, 
Williams et al. 2010, Alexanian et al. 2012, Donnelly et al. 2015, Shaik et al. 2015, Shekhar et al. 
2019). The following sections will introduce the biological roles of 20-HETE in the brain.
1.3.1 20-HETE and vascular tone  
20-HETE constricts cerebral arterioles. The role of eicosanoid on vascular tone was first 
discovered for EETs. 5,6-EET dose-dependently dilated rabbit and cat pial arterioles in vivo (Ellis 
et al. 1990). The mechanism of EETs dilatory effect was found to be related to increased frequency 
of channel opening, mean open time, and the open-state probability of a 98-pS K+ channel. 
(Gebremedhin et al. 1992). Later, the biological effect of 20-HETE on cat cerebral arterioles was 
studied by the same group. The homogenate of cat cerebral microvessels incubated with [14C]-
arachidonic acid in the presence of NADPH produced a metabolite that coeluted with synthetic 
20-HETE by reverse-phase high-pressure liquid chromatography (HPLC), with a mass-to-charge 
ratio of 391 m/z. The same value of the mass-to-charge ratio and 20-HETE molecular weight 
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suggested that 20-HETE was produced in the cat cerebral microvessels. The application of 
exogenous 20-HETE (0.1-10 nM) to isolated cat pial arteries (100-200 µM) induced a 
concentration-dependent reduction in arterial diameter. The mechanism of 20-HETE induced 
cerebral microvessel constriction was related to inhibition of a 217-pS K+ channel and activation 
of L-type Ca2+ channel, leading to the elevation of intracellular Ca2+ concentration and constricting 
cerebral arterial muscle (Harder et al. 1994, Gebremedhin et al. 1998, Harder et al. 2011). These 
results demonstrated that 20-HETE constrict cerebral microvasculature.  
1.3.2 20-HETE and cerebral blood flow autoregulation 
The endogenously formed 20-HETE plays a role in cerebral blood flow (CBF) 
autoregulation. 20-HETE was produced with cerebral arterial microsomes when incubated with 
[14C] arachidonic acid, suggesting the endogenous 20-HETE was formed in cerebral arteries. 
When increasing intravascular pressure from 20 to 140 mmHg on isolated cerebral arteries, a 6-
fold increase in 20-HETE concentration was induced. And treatment with a CYP450 inhibitor 
DDMS (10µmol/L) or a 20-HETE antagonist 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid (20-
HEDE) blocked pressure-induced constriction and increased the diameter at 140 and 160 mmHg 
compared to control (Gebremedhin et al. 2000). Additionally, when applying 20-HETE 
antagonists, 15-HETE and 20-HEDE, the pressure-induced arterial constriction was also 
attenuated. This suggested that 20-HETE is recognized as a mediator of pressure-induced 
myogenic constriction of cerebral arteries in vitro. 
The significance of 20-HETE in cerebral blood flow autoregulation was also demonstrated 
in vivo. When intracranial infused 50 uM DDMS, the autoregulation of CBF was impaired between 
pressure from 70 to 150 mmHg in Sprague Dawley rats (Gebremedhin et al. 2000). The 
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autoregulatory index (percentage change in CBF/percentage change in mean arterial pressure) 
increased from 0.10 of control to 0.92 of the DDMS treated group, when an autoregulatory index 
of 0 suggests perfect autoregulation. Fan et al. generated CYP4A1 transgenic rats that had eight-
fold higher CYP4A1 expression and produced six-fold higher 20-HETE in cerebral vessels 
compared to Dahl salt-sensitive (SS) rats (Fan et al. 2015). The myogenic response of the middle 
cerebral artery was impaired in SS rats with unaltered diameters when increasing perfusion 
pressure from 60 to 140 mmHg. When mean arterial pressure (MAP) increased from 100 to 160 
mmHg, CBF increased by 49.1 ± 6% in SS rats compared to 18.6 ± 2% and 25.9 ± 5% in CYP4A1 
transgenic and SS-5BN rats. Together, these data suggested either pharmacologic or genetic 
inhibition of 20-HETE formation, the pressure-induced myogenic response was blocked, implying 
the critical role of 20-HETE in CBF autoregulation in vivo.  
1.3.3 20-HETE and angiogenesis 
20-HETE can promote angiogenesis, the process of forming blood vessels. The role of 20-
HETE in angiogenesis was first reported in skeleton muscle. An increase in 20-HETE formation 
after chronic electrical stimulation was observed in skeletal muscle, and pharmacological blockade 
of 20-HETE by HET0016 abolished the increase in vessel density in response to electrical 
stimulation (Amaral et al. 2003). Similarly, Chen et al. demonstrated the 20-HETE induced 
angiogenesis was able to be inhibited by HET0016 in rat cornea in vivo (Chen et al. 2005). The 
promotion of angiogenesis by 20-HETE was contributed by the upregulation of hypoxia-inducible 
factor (HIF-1), superoxide, and vascular endothelial growth factor (VEGF) to increase the 
proliferation of epithelial cells (Guo et al. 2007, Guo et al. 2009).  
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There is limited information on 20-HETE and physiological angiogenesis in cerebral 
arteries. However, several studies reported the role of 20-HETE in angiogenesis under pathological 
conditions. In ischemic stroke patients, there were significantly increased microvessels in the 
infarcted tissues compared to the contralateral normal hemisphere. The new vessel formation also 
correlated with longer survival time in the patients (Krupinski et al. 1994). In astrocytes exposed 
to oxygen-glucose deprivation, HET0016 or CYP4A siRNA inhibited tube formation and 
prevented accelerating endothelial migration in endothelial cells, suggesting the role of 20-HETE 
in mediating endothelial cell proliferation and angiogenesis in vitro (Liu et al. 2019). Interestingly, 
in a mouse focal cerebral ischemia model, both CYP4A siRNA and HET0016 treatment 
suppressed microvessel density in the peri-infarct cortex by day 14 post-stroke. The suppressed 
angiogenesis was consistent with the neurological and functional outcome, where improvement 
was seen up to day 7, but a worse outcome was seen at day 14 post-stroke (Liu et al. 2019). This 
study suggests although inhibition of 20-HETE at an early time period demonstrated 
neuroprotection, but prolonged inhibition may be detrimental considering the possible protective 
proangiogenic effect of 20-HETE at a later phase. More research is required to further study the 
mechanisms of 20-HETE regulation of angiogenesis of the cerebral vasculatures.  
1.4 Therapeutic areas for developing 20-HETE formation inhibitors  
20-HETE synthase inhibitors have been evaluated as a potential intervention for several 
CNS diseases such as cardiac arrest and stroke. Despite different causes of the blood supply 
impediment to the brain, cardiac arrest and stroke develop secondary brain injury after the initial 
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insult. The biological effect of 20-HETE in the brain prompted researchers to investigate the effect 
of 20-HETE inhibition under these pathophysiological conditions.     
1.4.1 Cardiac arrest 
Cardiac arrest (CA) is the cessation of cardiac mechanical activity and is confirmed by the 
absence of signs of circulation. Whole-body ischemia during cardiac arrest and after the return of 
spontaneous circulation (ROSC) lead to a series of post-cardiac arrest syndrome, including post-
cardiac arrest brain injury, post-cardiac arrest myocardial injury, systemic ischemia/reperfusion 
response, and persistent precipitating pathology. Among all the organs, the brain, particularly the 
cerebral cortex, is vulnerable to ischemic/reperfusion injury and post-resuscitation neurological 
dysfunction represents the major cause of mortality and morbidity (Nolan et al. 2008). 
1.4.1.1 Cerebral hypoperfusion after cardiac arrest 
 
Alterations of CBF after cardiac arrest can be assessed with the development of clinically 
relevant cardiac arrest animal models. Upon successful resuscitation, CBF alterations can be 
divided into three phases, including immediate phase (0-20 min), early phase (20 min-12 h), and 
intermediate phase (12-72 h) (Iordanova et al. 2017).  
The benchmark of the immediate phase is early hyperemia that causes impaired cerebral 
autoregulation. Hyperemia was found in adult and pediatric rats, rabbits, and dogs cardiac arrest 
models (Blomqvist et al. 1985, Lee et al. 1989, Sterz et al. 1992, Manole et al. 2009). After 9 min 
asphyxial cardiac arrest in postnatal day 17 rats, subcortical areas were hyperperfused at 5 min and 
returned to baseline by 10 min. After 12 min asphyxial cardiac arrest, hyperemia was absent 
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(Manole et al. 2009). Researchers have debated whether hyperemia is beneficial as an indication 
of increased local metabolic rate or detrimental as it may enhance reperfusion injury (Iordanova et 
al. 2017). Antioxidants and transgenic rats with superoxide dismutase overexpression targeting 
early hyperemia have been shown to improve outcomes after cardiac arrest (Cerchiari et al. 1987, 
Xu et al. 2009).  
During the hypoperfusion phase, the cerebral metabolic fate gradually recovers, but the 
CBF is severely reduced, which usually lasts from hours to days. The prolonged phase of 
hypoperfusion may induce secondary injury after the initial insult and is correlated to 
neurocognitive, behavioral, sensory, and motor function deficit, representing a therapeutic target 
after cardiac arrest (Mongardon et al. 2011). Multiple mechanisms have been proposed to 
contribute to the hypoperfusion phase, including damage of endothelial cells, disturbance in 
vasoconstrictors and vasodilators, increased cerebral vascular resistance, and impaired 
autoregulation (Buunk et al. 1996, Sundgreen et al. 2001, Shaik et al. 2015, Iordanova et al. 2017). 
Manole et al. reported cortical hypoperfusion after 9 min asphyxial cardiac arrest from 10 to 150 
min and immediate hypoperfusion in the cortex and subcortical regions after 12 min insult (Manole 
et al. 2009). Li et al. reported the prominent microcirculatory disturbance during immediate and 
early phases that contributes to hypoperfusion. Among 59 cortical capillaries from 12 rats that 
underwent cardiac arrest injury, highly heterogeneous microcirculatory disturbances were found. 
25.4% and 13.5% capillary branches displayed no-reflow phenomenon at 30 and 60 min post-CA, 
and the time required for plasma to travel from the pial arterioles through capillaries into the pial 
venules increased post-CA (Li et al. 2019).  
CBF may returns to normal, remain low, or increase during the intermittent phase. In a 
prospective observational study in resuscitated cardiac arrest patients, the mean flow velocity 
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(MFV) in the middle cerebral artery gradually increases toward normal values in survivors during 
the first 72 h (van den Brule et al. 2017). In non-survivors, the MFV significantly increased 
compared to the survivors’ group, suggesting a decrease in cerebral vascular resistance in these 
patients (van den Brule et al. 2017).  
1.4.1.2 Beneficial effects of 20-HETE inhibition after cardiac arrest  
CBF disturbance is a potential target for therapeutic intervention for secondary brain injury 
after cardiac arrest. CYP450-derived arachidonic acid metabolites including 20-HETE and EETs 
constrict and dilate blood vessels, which provide a mechanism of regulating CBF. Interventions 
that inhibit 20-HETE formation were evaluated in cardiac arrest injury models. Shaik et al. studied 
20-HETE inhibition in PND 17 rats subjected to 9min or 12 min asphyxia cardiac arrest. Cortical 
20-HETE levels significantly increased at 5 min compared to sham after 9 min asphyxia, and 20-
HETE levels were significantly higher at 5 and 120 min after 12 min asphyxia (Shaik et al. 2015). 
The brain 20-HETE levels were parallel with the temporal profile of hypoperfusion as described 
previously after CA insult in this pediatric asphyxia cardiac arrest model (Manole et al. 2009). The 
elevated cortical and subcortical 20-HETE was reduced significantly by a single dose of HET0016 
(0.9 mg/kg) administered at resuscitation after 12 min CA, without affecting other AA metabolites. 
HET0016 decreased brain water content at 24 h, and improved cortical perfusion at 5 and 10min, 
but not at 30 min and 60min. HET0016 treatment (0.9 mg/kg, q6h) also improved short-term 
neurological outcomes at 3 h and 24 h measured by neurological deficit score and reduced 
neurodegeneration measured by cortical pyknotic neurons. These findings suggested that the 
beneficial effect of 20-HETE inhibition is multifactorial, including the direct improvement of 
perfusion on vascular smooth muscle, improved perfusion secondary to reduced brain edema, and 
direct neuronal protective effect. 
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Similarly, Yang et al. demonstrated the protective effect of 20-HETE inhibition in a global 
hypoxia-ischemia (HI) neonatal piglet model, which mimics neonatal HI injury. Administration of 
HET0016 1mg/kg or 10mg/kg at 5 min after reoxygenation significantly increased the density of 
viable neurons to 52 ± 20% and 62 ± 15%, respectively, compared to  21 ± 11% in the vehicle 
group (Yang et al. 2012). The protective effect was mediated by reducing the HI induced 
phosphorylation at PKC-sensitive sites and limit the HI–induced decrease in Na+, K+-ATPase 
activity, suggesting 20-HETE exhibit direct neuronal effect on proteins involved in neuronal 
excitocixity. The same group reported HET0016 1mg/kg treatment provided additional 
neuroprotection besides therapeutic hypothermia by increasing the density of viable neurons in the 
putamen, cortex, and thalamus in the same model (Zhu et al. 2015). Together, these studies 
suggested the role of 20-HETE in neuronal excitotoxicity, cerebral hypoperfusion, and 
neurodegeneration after cardiac arrest. And inhibition of 20-HETE is a promising strategy to 
improve neuroprotection and reduce neurodegeneration after cardiac arrest.  
1.4.2 Stroke  
Ischemic strokes are caused by an obstruction within a blood vessel that supplies blood to 
the brain, which accounts for 87% of all strokes (Virani et al. 2020). Hemorrhagic strokes such as 
intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH) are less common, 
accounting for 13% of all stroke cases (Virani et al. 2020). Post-stroke sequelae such as 
neurological deterioration, cognitive impairment, cerebral vasospasm, and delayed cerebral 
ischemia are common complications after ischemic or hemorrhage stroke (Balami et al. 2011, 
Macdonald 2014). 
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1.4.2.1 Cerebral hypoperfusion after ischemic stroke  
The pathophysiology of ischemic stroke is complex and involves multiple mechanisms. 
Oxygen-rich vascular supply is disrupted during ischemic stroke. Ischemia causes brain damage 
by oxygen or glucose depletion, energy failure, and disturbance of subsequent energy-dependent 
processes. Depletion of cellular energy causes elevation of intracellular Na+, Ca2+, and 
extracellular K+, which will cause cytotoxic edema (Durukan et al. 2007). With energy depletion, 
glutamate is released, activating of glutamate receptors which leads to Na+, Ca2+ influx, 
exacerbating edema and toxicity (Durukan et al. 2007). Generation of oxygen-free radicals and 
reactive oxygen species can react with cellular components and trigger inflammation and apoptotic 
pathways (Deb et al. 2010). Inflammation molecules, free radicals, hypoxia damage, and 
destruction of basal lamina by matrix metalloproteinases could disrupt the blood-brain barrier 
(BBB) (Durukan et al. 2007). Increased expression of mRNA of angiogenesis genes and 
angiogenic protein was observed in the ischemic area; however, it is still unclear if angiogenesis 
response could lead to the development of functional new blood vessels and improve brain 
function after ischemic stroke (Ergul et al. 2012). The cascade of events leads to neuronal death 
and irreversible loss of neuronal function.  
The inner core of the cerebral vascular tissue that undergoes ischemia is hypoperfused (18–
20 ml/100 g/min) and is at risk of dying within hours. The penumbra perfused at 60 ml/100 g/min 
is less likely to die (Deb et al. 2010). Treatment strategies have been developed to restore cerebral 
blood flow. Pharmacological intervention or mechanical recanalization to restore blood flow at an 
early time point has proven to salvage neurons and glia cells from the inner core and the penumbra. 
Despite successful recanalization, some patients experienced reperfusion injury, cytotoxic or 
vasogenic edema, and intracranial hemorrhage after reperfusion (Pan et al. 2007). 
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Reactive hyperemia occurs after reperfusion, where there is an elevation of regional blood 
flow along with loss of cerebral autoregulation and increased BBB permeability (Sundt et al. 1971, 
Olsen et al. 1981, Khatri et al. 2012). The length of post-ischemic hyperemia is directly 
proportional to the duration of the ischemic phase (Gourley et al. 1984). Reactive hyperemia is 
attributed to the abnormal vasodilation in the ischemic region caused by lactic acidosis and the 
release of vasoactive mediators (Rehncrona et al. 1981, Silver et al. 1992, Moore et al. 1994). A 
secondary hypoperfusion phase occurs after post-ischemic hyperperfusion, which lasts for 18 to 
96 hours. The hypoperfusion is attributed to elevated microvascular resistance, astrocytic end-feet 
swelling, cerebral metabolic depression, and formation of endothelial microvilli (Khatri et al. 
2012, Xiang et al. 2016, Ng Felix et al. 2018). These changes contribute to increased paracellular 
permeability, which is associated with vasogenic edema that worsens reperfusion injury.  
The basis for stroke treatment is to remove the blockade to relieve the brain damage caused 
by loss of oxygen and reduced blood flow. Recombinant tissue-type plasminogen activator (rt-PA) 
is the only FDA-approved treatment for ischemic stroke by its antithrombotic effect in dissolving 
clots to improve blood flow (Adams Harold et al. 2007). The limitation of intravenous rt-PA is the 
risk of causing symptomatic intracranial hemorrhage and a  therapeutic window within 4.5 hours 
after stroke symptoms onset to elicit benefits (The 1997, Hacke et al. 2008, Kernan Walter et al. 
2014). The DEFUSE study has shown that a perfusion-weighted imaging (PWI) and diffusion-
weighted imaging (DWI) mismatch ratio of 2.6 provides the highest sensitivity and specificity to 
identify patients who will benefit from reperfusion treatment (Albers et al. 2006, Kakuda et al. 
2008). Relying on MRI imaging, patients who displayed PWI/DWI mismatch may still benefit 
from rt-PA beyond the 4.5 h therapeutic window (Ebinger et al. 2012, Fisher et al. 2013, Bai et al. 
2019, Yi et al. 2019). Therefore, developing treatments that prolong the perfusion diffusion 
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mismatch by improving collateral flow is a potential adjunctive therapy to increase patients’ 
opportunity to be treated with rt-PA.  
1.4.2.2 Beneficial effect of 20-HETE inhibition after ischemic stroke 
Given the vasoconstrictive and proangiogenic effect of 20-HETE, experimental therapies 
were developed to test whether pharmacological inhibition of 20-HETE formation can induce a 
protective effect in ischemic stroke models. Several research groups utilized the temporal focal 
ischemia middle cerebral artery occlusion (MCAO) model in rats to study the effect of 20-HETE 
inhibition in ischemic stroke. Poloyac et al. used HET0016 (10 mg/kg i.p.), and Roman’s group 
used TS-011 (0.01 – 1.0 mg/kg/h i.v.) to achieve either acute or long-term blockade of 20-HETE.  
Both groups reported favorable treatment outcomes, including decreased cortical 20-HETE levels, 
reduced lesion volume, attenuation of the decreased CBF, and improved neurological and 
functional outcomes up to 7 days after the injury (Miyata et al. 2005, Omura et al. 2006, Poloyac 
et al. 2006, Tanaka et al. 2007, Dunn et al. 2008, Renic et al. 2009).  Conflicting results of TS-011 
beneficial effect on CBF were reported. Renic et al. showed that TS-011 0.1 mg/kg IV infusion 
over 2h had no improvement on cerebral blood flow in the cerebral cortex after MCAO injury in 
rats (Renic et al. 2009). Marumo et al. showed that TS-011 0.3 mg/kg IV infusion over 1h 
administered every 6h maintained the blood flow velocities in microvessels at values equivalent 
to pre-occlusion (Marumo et al. 2010). The discrepancies may be due to differences in TS-011 
dosing regimen and different locations of CBF being monitored in the two studies. Moreover, the 
effect of TS-011 was also tested in a thromboembolic stroke model in monkeys. TS-011 
significantly reduced neurological deficit score at 24 hours after the stroke onset. The infarct 
volume showed a trend of reduction compared to control treatment. The combination of rt-PA and 
TS-011 provided additional protection compared to a single therapy, where monkeys treated with 
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the combination therapy had significantly lower neurological deficit scores and smaller infarct size 
(Omura et al. 2006). In these studies, treatment was given either pre-injury, immediately after the 
onset of reperfusion, or up to 4 hours post MCAO. The positive results suggested inhibiting 20-
HETE could be employed over a wider therapeutic window compared to other treatments such as 
endothelin receptor antagonist S-0139(Zhang Rui et al. 2008). Future studies with later initiation 
of the 20-HETE inhibition could test if the treatment would produce any protective effect if 
initiated beyond 4.5 hours. The combinational therapies targeting two distinct mechanisms appear 
to be a promising research direction, given more data are needed on the safety and efficacy.   
The mechanism by which 20-HETE formation inhibitors improve neurological outcomes 
was studied by different groups. HET0016 reduced brain edema and protected and restored BBB 
integrity through reducing ROS production, suppressing MMP-9 expression and JNK pathway, 
and restoring tight junction proteins  Claudin-5 and ZO-1  after the MCAO in rats (Liu et al. 2014). 
Inhibition of 20-HETE also produces a direct neuronal protective effect in an organotypic 
hippocampal slice and cortical neuron cultures under oxygen-glucose deprivation. The reduced 
neuronal death is associated with a decrease in superoxide production and attenuation of the cell 
death pathway via caspase-3 (Renic et al. 2012, Zhang et al. 2017). Therefore, 20-HETE synthase 
inhibitors are proposed to improve neurological outcomes by improving blood flow and via a direct 
effect on neuronal survival. 
Clinical findings of 20-HETE in ischemic stroke raise the importance of its role in 
pathogenesis and clinical outcome. Lee et al. measured multiple HETEs, including 20-HETE, after 
stroke and found elevated HETE levels in stroke patients compared to controls (Lee et al. 2008). 
Similarly, Ward et al. reported plasma 20-HETE, EETs, DiHETs, and F2-isoprostane levels 
significantly increased in acute ischemic stroke patients compared with healthy controls in a 
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retrospective study, and 20-HETE and EETs levels attenuated at 30 days post-ischemic stroke 
(Ward et al. 2011). The association of 20-HETE with lesion size and reduced functional outcome 
in ischemic patients supported and strengthened the preclinical findings (Ward et al. 2011). The 
relationship was also found in a prospective study in acute ischemic stroke patients. Yi et al. 
reported that elevated levels of 20-HETE in cerebrospinal fluid and plasma from patients are 
associated with poor prognosis (Yi et al. 2016). Additionally, genetic polymorphism of CYP4A11 
and CYP4F2 have been reported to be related to stroke. Stec et al. first demonstrated that the 
CYP4F2 M433 allele is associated with a 50% reduction in 20-HETE production (Stec et al. 2007). 
CYP4F2 V433M has been found to be associated with ischemic stroke in different populations, 
including male Swedes, male Northern Chinese Han population (Fava et al. 2008, Deng et al. 
2010). In a Japanese male population, CYP4F2 G allele of rs2108622 and CYP4A11 GG genotype 
was associated with cerebral infarction and the T–C–G haplotype could be a risk factor for cerebral 
infarction in male Japanese (Fu et al. 2008, Fu et al. 2008). Together, these clinical findings 
provide incentives to develop safe and efficacious 20-HETE synthase inhibitors to investigate the 
effect of 20-HETE inhibition on clinical outcomes.   
1.4.2.3 Cerebral hypoperfusion after SAH  
According to the temporal progression of brain injury, early brain injury (EBI) and delayed 
brain injury (DBI) are used to describe the pathophysiology changes after SAH (Chen et al. 2014). 
Early brain injury (EBI), the immediate brain injury within 72 h of SAH onset, is an emerging 
cause of morbidity and mortality after SAH. The intracranial pressure (ICP) elevation after SAH 
aneurysmal rupture leads to a reduction in cerebral perfusion pressure (CPP) and reduced CBF, 
causing global cerebral ischemia (Cahill et al. 2006). ICP elevation can be induced by volume 
increase secondary to SAH, vasoparalysis, and cerebral spinal fluid (CSF) drainage obstruction 
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(Cahill et al. 2006). Prolonged and ICP-independent hypoperfusion was found in the acute phase 
in SAH patients and experimental SAH, suggesting early vasospasm (Schubert et al. 2011). 
Vasoconstriction was seen as early as 10 min after SAH in rats attributed to decreased levels of 
NO metabolites and increased endothelin-1 levels (Sehba et al. 2000). Abnormal Cerebral pial 
microcirculation and reduced cerebral blood flow were found in SAH mice within 180 min, where 
the acute vasoconstriction occurred predominantly in the arterioles instead of the venules (Yang 
et al. 2018). Targeting vasoconstriction, administration of NO donor S-nitrosoglutathione 
preserved vascular structure, increased CBF, increased internal carotid artery diameter, and 
decreased extracellular glutamate levels (Sehba et al. 1999, Sehba et al. 2007). Administration of 
endothelin receptor antagonist, clazosentan, prevented continuous CBF reduction in SAH rats  
(Schubert et al. 2008). 
After the first 3 days, angiographic cerebral vasospasm is a common complication after 
SAH that may contribute to delayed cerebral ischemia (DCI). Approximately 70% of patients were 
estimated to have angiographic vasospasm, and 25% of patients develop symptomatic cerebral 
vasospasm after aSAH (Carr et al. 2013). Cerebral vasospasm describes the narrowing of cerebral 
arteries that can be detected by angiography or sonography (Durrant et al. 2015). Vasospasm 
usually onset at 3 days after SAH, reaches maximum constriction on 5 to 14 days, and gradually 
resolves at 2 to 4 weeks (Durrant et al. 2015). Several factors have been shown to be involved in 
vasospasm, such as abnormal and prolonged vascular smooth muscle contraction, blood 
breakdown products, endothelial dysfunction, imbalance in arachidonic acid metabolites, and loss 
of autoregulation (Boullin et al. 1979, Macdonald et al. 1991, Rubanyi 1991, Eiichi et al. 2004, 
Roman et al. 2006, Otite et al. 2014). Cerebral vasospasm has been found to be associated with 
the reduction in rCBF in SAH patients. During cerebral vasospasm, luminal narrowing of the large 
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extraparenchymal arteries was observed, inducing significantly reduced rCBF (Ohkuma et al. 
2000). Cerebral vasospasm also decreases cerebral perfusion, but regional hypoperfusion can 
happen without vasospasm. The association is supported by the fact that hypoperfusion was seen 
in 46 regions in SAH patients, but 66% of the regions were supplied by vessels with no significant 
vasospasm (Dhar et al. 2012). Approximately30% of the patients who develop cerebral vasospasm 
will develop DCI. DCI is one of the most important causes of poor neurological outcomes in SAH 
patients. A meta-analysis showed that clazosentan treatment significantly reduced vasospasm and 
the risk of delayed ischemic neurologic deficit but did not alter vasospasm-related morbidity or 
outcome (Cho et al. 2019). Similarly, Dhar et al. found that delayed cerebral infarction could 
develop in brain regions without vasospasm and it accounts for >25% of infarct from DCI. This 
suggests that vasospasm is not the sole mechanism for causing DCI, and there is an association 
between cerebral vasospasm and multifactorial mechanisms for DCI development (Pluta et al. 
2009, Dhar et al. 2012).   
Early prevention and or treatment of cerebral vasospasm are important. Oral administration 
of nimodipine, a calcium channel blocker, is the only FDA-approved drug to treat vasospasm that 
improves outcomes after aSAH. In a British Aneurysm Nimodipine Trial, patients who had oral 
nimodipine demonstrated a 34% reduction in cerebral infarction and a 40% reduction in poor 
outcomes at three months (Pickard et al. 1989). Clazosentan reversed arterial narrowing and 
reduced angiographic vasospasm but failed to show any effect on long-term outcomes (Vajkoczy 
et al. 2005, Macdonald et al. 2012). Since the process of developing vasospasm is multifactorial, 
therefore, it is important to investigate new therapies that target other mechanisms, as well as 
developing combination therapies to manage cerebral vasospasm.  
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1.4.2.4 Beneficial effect of 20-HETE inhibition after SAH 
SAH may also benefit from the intervention of 20-HETE formation. Kehl et al. studied the 
effect of 20-HETE on CBF in SAH rats by utilizing two different 20-HETE formation inhibitors, 
a non-selective inhibitor 17-octadecynoic acid (17-ODYA) and a selective 20-HETE formation 
inhibitor HET0016. The 30% drop of cerebral blood flow at 10 min after SAH induction was 
attenuated by 20-HETE formation inhibitors by around 40%, and CSF 20-HETE production was 
brought down to control level by HET0016 (10mg/kg i.v.) or 17-ODYA (1.5 nmol) (Kehl et al. 
2002). Pretreatment of TS-011 0.01–0.1mg/kg i.v. prevented sustained fall in CBF in rats after 
induction of SAH (Kehl et al. 2002, Miyata et al. 2005). Rats received TS-011 (0.1 mg/kg i.v.) 
showed recovery of cerebral artery diameter, CBF returned to control values and reversion of 
delayed vasospasm (Takeuchi et al. 2005). Crago et al. reported that CSF 20-HETE concentrations 
were associated with delayed cerebral ischemia (DCI) and Hunt & Hess score in aSAH patients 
(Crago Elizabeth et al. 2011). This was the first clinical evidence that supported an association 
between 20-HETE CSF levels with poorer aSAH outcomes. Later, Donnelly et al. found that aSAH 
patients with moderate or high 20-HETE CSF concentrations were more likely to have unfavorable 
3 and 12-months Modified Rankin Scale, quicker onset to develop clinical neurologic 
deterioration, and three-fold higher 3 and 12-month mortality (Donnelly et al. 2015).   
To summarize, regardless of the different CNS insults, imbalance in eicosanoids was 
observed in animal models in cardiac arrest and stroke. Specifically, brain tissue and CSF 20-
HETE levels were upregulated. Favorable neurological outcomes in animal models when 
inhibiting 20-HETE and the associations seen between 20-HETE and clinical outcomes are 
motivations to develop novel compounds that modulate CYP4 enzymes. This is a potential strategy 
in the development of new treatments for ischemia-reperfusion injury in the brain.  
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1.5 Medicinal chemistry efforts to develop 20-HETE formation inhibitors 
The appealing effect of inhibiting 20-HETE formation or antagonizing its effect based on 
previously mentioned biological rationales encouraged the discovery of 20-HETE formation 
inhibitors or epoxyeicosatrienoic acid mimics. Several pharmaceutical companies and academic 
institutions have reported 20-HETE formation inhibitors. Table 1.2 provides a summary of the 
known 20-HETE inhibitors and mimetics. Early assays to quantify AA metabolites were hindered 
by long assay duration, low sensitivity, and a limited number of metabolites. The development of 
highly sensitive UPLC-MS/MS measurement for lipophilic metabolites of endogenous substrate 
AA was an effective way to verify the activity of lead compounds as well as the selectivity of the 
compounds because of its ability to simultaneously measure HETEs, EETs, DiHETs, and 
prostanoids (Miller et al. 2009, Shaik et al. 2014). 
1.5.1 Early 20-HETE formation inhibitors 
Most of the early compounds nonselectively inhibit ω-hydroxylase and epoxygenase 
pathways of arachidonic acid metabolism. β-diethylaminoethyldiphenylpropylacetate (SKF-
525A) inhibits EETs and 20-HETE formation by binding to the heme in CYP enzymes and reduces 
the availability of the heme to incorporate into CYP enzymes (Borrello et al. 1986, Roman 2002). 
Administration of SKF525A (100 μM) to isolated dog renal arteries reversed the arachidonic acid-
induced constriction (Kauser et al. 1991). 17-octadecynoic acid (17-ODYA) introduced by Ortiz 
de Montellano et al., is a fatty acid analog that inhibits 20-HETE formation avidly depending on 
the terminal acetylenic moiety as a suicide-substrate inhibitor (Ortiz de Montellano et al. 1981, 
Shak et al. 1985). However, 17-ODYA also inhibited epoxygenases effectively at the same 
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concentration (Zou et al. 1994). Compound 1-aminobenzotriazole (ABT) (50 mg/kg) administered 
intraperitoneally completely inhibited 20-HETE and EETs formation by disrupting the CYP450 
function via the formation of a heme adduct (Ortiz de Montellano et al. 1981, Maier et al. 2000). 
In addition to these compounds, endogenous vasodilators, nitric oxide (NO) and carbon monoxide 
(CO), bind to the heme in the CYP enzymes and block 20-HETE and EETs formation 
simultaneously even though NO donor dose-dependently inhibited 20-HETE formation in renal 
microsomes (Sun et al. 1998).  
1.5.2 Selective 20-HETE formation inhibitors  
The discovery of the first potent and selective 20-HETE formation inhibitor was reported 
in 2001 by the Taisho Pharmaceutical Co., Ltd. using high throughput screening. The potency of 
N-(4-Butyl-2-methylphenyl)-N’-hydroxyformamidine (HET0016) in human and rat kidney 
microsome were 8.9 ± 2.7 and 35 ± 4 nM, respectively (Sato et al. 2001). The group reported the 
N-hydroxyformamidine moiety and a substitution at para position larger than the methyl group is 
necessary for potency. HET0016 inhibited EETs in rat kidney microsome with IC50 value (2800 ± 
300 nM) around 80-fold for IC50 of 20-HETE formation inhibition (Miyata et al. 2001). The 
compound was selective, exhibiting over 370-fold selectivity for the inhibition of 20-HETE 
formation vs. the inhibition for CYP2C9, 2D6, and 3A4 in the human kidney microsome. It also 
did not affect COX enzymes (IC50 = 2300 nM). This compound was then used in various in vitro 
and in vivo disease models, including ischemic and hemorrhagic stroke, cardiac arrest, preventing 
the fall of cerebral perfusion and CBF (Kehl et al. 2002, Poloyac et al. 2006, Shaik et al. 2015).  
Although HET0016 was potent and selective, it was plagued by low water solubility (3.7 
μg/ml), short half-life (39.6 ± 20.0 min), and instability under acidic environment (43.2% 
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remaining at pH 4.0) due to the formamidine moiety (Nakamura et al. 2003, Mu et al. 2008). The 
low water solubility and the rapid metabolism by CYP450 enzymes require frequent 
administration and limited the use of the compound in preclinical studies. To improve 
physicochemical properties, specifically solubility and PK properties, Taisho Pharmaceutical 
explored derivatives with acid-stable isosteric moieties and conducted extensive structure-activity 
relationship (SAR) studies. Different derivatives with imidazole, triazole, pyridine, oxazole, 
isoxazole, isothiazole, pyrazole, pyrazine, pyrimidine, pyrrole, and tetrazole were synthesized. The 
SAR study suggested the crucial role of the nitrogen at the 3’-position of the various heterocyclic 
rings for the potent 20-HETE formation inhibition activity and a low spatial tolerance around 
nitrogen at the 3’-position (Nakamura et al. 2003). Among these derivatives, isoxazole (23) and 
pyrazole (24) derivatives maintained the potency and selectivity with improved stability under an 
acidic environment (Fig 1.2) (Nakamura et al. 2003). Comparing to HET0016, although the 
potency of compound 24 decreased by 2-fold (IC50 = 23 ± 12 nM), its stability improved under an 
acidic environment (100% remaining at pH 4.0, 50 °C, 1 day). Imidazole derivative (3a) exhibited 
good potency, but it also inhibited other CYP drug metabolizing enzymes (DMEs), which may 
cause drug-drug interactions (DDI).  
 
Figure 1.2 Evolution of 20-HETE formation inhibitors and pharmacophores 
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HET0016 was the first potent and selective 20-HETE formation inhibitor. Compound 3a, 23, and 
24 were imidazole, isoxazole, and pyrazole derivatives of HET0016. The numbering of the 
compound follows the numbering from the referenced publication (Nakamura et al. 2003). 
 
Multiple compounds showed 20-HETE formation inhibitory activity during the initial high 
throughput screening, including HET0016 and a phenylimidazole derivative (1) (Fig. 1.3). 
Compound 1 had a moderate potency (IC50 = 310 nM). To further improve the activity of 
compound 1, carboxyalkoxy moiety with 3-9 methylene groups was introduced to either 2’- or 4’-
position of benzene of 1. Derivatives with a side chain at 4’-position had improved the activity by 
4- to 40-fold compared to compound 1 (e.g., 7c, IC50 = 7.9 nM), while derivatives with a side chain 
at 2’-position had reduced potency (Nakamura et al. 2004). The potency is also related to the length 
of the methylene group. An n of 5 for the methylene group for the carboxyalkoxy moiety at the 4’-
position on benzene showed an optimum 40-fold increase of activity compared to compound 1. 
The optimization also improved selectivity towards other DMEs.  
The Taisho Pharmaceutical adopted multiple approaches to improve the properties of 20-
HETE formation inhibitors. To decrease the affinity of 3a to other DMEs, polar functional groups, 
such as amino groups, were introduced to the alkoxy side chain. Introduction of cyclic amino 
substituents maintained the activity against 20-HETE formation and reduced inhibition for other 
DMEs. Replacement of butoxy group with 2-dimethylaminohexyloxy derivative (3g) also yields 
a potent inhibitor with an IC50 value of 2.2 nM and an approximately 180- to 15,000-fold selectivity 
window toward CYP1A2, 2C9, 2C19, 2D6, and 3A4, suggesting the longer alkoxy side chain may 
be preferable for inhibition of 20-HETE formation (Fig. 1.3) (Nakamura et al. 2004). For the 
pyrazole derivatives, the introduction of polar substituents such as amino group or ether group on 
the side chain of compound 24 further improved the water solubility by around 100-fold. However, 
the increased solubility with acyclic aliphatic amino or cyclic aliphatic amino substituent was often 
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associated with a 10-fold loss of activity. Some piperazine derivatives with a rather bulky 
substitution at 4-position of the piperazine ring showed good activity, such as 3e and 6b (Fig. 1.3). 
Compound 3e and 6b also demonstrated attractive therapeutic potential in animal models of 
cerebrovascular disease (Nakamura et al. 2004). Unfortunately, there is no publicly available data 
regarding whether these derivatives have improved PK profiles. Our previous pharmacokinetic 
evaluation of HET0016 suggested that it has a high brain penetration with a brain to plasma ratio 
of 6 in adult rats (Mu et al. 2008). However, there were no publications reporting the brain 
penetration for the aforementioned derivatives. Therefore, without knowing the brain tissue 
concentrations of the derivatives, they might not be more optimal than HET0016 to be used as a 
20-HETE formation inhibitor in preclinical cerebrovascular disease models. 
N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide (TS-011) is a newer 
selective, potent 20-HETE formation inhibitor synthesized by Taisho Pharmaceutical, with an IC50 
range of 10-50 nM in human renal microsomes and recombinant CYP4A11, 4F2, 4F3B against 
20-HETE formation and has > 8000-fold selectivity window against other DMEs (Fig. 1.3) 
(Miyata et al. 2005). TS-011 reduced CBF fall following SAH and reduced infarct size after 
ischemic stroke in rats. However, TS-011 has an extremely short half-life of 10 min in rats. TS-
011 metabolic turnover in human liver microsomes or other in vitro human systems has not been 
disclosed, but the authors confirmed that its main metabolite did not show inhibitory effects against 
20-HETE formation in human renal microsomes, suggesting the metabolite does not contribute to 
the pharmacological effect(Miyata et al. 2005). Therefore, the short half-life of TS-011 could be a 
challenge in compound development if the PD effect is driven by the compound’s PK profile. 
Although TS-011 has a short biologic half-life in rats,  the positive outcomes of TS-011-treatment 
in reducing infarct volume, improving CBF, and improving neurological outcomes in various 
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preclinical cerebrovascular disease models make it an exciting compound for structure 
optimization to generate novel molecules with improved PK and physicochemical properties that 
may also possess neuroprotective effects (Miyata et al. 2005, Tanaka et al. 2007, Renic et al. 2009, 





Figure 1.3 Various 20-HETE formation inhibitors 
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TS-011 is a newer 20-HETE formation inhibitor. Compound 1 was discovered together with 
HET0016 in high throughput screening. Compound 7c is the derivative of compound 1 with side 
chain at 4’-position of benzene. Compound 3g is a dimethylaminohexyloxy derivative of 3a that 
showed decreased inhibition of DMEs. Compound 3e and 6b are derivatives of compound 24 with 
improved solubility and were tested in animal models of cerebrovascular disease. The numbering 
of the compounds follows the same numbers from the referenced papers (Nakamura et al. 2003, 
Nakamura et al. 2004, Nakamura et al. 2004, Nakamura et al. 2004). 
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1.5.3 20-HETE mimetics  
Dr. John R Falck’s group from The University of Texas Southwestern Medical Center 
reported multiple fatty acid analogs that have shown to be effective 20-HETE formation inhibitors. 
Four regioisomeric arachidonate isonitriles inhibited overall CYP450 arachidonic acid metabolism 
nonselectively with equipotency (Capdevila et al. 1988, Falck et al. 1990). At 5μM, 5,6-, 8,9-, 
11,12-, and 14,15-NC regioisomers inhibited arachidonic acid metabolism by 51, 60, 66, and 73% 
(Fig. 1.4). 14,15-EET analog 14,15-EET aziridine exhibited similar potency compared to 
isonitriles, while the 14,15-thiirane analog was less potent.  
12-12-dibromododec-11-enoic acid (DBDD) and its derivative N-methylsulfonyl-12,12-
dibromododec-11-enamide (DDMS) and are dibromoolefinic fatty acids reported to selectively 
inhibit ω-hydroxylation of AA with an IC50 of 2 μM (Fig. 1.4) (Falck et al. 1997, Wang et al. 
1998). Although the activity of both compounds is similar, DDMS was reported to have improved 
the resistance to β-oxidation. DDMS and DBDD inhibited the epoxygenase pathway with an IC50 
of 60 μM and 51 μM, respectively (Wang et al. 1998). DPMS was less potent than DDMS and 
DBDD, suggesting that a carboxylic acid or N-methyl sulfamide with 12 carbons may better fit 
the active site of CYP4A isoforms. One-hour intravenous infusion of DDMS (10 mg/kg) reduced 
rat renal 20-HETE formation by 70% (Alonso-Galicia et al. 1997). DDMS and DBDD had high 
IC50 values for 20-HETE formation inhibition and an approximately 25 – 30-fold selectivity 
window for the epoxygenase pathway. 
20-HETE effects on vascular tone are associated with activation of protein kinase C and 
mitogen-activated protein kinase signal transduction cascades, which suggests that the biological 
effect of 20-HETE is usually mediated by binding to a receptor. The 20-HETE receptor has long 
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been a mystery to be solved in the field. Before the discovery of the 20-HETE receptor, a series of 
synthetic 20-HETE analogs were developed to study whether vasoconstriction of 20-HETE can be 
mimicked or blocked by 20-HETE analogs (Fig. 1.5). A 19(S)-HETE analog 19-
hydroxynonadecanoic acid (sC19 analog) at 1 μM and 20- hydroxyeicosa-6(Z),15(Z)-dienoic acid 
[6(Z),15(Z)-20-HEDE] at 1 μM eliminated the isolated perfused renal interlobular arteries’ 
vasoconstrictor response to 20-HETE (Alonso-Galicia et al. 1999). In the presence of sC19 analog, 
the vasoconstrictor response reduced by about 50%. Similarly, the saturated derivative of 20-
HETE (20-HE) displayed competitive antagonist activity (Fig. 1.5). Additional 20-HETE 
antagonists such as 2, 5, 8, 11, 14, 17-hexaoxanonadecan-19-yl 20-hydroxyeicosa-6(Z), 15(Z)-
dienoate (20-SOLA) and N-disodium succinate-20-hydroxyeicosa-6(Z),15(Z)-diencarboxamide 
(AAA), more water-soluble 20-HETE antagonists, were disclosed. Administration of 20-SOLA 
(10 mg/kg/day) normalized the blood pressure in male hypertensive CYP4a14 KO mice (Garcia 
et al. 2015). Treatment of AAA in Cyp4a11 transgenic mice and Cyp1a1-Ren-2 transgenic rats 
induced with hypertension reduced systolic blood pressure(Savas et al. 2016, Sedláková et al. 
2018).    
Derivatives of endogenous 20-HETE antagonist, 19-HETE, were also explored (Fig 1.5). 
Appending azide to the terminal carbon of 19-HETE resulted in a 6-8 fold increased antagonism 
activity (compound 6, 7) compared to 19-HETE, which could be attributed to the increased 
hydrogen binding to the azide at the receptor binding site (Tchertanov 1999, Dakarapu et al. 2019). 
The addition of N-glycinates (10, 11) led to improved potency and water solubility compared to 4, 
5 (10 and 11 ≈ 0.5 mg/mL). N-aspartate derivative (13) also had improved activity but was not as 
potent as compound 11. Intraperitoneal injection of compound 13 (10 mg/kg) to cyp4a14 (-/-) mice 
significantly decreased systolic blood pressure over a 10-day course.  
 36 
In 2017, Garcia et al. used crosslinking analogs, click chemistry, and binding assays and 
identified G-protein receptor 75 (GPR75) as the 20-HETE receptor (Garcia et al. 2017). G protein-
coupled receptors (GPCRs) are the largest family of transmembrane receptors that are involved in 
signal transduction, which mediates an array of intracellular responses (Howard et al. 2001). G 
protein-coupled receptor 75 (GPR75) is a 540 amino acid polypeptide, which maps to chromosome 
2p16 and is identified as a novel human GPCR in 1999 by Emma E.T. et al. (Tarttelin et al. 1999). 
GPR75 is ubiquitously expressed in the human body, with the highest protein expression in the 
brain regions such as the cerebral cortex, basal ganglia, hippocampus, and amygdala (The Human 
Protein Atlas). The receptor has been shown to respond to stimulus through the chemokine CCL5/ 
RANTES in a neuroprotective manner against amyloid B toxicity (Liu et al. , Ignatov et al. 2006). 
The identification of the 20-HETE receptor provided a new target and a new direction for novel 
compound development.  
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Figure 1.4 Chemical structures of nonselective and selective arachidonic acid analogs that 





Figure 1.5 Evolution of 20-HETE antagonists 
 
1.5.4 Repurposing drugs and supplements as 20-HETE formation inhibitors 
Several clinically approved drugs and supplements have been reported to inhibit 20-HETE 
formation. Fluoxetine has been proven to have protective effects by preventing BBB disruption in 
global ischemia-induced neuronal death (Lee et al. 2014). In a study done in neonatal mice, 
transient postnatal fluoxetine (10 mg/kg) exposure reduced brain 20-HETE concentration by 
70.3%, suggesting the potential protective effect of fluoxetine in ischemic brain injury patients 
(Yuan et al. 2015). Isoniazid-treated male Sprague Dawley rats induced CYP2E1 protein and 
enzymatic function in liver and kidney, which led to increased 19-HETE levels, an endogenous 
20-HETE antagonist. In isoniazid-treated animals, the 20-HETE tissue content in the liver and 
kidney was reduced by 34±10% and 15.6±5.3%. The 20-HETE formation rate in isolated kidney 
and liver tissues from isoniazid-treated rats also significantly decreased, which is in 
correspondence with reduced CYP4A protein expression (Poloyac et al. 2004). Similarly, in 
cardiac hypertrophy-induced rats treated with isoniazid (200mg/kg/day), there were increased 
cardiac 19-HETE levels by 20-fold and reduced 20-HETE levels by 98% (Elkhatali et al. 2015). 
In vitro incubation of arachidonic acid with resveratrol showed decreased 20-HETE formation 
rate, with IC50 values for CYP4F2, 4F3B, and 4A11 of 4 µM, 109 µM, and 90 µM, respectively 
(El-Sherbeni et al. 2016). Using Monte Carlo simulation, the authors also predicted that 2.5g daily 
high and safe oral resveratrol would decrease 20-HETE levels by 16-35% in 90% of the human 
population (El-Sherbeni et al. 2016). Sesamin and sesamolin are plant lignans derived from sesame 
seeds, which inhibited 20-HETE formation both in vitro and in vivo and inhibited epoxygenase 
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activity at IC50 of 50 μM (Wu et al.). Recently, rubiarbonone C was identified as a selective CYP4F 
inhibitor (CYP4F2: IC50 = 4.2 µM; CYP4F3B: IC50 = 4.2 µM) among 50 natural compounds being 
tested. Its potency for CYP4A11 was greater than 50 µM. The selectivity window was greater than 
10-fold against CYP1, 2, and 3 families (Choi et al. 2018). Drugs or supplements identified through 
repurposing could potentially be evaluated for 20-HETE formation inhibitory effect in preclinical 
studies. These compounds could also be further optimized to explore the potency of derivatives. 
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Table 1.2 20-HETE formation inhibitors and 20-HETE mimetics   
Compound Structure 
IC50 (nM) in 
Human 







- - Mechanism-based 
(Borrello et al. 
1986, Roman 2002) 
17-ODYA 
 




(Zou et al. 1994, 
Sato et al. 2001, 
Edson et al. 2013) 
1-ABT 
 
µM range - Mechanism-based 
(Sato et al. 2001, 
Sun et al. 2011) 
10-SUYS 
 
NA 10.1 ± 2.6 Mechanism-based 
(CaJacob et al. 




8.9 ± 2.7a  
 




(Miyata et al. 2001, 
Sato et al. 2001, 
Seki et al. 2005) 
3a 
 
5.7 ± 1.0   - - 




38 ± 10   - - 




23 ± 12  - - 





2.2 - - 




310 - - 




7.9 - - 




21.2 - - 




14.0 - - 













(Yuan et al. , 











3 µM (HLM)  
Alter CYP4A 
expression 
(Chang et al. , 
Elbarbry et al. 
2014, El-Sherbeni 




5.3 µM (human)  - (Wu et al.) 
Sesamolin 
 






















Reversible  (Wang et al. 1998) 
6(Z),15(Z)-
20-HEDE  





- - Antagonist  (Garcia et al. 2015) 
AAA 
 
- - Antagonist 
(Savas et al. , 
Sedláková et al. 
2018) 
“-”: data not available.  
a IC50 was measured
 in HKM. 
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1.5.5 Conclusions 
In summary, the arachidonic acid metabolism pathways and 20-HETE play important roles 
in cerebral vascular tone, cerebral blood flow autoregulation, and angiogenesis. A number of 
preclinical studies suggested that 20-HETE formation inhibition or 20-HETE antagonism is a 
promising strategy to ameliorate secondary brain injury after ischemic stroke, hemorrhagic stroke, 
and cardiac arrest. At this time, the available 20-HETE formation inhibitors and 20-HETE 
antagonists are not suitable for clinical use. As such, the development of small molecules targeting 
either the production of 20-HETE or antagonize the 20-HETE effect is highly desirable given their 
potential to provide benefits in cerebrovascular diseases. We have been interested in the 
development of novel drug-like 20-HETE formation inhibitors. The development of bioanalytical 
assays and the preclinical evaluation of novel compounds to inhibit 20-HETE formation is 
presented in Chapters 2, 3, and 4.   
 
 45 
2.0 Development of Bioanalytical Assays to Support Preclinical Evaluation of Novel 20-
HETE Formation Inhibitors 
2.1 Introduction  
Drug discovery and development require a significant investment in both time and money. 
The median cost of getting a new drug into the market is 985 million, and it takes a minimum of 
ten years to complete the journey from initial discovery to the market (Mohs et al. 2017). The 
development time of the central nervous system (CNS) drugs, which requires an enormous 
multidisciplinary collaborative effort, takes up to 12 to 15 years (Grabowski et al. 2002).  
The attrition rates of new chemical entities (NCEs) are high. Approximately 80-90% of the 
compounds fail before they get tested in humans. And among the drugs that enter the clinical trials, 
95% failed (Seyhan 2019). The primary cause of failures includes lack of safety and efficacy in 
humans, suboptimal pharmacokinetics (PK) properties, nonclinical toxicity, commercial and 
regulatory reasons (Meanwell 2016, Fogel 2018). Twenty years ago, issues related to 
pharmacokinetics made up nearly 40% of drug development failures (Darvas et al. 2002). The 
attrition due to poor PK was around 10% when anti-infective compounds were excluded (Alavijeh 
et al. 2004). A more recent analysis of the 812 oral small molecule drug candidates that were 
developed within four major pharmaceutical companies between 2005 to 2010 showed a 5% 
failure due to pharmacokinetics and bioavailability (Waring et al. 2015). The decrease in 
suboptimal PK properties-induced failure implies the crucial knowledge that drug metabolism and 
pharmacokinetics (DMPK) could provide in drug development. Therefore, implementing DMPK 
screening during early drug development is essential to generate information for early stage drug 
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molecule design as well as late stage clinical study design. Developing reliable bioanalytical assays 
becomes an inseparable part of DMPK evaluation.  
In this chapter, we reported the development of three in-house bioanalytical assays to 
facilitate the early profiling of novel chemical entities (NCEs). Metabolic stability (hepatic 
clearance) is recognized as one of the main determinants of drug concentrations. In vitro 
approaches have been extensively used to monitor metabolic stability and predict human clearance 
(Poloyac et al. 2020). Herein, we developed a metabolic stability assay by quantifying the 
depletion of the test compounds in the presence of human liver microsome using UPLC-MS/MS 
and derive the intrinsic clearance and half-life values. A potent CYP450 inhibitor may greatly 
inhibit the metabolism of a co-administered drug. Therefore, it is also essential to screen in vitro 
inhibition of major CYP450 isoforms for NCEs. We developed a UPLC-MS/MS assay that offers 
reliable quantification of the metabolites in the CYP cocktail assay. The observation of liabilities 
in these assays will provide an understanding of structural features that affect the developability 
of NCEs, which can be applied to guide drug design. We also developed an assay to measure a 
novel 20-HETE formation inhibitor in biological samples for subsequent pharmacokinetic 
analysis.  
2.2 Materials and Methods  
2.2.1 Materials 
Acetaminophen, phenacetin, diclofenac, spectrophotometric grade dimethyl sulfoxide 
(DMSO), methanol (MeOH), ethyl ether, acetic acid, and other solvents were purchased from 
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Fisher Scientific (Pittsburgh, PA). (±)-Metoprolol (+)-tartrate, (±)-verapamil hydrochloride and 
warfarin were purchased from Sigma-Aldrich (St. Louis, MO). S-mephenytoin, 4’-
hydroxydiclofenac, s-hydroxymephenytoin, dextromethorphan, dextrorphan, midazolam, 1’-
hydroxymidazolam, and miconazole were purchased from Toronto Research Chemicals (Ontario, 
Canada). Acetaminophen-d4, dextrorphan-d3, 4’-hydroxymephenytoin-d4, midazolam-d4, and 
diclofenac-d3 were purchased from Cerilliant (Round Rock, TX). Human liver microsome (HLM), 
rat liver microsomes (RLM), and recombinant CYP4F2 (rCYP4F2) were purchased from Seikisui 
Xenotech (Lenexa, KS). 
2.2.2 Methods 
2.2.2.1 Metabolic stability assay  
Microsomal incubates contained HLM (500 μg/ml), test compounds (1 μM), and NADPH 
(1.3 mM) in a 1 ml total volume of microsomal incubation buffer (0.12 M potassium phosphate 
buffer containing 5mM magnesium chloride). Each compound had three replications (n=3).  
The reaction was started by adding NADPH to the incubates and was carried out at 37°C 
in a shaking water bath for 60 min. At 0, 15, 30, 45, 60 min, a 50 μl aliquot of incubates was 
removed and the reaction was stopped by adding aliquot into 200 μl ice-cold acetonitrile. After 
centrifugation at 14000×g for 5 min, 200 μl supernatant was used for UPLC-MS/MS analysis. 
Values at 0 min were used as corresponding control for test compounds. The disappearance of the 
parent compound over time was measured with the amount of drug at time zero as the reference. 
Verapamil, metoprolol, and warfarin, categorized as fast, moderate, and slow metabolized drugs, 
were used as positive controls. Incubates without NADPH group served as the negative control to 
reveal any chemical instability or non-NADPH dependent degradation. An incubation was also 
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performed in the boiled microsome to identify any unspecific binding. The substrate depletion 
method was used to calculate in vitro intrinsic clearance.  
2.2.2.2 CYP cocktail assay  
HLM was incubated with a substrates cocktail. Incubation mixtures (500 µL) contained 0.1 
M potassium phosphate buffer (pH 7.4), 3mM MgCl2, 0.1 mg protein/ml of human liver 
microsomes, and NADPH (1 mM). Final concentrations of substrate cocktail listed in Table 2.2 
are below their reported Km values, i.e., 20, 2.0, 40, 5, and 2 µM for phenacetin, diclofenac, S-
mephenytoin, dextromethorphan, and midazolam, respectively. The reactions were initiated by 
adding NADPH to the incubation systems. The incubation was conducted at 37 ˚C for 10 min. The 
reaction was terminated by adding 12.5ul ice-cold internal standard mixtures. The samples were 
extracted with 1.5 ml diethyl ether, dried down under nitrogen gas, and reconstituted in 125 μl 
70:30 0.1% formic acid in H2O: 0.1% formic acid in ACN for analysis. 
2.2.2.3 Biologic sample extraction for UPMP107 and 20-HETE  
UPMP107, a novel 20-HETE formation inhibitor, was identified as a preclinical candidate 
and is currently under in vivo evaluation in animals.  A bioanalytical assay was developed to 
support the in vivo evaluation of UPMP107.  UPMP107 and 20-HETE concentrations were 
determined in brain tissue samples and plasma samples using solid phase extraction. Tissue 
samples were homogenized in a 0.12 M potassium phosphate buffer containing 5mM magnesium 
chloride and 0.113 mM butylated hydroxytoluene (BHT) and centrifuged for 30 minutes at 10,000 
rpm. The supernatant was removed, 7.5ng of 20-HETE-d6 and 6.6 ng of N1-(4-butyl-2-
methylphenyl) acetamide (SMIP004) (Maybridge, Cambridge, UK) were added as the internal 
standards. Supernatant was extracted using hydrophilic–lipophilic balance (HLB) solid phase 
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cartridges (Oasis, Waters, Milford, MA). Columns were washed with three 1 ml of 5% methanol 
and were eluted with 100% methanol. Extracts were dried under nitrogen gas at 37˚C and 
reconstituted in 125 ul of 80:20 Methanol: deionized water. Plasma samples were added to 1ml of 
potassium phosphate buffer containing magnesium chloride and BHT for solid phase extraction. 
The eluent was processed the same as the brain samples.   
2.2.2.4 Chromatographic conditions  
Novel compound entities, CYP cocktail assay metabolites, and UPMP107 separation were 
conducted using a UPLC BEH C18, 1.7 μm (2.1 × 100 mm) reversed-phase column (Waters, 
Milford, MA).  
For metabolic stability assay, the column temperature was maintained at 50°C. Mobile 
phases consisted of 0.1% formic acid in deionized water (A) and acetonitrile (B) with a flow rate 
of 0.25 ml/min. The initial mixture of mobile phase was 80:20 of A and B. Mobile phase B 
increased from 20% to 95% at 0.5 minutes after injection in a linear gradient over 3 minutes and 
maintained for 0.5 minutes. This was followed by a linear return to initial conditions over 1.5 
minutes. Total run time per sample was 5 minutes and all injection volumes were 7.5μl.  
For the CYP cocktail assay, the column temperature was maintained at 50°C. Mobile 
phases consisted of 0.1% formic acid in deionized water (A) and 0.1% formic acid in acetonitrile 
(B) with a flow rate of 0.25 ml/min. The initial mixture of mobile phase was 70:30 of A and B. 
The percentage of B was increased linearly from 30 to 100% from 3 min to 4 min, then returned 
to 30% at 5min and maintained at 30% B for 1.5 min. Total run time per sample was 6.5 minutes 
and all injection volumes were 7.5μl. 
For UPMP107 separation, the column temperature was maintained at 55°C. Mobile phases 
consisted of 0.005% acetic acid, 5% acetonitrile in deionized water (A) and 0.005% acetic acid in 
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acetonitrile (B) with a flow rate of 0.5 ml/min. The initial mixture of mobile phase was 80:20 of 
A and B. The percentage of B was increased linearly from 20 to 70% from 2 min to 4 min and 
maintained at 70% B for 0.5 min. Total run time per sample was 5.5 minutes and all injection 
volumes were 7.5μl. 
2.2.2.5 Mass spectrometric conditions  
Mass spectrometric analysis for NCEs, CYP cocktail metabolites, and UPMP107 was 
performed using a TSQ Quantum Ultra (Thermo Fisher Scientific, San Jose, CA) triple quadrupole 
mass spectrometer coupled with heated electrospray ionization (HESI) operated in positive 
selective reaction monitoring (SRM) mode with unit resolutions at both Q1 and Q3 set at 0.70 full 
width at half maximum.  
For metabolic stability assay, the vaporizer temperature was 300°C; spray voltage was set 
at 3000V; capillary temperature was set at 270 °C. Quantitation by SRM analysis on compounds 
was performed by monitoring their m/z transitions listed in Table 2.1.  
For CYP cocktail assay, the vaporizer temperature was 314 °C; spray voltage was set at 
3500V; capillary temperature was set at 202 °C. The MS conditions are presented in Table 2.2. 
For UPMP107, the vaporizer temperature was 314 °C; spray voltage was set at 3500V; 
capillary temperature was set at 202 °C. To measure 20-HETE, the vaporizer temperature was 
275°C; spray voltage was set at 5000V; capillary temperature was set at 399 °C. The MS conditions 
for UPMP107, 20-HETE, and internal standards are presented in Table 2.3.  
Quantitation by SRM analysis on compounds was performed by monitoring their m/z 
transitions. Scan time was set at 0.01 s and collision gas pressure was set at 1.2 mTorr. Analytical 
data were acquired and analyzed using Xcaliber 3.0 data system (ThermoFisher, San Jose, CA).  
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Table 2.1 Analytical parameters for NCEs  
 
Compound Precursor-product (m/z) Collision energy (V) Retention time (min) 
Verapamil 455.3-165.0 27 2.68 
Metoprolol 268.0-116.2 20 2.08 
warfarin 309.1-163.3 20 3.41 
UPMP037 286.3-254.3 18 2.87 
UPMP038 286.1-254.2 18 2.29 
UPMP039 286.2-254.4 20 2.91 
UPMP040 286.3-254.3 20 2.32 
UPMP043 244.1-150.3 26 2.42 
UPMP045 286.2-126.2 14 2.44 
UPMP046 242.1-96.2 26 3.20 
UPMP047 242.2-150.2 20 2.51 
UPMP048 320.1-227.4 31 1.69 
UPMP049 320.2-227.3 31 2.49 
UPMP050 259.2-122.2 21 0.96 
UPMP051 272.1-96.2 33 2.81 
UPMP054 272.2-96.2 32 2.17 
UPMP057 260.1-96.2 26 2.72 
UPMP060 299.0-150.0 21 1.06 
UPMP107 325.0-251.0 27 1.38 
UPMP117 276.0-150.1 20 1.65 
UPMP124 311.3-150.2 21 2.13 
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Table 2.2 Analytical parameters for the individual metabolites and internal standards 
 
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Substrate  Phenacetin Diclofenac S-Mephenytoin Dextromethorphan Midazolam 
Concentration 20 µM 2 µM 40 µM 5 µM 2 µM 
Metabolite Acetaminophen 4'-OH-diclofenac 4'-OH-mephenytoin Dextrorphan 1'-OH-midazolam 
Internal standard Acetaminophen-d4 Diclofenac-d3 4'-OH-mephenytoin-d4 Dextrorphan-d3 Midazolam-d4 
Retention time (min) 1.25 4.78 1.69 1.30 2.49 
Ionization mode + + + + + 
Collision energy (V) 15 33 16 37 25 
Precursor-product (m/z) 152.1-110.2 312.1-230.1 235.3-150.4 258.1-157.2 342.1-203.1 
Linearity range (ng on column) 25-6000 25-3000 25-6000 25-6000 25-6000 
QC high 1250 1250 1250 1250 1250 
QC medium 450 450 450 450 450 
QC low 75 75 75 75 75 
 
Table 2.3 Analytical parameters for UPMP107, 20-HETE and internal standards 
Analyte  UPMP107 20-HETE  
Internal standard SMIP004 20-HETE-d6 
Retention time (min) 1.25 3.70 
Ionization mode + - 
Collision energy (V) 17 20 
Precursor-product (m/z) 325.3-240.3 319.3-245.1,  
Linearity range (ng on column) 12.5-1500 12.5-1500 
QC high 900 900 
QC medium 450 450 
QC low 45 45 
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2.2.2.6 Method validation  
Analysis on three separate days was performed to confirm the precision and accuracy of 
the LC-MS/MS method for the simultaneous quantification of six CYP-specific probe metabolites. 
Calibration curves were prepared at different concentration levels in microsomal incubation buffer. 
The deviation of the lower limit of quantification (LLOQ) should be within 20% and the accuracy 
of each concentration level should be within 85-115% according to the US Food and Drug 
Administration Bioanalytical Method Validation Guidance (2018). Quality control (QC) samples 
at three different concentrations were used to evaluate accuracy and precision. Intra-day precision 
and accuracy were determined by analyzing the QC samples on the same day. Inter-day precision 
was evaluated by analyzing the QC samples on three separate days. Precision and accuracy should 
not exceed ± 15%. The limit of detection (LOD) was defined as the signal-to-noise ratio = 3. LLOQ 
samples (n=5) were measured with precision (± 20% RSD) and accuracy (80-120%). The lowest 
quantifiable concentration on the curve was the LLOQ.  
2.3 Results 
2.3.1 Validation of metabolic stability assay experimental system  
The primary purpose of developing the metabolic stability assay is to set up an in-house 
assay to determine in vitro metabolism and obtain estimates of in vitro intrinsic clearance for 
NCEs. 
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The assay conditions were determined based on literature reported values (Di et al. 2003). 
Test compounds concentration was set at 1 µM to ensure the reaction is under a linear condition. 
The percentage of organic solvent was set at 0.5% to reduce the inhibitory effect on enzymatic 
activity. The protein concentration was 0.5 mg/ml to prevent non-specific binding. The amount of 
NADPH was 1.3 mM to ensure a saturated amount of cofactor in the system during a 1-hour 
incubation period. The peak area was used for each test compound as a surrogate for the amount. 
The assay was validated with verapamil, metoprolol, and warfarin known as fast, moderate, and 
slow metabolism positive controls in HLM (Fig. 2.1).  
 
Figure 2.1 Metabolic stability for verapamil, metoprolol, and warfarin 
The remaining percentage of verapamil, metoprolol, and warfarin was 98%, 77% and 6.5%, 
respectively.  
2.3.2 Chromatography and specificity for CYP probe metabolites 
The primary purpose of developing the CYP inhibition assay is to set up an in-house 
method to assess CYP-mediated inhibition for NCEs. The probe substrates used for the cocktail 
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assay included phenacetin (CYP1A2), diclofenac (CYP2C9), S-mephenytoin (CYP2C19), 
dextromethorphan (CYP2D6), and midazolam (CYP3A4). The substrates were selected based on 
the U.S. FDA recommendation. Internal standards include acetaminophen-d4, diclofenac-d3, 4'-
OH-mephenytoin-d4, dextrorphan-d3, and midazolam-d4. The mixture of internal standards was 
added to the microsomal incubation system at the end of the reaction. All metabolites were eluted 
within 6 min. This saved time compared with previously published methods. The elution profiles 
of all metabolites and internal standards are shown in Fig. 2.2.  
An incubation time of 10 minutes was used for the cocktail assay based on the reported 
literature where metabolite formation rates were linear during this incubation period (Li et al. 






Figure 2.2 Chromatograms of metabolites and internal standards 
(A) Metabolites for five CYP isoforms including acetaminophen, dextrorphan, 4’-OH-
mephenytoin, 1-OH-midazolam, 4’-OH-diclofenac. (B) Internal standards including 
acetaminophen-d4, dextrorphan-d3, 4’-OH-mephenytoin-d4, midazolam-d4, and diclofenac-d4. 
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2.3.3 UPLC-MS/MS method validation for CYP inhibition assay 
The concentration ranges of calibration curves and the QC samples are shown in Table 2.2. 
The calibration curves for each metabolite were: y = -0.0054 + 0.0109X for acetaminophen; y = -
0.0104 + 0.0051X for dextrorphan; y = 0.0177+0.0031X for 4'-hydroxymephenytoin; y = -0.0171 
+ 0.0046X for 1'-hydroxymidazolam; y = -0.0688 + 0.0149X for 4'-hydroxydiclofenac; y 
represents the peak area ratio of metabolite vs corresponding internal standard. A weighting factor 
of 1/y was placed on the calibration curve. The calibration curves showed good linearity in the 
concentration range for each metabolite (R2 > 0.995). The accuracy of each standard level in the 
calibration curve meets the recommended limits (85-115%) and LLOQ meets the 80-120% limit 
shown in Table 2.4.  
The within-day and between-day precisions were below 10% and 16%, respectively. The 
precision for LLOQ was < 20%, the accuracy obtained from LLOQs was within 80-120%.  
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Table 2.4 Validation data: within-day precision, between-day precision and accuracy (n=5) 




HQC -5.12% 8.57% 0.36% -0.46% 2.83% 
MQC 3.06% 3.30% 2.62% -4.04% -4.84% 
LQC -0.15% -4.63% -1.41% -5.14% 3.45% 




HQC 4.59% 10.7% 2.12% 5.16% 7.61% 
MQC 0.43% 5.07% 0.57% -2.95% -1.19% 
LQC -1.50% -4.11% -1.38% -3.40% 1.06% 





HQC 8.02% 9.26% 7.02% 2.89% 4.36% 
MQC 4.60% 5.78% 3.80% 3.62% 5.16% 
LQC 5.60% 7.34% 6.09% 3.19% 7.75% 





HQC 10.7% 6.70% 6.40% 9.00% 6.10% 
MQC 6.40% 6.90% 5.90% 6.80% 6.10% 
LQC 6.70% 8.50% 9.20% 7.50% 9.30% 
LLOQ 12.0% 11.5% 16.6% 13.7% 16.0% 
 60 
 
2.3.4 Validation of the CYP cocktail assay experimental system  
Typically, a reliable in vitro CYP inhibition study should be conducted under a linear 
condition, where the formation of a metabolite is linearly correlated with the enzyme concentration 
and incubation time. High microsomal protein might complicate data interpretation, such as non-
specific binding. Based on the FDA recommendation, the protein concentration should no more 
than 1mg/ml. Industrial scientists have suggested using a microsomal protein concentration as low 
as feasible (Obach 1997). We chose 0.1 mg protein/ml in our assay based on the reported values 
used in most of the literature.  
We adopted the incubation conditions including protein amount, incubation time, substrate 
concentration from the most often reported values in the literature. The assay was partially 
validated by comparing the metabolite formation rates from our study to published literature values 
(Table 2.5). Broad inhibition with pan-inhibitor miconazole (3 µM) was observed (Table 2.5). Our 
assay results were generally consistent with the published data (Liu et al. 2015, Chen et al. 2016).  












by miconazole  
CYP1A2 Phenacetin 295 ± 20.0 162 ± 3.00 51.8 ± 2.95% 
CYP2C9 Diclofenac 198 ± 37.0 155 ± 1.09 91.6 ± 1.05% 
CYP2C19 S-Mephenytoin 11.1 ± 3.75 15.0 ± 0.70 99.6 ± 0.32 % 
CYP2D6 Dextromethorphan 71.0 ± 14.6 87.8 ± 4.10 56.7 ± 1.43% 
CYP3A4 Midazolam 249 ± 41.0 280 ± 1.32 95.5 ± 0.32 % 
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2.3.5 Chromatography and specificity for UPMP107 and 20-HETE 
The goal of developing an analytical method for a novel 20-HETE formation inhibitor - 
UPMP107 is to evaluate its amount in biological samples for subsequent pharmacokinetic or 
pharmacodynamic study. We evaluated the solid phase extraction sample processing method and 
developed a UPLC-MS/MS method to quantify UPMP107. The advantage of this assay is the 
application of the same mobile phase as AA metabolite quantification, which can improve the 
sample processing and quantification efficiency. Figure 2.3 displays typical chromatographs of 
UPMP107 and 20-HETE along with the internal standards SMIP004 and 20-HETE-d6.   
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Figure 2.3 Chromatograms of (A) blank, (B) UPMP107, (C) SMIP004, (D) 20-HETE, and 
(E) 20-HETE-d6 in plasma and brain samples 
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2.3.6 UPLC-MS/MS method validation for UPMP107  
The calibration standards ranged from 12.5 to 1500 pg on column. The QC levels are listed 
in Table 2.6. A weighting factor of 1/Y was placed on the calibration curve. The calibration curves 
showed good linearity in the concentration range for each metabolite (R2 > 0.995). The accuracy 
of each standard level in the calibration curve meets the recommended limits (85-115%) and 
LLOQ meet the 80-120% limit shown in Table 2.6.  
The within-day and between-day precisions were below 14% and 18%. The precision for 
LLOQ was < 20%, the accuracy obtained from LLOQs was within 80-120%.  
Table 2.6 UPMP107 validation data: within-day precision, between-day precision and 
accuracy (n=5) 
    Levels UPMP107 20-HETE 
Within-day Accuracy  
HQC 900 6.22% -0.11% 
MQC 450 0.25% -0.49% 
LQC 40 0.33% -1.02% 
LLOQ 12.5 4.68% -2.08% 
Between-day accuracy  
HQC 900 2.97% -2.32% 
MQC 450 0.59% -0.83% 
LQC 90 3.29% -1.51% 
LLOQ 12.5 8.92% 7.74% 
Within-day precision 
(%RSD) 
HQC 900 4.71% 4.47% 
MQC 450 6.19% 2.24% 
LQC 90 4.46% 7.29% 
LLOQ 12.5 9.09% 13.7% 
Between-day precision 
(RSD%) 
HQC 900 8.88% 6.87% 
MQC 450 14.8% 2.45% 
LQC 90 10.2% 5.74% 
LLOQ 12.5 11.3% 17.5% 
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2.4 Discussion and conclusions 
In this chapter, we developed three bioanalytical assays to support the early stage 
characterization and profiling of novel compounds. The employment of the assays will be used for 
metabolic stability evaluation, drug-drug interaction evaluation, and quantification of a preclinical 
candidate. These assays are integral parts of DMPK evaluation and can aid decision-making for 
NCEs advancement. 
We developed a metabolic stability assay in HLM and UPLC-MS/MS method to enable 
fast screening of the in vitro clearance for NCEs. Drug metabolism can be classified as phase I and 
phase II, where phase I reactions like oxidation, reduction, and hydrolysis, which provide 
metabolites that may then get conjugated with glucuronic acid to increase water solubility during 
phase II reactions by enzymes, such as UDP-glucuronyl transferases (Sheweita 2000). Metabolic 
stability can be evaluated in liver microsomes or hepatocytes. Microsomes are commonly used 
systems for CYP-mediated phase I metabolism. Hepatocytes contain intact cell organelles that can 
be used to evaluate both phase I and phase II metabolism in a relatively more physiologically 
relevant system (Baranczewski et al. 2006). Regardless of the testing systems, the results generated 
from the assay include in vitro intrinsic clearance and in vitro half-life, which can be used to scale 
to in vivo intrinsic clearance using scaling factors (Bowman et al. 2019). The use of an in vitro 
drug metabolism approach to predict in vivo PK parameters has been widely practiced in the 
pharmaceutical industry. Compounds can be ranked based on their half-life or clearance values. 
Molecules demonstrating a low in vitro clearance and a prolonged in vitro half-life are favorable 
since they may be removed from the body slowly to ensure an adequate exposure for therapeutic 
effect. We acknowledge the limitation of using HLM as the testing system. However, in drug 
discovery, microsomes are more convenient for screening assays due to their commercial 
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availability and long storage time. Our metabolic stability assay obtains data at multiple time points 
throughout a 60-min incubation period. The data at multiple time points increased the 
predictability of in vitro half-life and the long incubation duration is able to differentiate stable 
compounds from unstable compounds. The limitation for a longer incubation duration is the lack 
of information to differentiate unstable compounds that may have half-lives shorter than 5 min (Di 
et al. 2004). Since our goal is to identify compounds with high metabolic stability, a 60-min 
incubation duration is deemed reasonable. The assay will be applied to test metabolic stability for 
novel molecules to ensure the selection of optimal compounds for further evaluation as well as 
guiding the design of compounds with improved metabolic stability properties. 
We transferred an in vitro CYP cocktail assay in our lab and developed a UPLC-MS/MS 
method to assess the potential of drug-drug interaction for NCEs on five drug metabolizing CYP 
enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). Drug interactions can have a 
significant impact on the efficacy and safety of drugs. Polypharmacy is common in clinical practice 
and is more pronounced in critically ill patients, where there is a potential for drug-drug 
interactions (DDIs) (Dai et al. 2016). Therefore, evaluation of potential DDIs during early drug 
development can provide essential information on specific pathways to guide future clinical DDI 
studies (Tornio et al. 2019). HLM is a useful in vitro system to evaluate DDIs for molecules during 
early drug development (FDA 2017). Traditionally, DDI studies have been performed with 
individual CYP450 isoform. However, this approach is time-consuming and costly. A cocktail 
method by incubating several probe substrates simultaneously decreases the time and money costs. 
One of the major concerns in the cocktail assay is substrate interactions. CYP enzyme activities 
will be compromised as a result of potential substrate interactions. The probe substrate 
concentrations were selected below the reported Km values to ensure the reaction falls within the 
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linear formation range. The lower concentrations of substrates also decrease the interactions in the 
cocktail assay (Spaggiari et al. 2014). We selected a 5-in-1 cocktail since CYP1A2, 2C9, 2C19, 
2D6, and CYP3A4 account for the metabolism of approximately 90% of drugs (Lynch et al. 2007). 
Phenacetin was selected for CYP1A2 because of its specificity and it is the most often used 
substrate in other studies. Tolbutamide and diclofenac are frequently used probe substrates for 
CYP2C9. Bufuralol and dextromethorphan are commonly used probe substrates for CYP2D6. 
Although either probe substrate can be used, we selected diclofenac 4’-hydroxylation and 
dextromethorphan O-demethylation for CYP2C9 and 2D6 as these reactions were more frequently 
used in published papers (Spaggiari et al. 2014). For CYP2C19, we selected the FDA preferred 
probe substrate (S)-mephenytoin. For CYP3A4, we selected midazolam as recommended by the 
FDA (FDA 2020). The addition of chlorzoxazone doubled the run time due to its negative SRM 
mode for mass spectrometry quantification and unsatisfactory results with rapid polarity switching. 
Therefore, chlorzoxazone was not included in the cocktail. A limitation of the cocktail assay is 
that we did not conduct a full validation. An ideal full validation requires the determination of Km 
values within the laboratory, testing the incubation conditions to ensure linear formation of the 
metabolites, and comparing cocktail formation rates with the individual incubation formation rates 
to validate the minimal interaction between substrates. In this method transfer between reported 
literature and our laboratory, we partially validated the assay by comparing the metabolite 
formation rates with published values. The overall less than 2-fold difference in enzymatic activity 
suggested the analytical method transfer was successful (Table 2.5). We also developed and 
validated a UPLC-MS/MS method to measure metabolites in the cocktail assay that meet the FDA 
recommendations. The quantification of metabolites was completed by a precise, sensitive, and 
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accurate UPLC-MS/MS method. The developed assay will be used to screen DDI potentials for 
novel molecules. 
Herein, we reported the development and validation of a simple UPLC-MS/MS method for 
UPMP107 and 20-HETE quantification with good linearity, sensitivity, accuracy, and precision. 
This is the first method for UPMP107 quantification and will be applied to a pharmacokinetic 
study in Sprague-Dawley rats to measure UPMP107 and 20-HETE concentrations in biological 
samples. In conclusion, we have developed three assays that would be employed to evaluate the 
preclinical profile of novel 20-HETE formation inhibitor compounds.    
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3.0 In vitro Evaluation of Novel Compounds: Discovery of UPMP107 as a Potent and 
Selective Inhibitor of 20-HETE Synthesizing Enzymes 
3.1 Introduction  
Greater than 50% of survivors who were successfully resuscitated from cardiac arrest have 
neurological disabilities, which is the major limiting factor for full recovery (Iordanova et al. 
2017).  Alterations of cerebral blood flow (CBF) have been reported in both humans and various 
animal models after cardiac arrest. Post-cardiac arrest CBF disturbance can be classified into three 
stages. The initial stage is the absence of flow during cardiac arrest and cardiopulmonary 
resuscitation. The second stage is cerebral hyperemia that usually occurs at 5- 30 min after 
resuscitation following the return of spontaneous circulation. The last stage is cerebral 
hypoperfusion that occurs at 30 min – 6 h after hyperemia (Buunk et al. 2000). CBF-directed 
therapies have shown promising results in various animal species after cardiac arrest, encouraging 
the discovery and development of relevant molecules targeting specifically at the hypoperfusion 
phase of CBF alteration (Li 2019). 
20-hydroxyeicosatetraenoic acid (20-HETE), a major metabolite of arachidonic acid (AA), 
plays a key role in CBF autoregulation by constricting brain arteries (Gebremedhin et al. 2000, 
Kehl et al. 2002). The formation of 20-HETE is catalyzed by cytochrome P450 (CYP) 4A and 4F 
enzymes in rats and humans (Ito et al. 1998, Powell et al. 1998). Elevations in 20-HETE 
concentrations contribute to the acute fall of CBF, neuronal toxicity, and delayed vasospasm after 
experimental ischemic stroke and subarachnoid hemorrhage (Kehl et al. 2002, Roman et al. 2006, 
Yang et al. 2012). The protective effect of 20-HETE inhibition is not only contributed by the 
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improvement in cerebral perfusion and cerebral blood flow, but also in the reduced brain edema, 
decreased blood-brain-barrier (BBB) leakage, and direct neuron protection (Poloyac et al. 2006, 
Lee et al. 2011, Renic et al. 2012, Shaik et al. 2015, Lu et al. 2018). Several studies in humans 
revealed the unfavorable role of 20-HETE where increased CSF 20-HETE levels are associated 
with delayed cerebral ischemia, poor neurological outcomes, and three-fold higher mortality in 
subarachnoid hemorrhage patients and plasma 20-HETE has found to be a predictor of 
neurological deterioration in acute minor ischemic stroke. (Crago Elizabeth et al. 2011, Donnelly 
et al. 2015, Yi et al. 2016). Therefore, developing therapies targeting 20-HETE formation is a 
promising approach to improve CBF after cardiac arrest.  
Despite a number of efforts in medicinal chemistry, computational chemistry, and 
repurposing from natural products, no molecule that inhibits 20-HETE formation is in the clinical 
development stage. Figure 3.1 displays several currently available molecules that reported to 
inhibit 20-HETE formation in the literature. Available compounds have either unfavorable 
physicochemical properties or lack proper pharmacokinetic properties. Natural products like 
sesamin and resveratrol require large doses to inhibit 20-HETE (Wu Jason et al. 2009). Some 
arachidonic acid analogs like 17-ODYA nonselectively inhibit 20-HETE and EETs formation 
(Sato et al. 2001). Potent and selective inhibitors such as HET0016 and TS-011 are hampered by 
either fast metabolism or low water solubility (Mu et al. 2008). Therefore, there is a pressing need 
for the discovery and development of novel clinical viable 20-HETE formation inhibitors.  
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Figure 3.1 Representative examples of 20-HETE formation inhibitors 
To identify compounds that overcome the disadvantages of previously reported molecules 
and identify preclinical candidates with improved physicochemical and pharmacokinetic 
characteristics, we proposed a tiered approach for screening and assessing novel compounds (Fig. 
3.2). Tier 1 encompasses in silico assessment of physicochemical properties of designed 
compounds for being within a range seen in other central nervous system (CNS) acting drugs. Tier 
2 involves the single concentration screening of synthesized compounds to evaluate their ability 
to inhibit 20-HETE formation in three types of microsomes. Tier 3 includes a more thorough in 
vitro evaluation, where compounds were subjected to various in vitro assays to assess potency, 
selectivity, solubility, metabolism, CYP inhibition, brain penetration, and in vitro toxicology. 
Successful compounds that met the criteria set for each of the steps in Tier1 to 3 would be 
considered as preclinical candidates. The evaluation from Tier 1 to Tier 3 is iterative. The best 
compounds that meet all criteria would be selected and be taken forward to Tier 4 in vivo 
pharmacokinetic and pharmacodynamic evaluation. Upon demonstration of good in vivo PK and 
target engagement in the brain, preclinical candidates would be assessed in a pediatric cardiac 
arrest injury model to test in vivo neuroprotective effects. Compounds would advance through tiers 
if they satisfy benchmarks in prior tiers.  By applying this tiered evaluation approach, it ensures 
the efficient use of resources to select compounds. Specifically, in Tier 3, compounds that did not 
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meet the criteria for any single assay would be considered to be precluded from the preclinical 
candidate pool. Therefore, not every compound that entered Tier 3 was tested in all the proposed 
assays. With the data we obtained throughout the tiered evaluation, we present a decision tree in 
section 3.3.5 to illustrate the selection of a preclinical candidate to be advanced to in vivo 
evaluation. 
  
Figure 3.2 A tiered approach to evaluate novel compounds  
The purpose of this study is to identify novel 20-HETE formation inhibitors with strong 
potency, CYP4 selectivity, improved physicochemical and pharmacokinetic properties compared 
to currently available molecules. The key objective is to identify a 20-HETE formation inhibitor 
that could have a high probability of advancement into clinical development as a neuroprotective 
agent. Here, we report the preclinical evaluation of a library of novel small molecules and the 
discovery of UPMP107, a novel 20-HETE formation inhibitor that fulfilled all criteria from Tier 
1 to 3. This novel 20-HETE formation inhibitor is a promising preclinical candidate. It has (1) 
strong potency against 20-HETE formation; (2) high selectivity for CYP4 enzymes over CYP1A2, 
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2C9, 2C19, 2D6, 3A4, and epoxygenases; (3) low in vitro intrinsic clearance in human liver 
microsomes; (4) good in vitro BBB penetration in MDCK-MDR1 assay with (6) no safety flags 
when assessed at 10 µM in the in vitro Cerep SafetyScreen44 panel.  
3.2 Materials and methods  
3.2.1 Materials  
Novel compounds UPMP001-143 were designed and synthesized in the lab of our 
collaborator Dr. Lee McDermott (School of Pharmacy, University of Pittsburgh). Stock standards 
of (±)5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid (5,6-DiHET), (±)8,9-dihydroxy-5Z,8Z,14Z-
eicosatrienoic acid (8,9-DiHET), (±)11,12-dihydroxy-5Z,8Z,14Z-eicosatrienoic acid (11,12-
DiHET), (±)14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic acid (14,15-DiHET), (±)8(9)-epoxy-
5Z,11Z,14Z-eicosatrienoic acid (8,9-EET), (±)11(12)-epoxy-5Z,8Z,14Z-eicosatrienoic acid 
(11,12-EET), (±)14(15)-epoxy-5Z,8Z,11Z-eicosatrienoic acid (14,15-EET), 20-hydroxy-
5Z,8Z,11Z,14Z-eicosatetraenoic acid (20-HETE), 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic-
16,16,17,17,18,18-d6 acid (20-HETE-d6), 12S-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic acid 
(12-HETE), 15S-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid (15-HETE) and arachidonic acid 
(peroxide free) were purchased from Cayman Chemical (Ann Arbor, MI). Spectrophotometric 
grade dimethyl sulfoxide (DMSO) was purchased from Sigma-Aldrich (Milwaukee WI), high 
purity methanol (MeOH), ethyl ether, acetic acid, and other solvents were purchased from Fisher 
Scientific (Pittsburgh, PA). (±)-Metoprolol (+)-tartrate, (±)-verapamil hydrochloride and warfarin 
were purchased from Sigma-Aldrich (St. Louis, MO). Acetaminophen, phenacetin, and diclofenac 
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were purchased from Fisher Scientific (Pittsburgh, PA). S-mephenytoin, 4’-hydroxydiclofenac, s-
hydroxymephenytoin, dextromethorphan, dextrorphan, midazolam, 1’-hydroxymidazolam, and 
miconazole were purchased from Toronto Research Chemicals (Ontario, Canada). 
Acetaminophen-d4, dextrorphan-d3, 4’-hydroxymephenytoin-d4, midazolam-d4, and diclofenac-
d3 were purchased from Cerilliant (Round Rock, TX). Human liver microsome (HLM), rat liver 
microsomes (RLM), and recombinant CYP4F2 (rCYP4F2) were purchased from Sekisui Xenotech 
(Lenexa, KS). 
3.2.2 Methods 
3.2.2.1 In vitro screening: AA metabolism 
3.2.2.1.1 Incubation conditions 
To screen the inhibitory effects against 20-HETE formation, compounds were tested in 
three different types of microsomes, including HLM, RLM, and rCYP4F2. Compounds were 
dissolved in DMSO to yield 10 mM stock solutions. Microsomal incubation conditions were 
previously optimized. Microsomal incubations contained HLM, RLM (300 μg/ml) or rCYP4F2 
(25 pmol/ml), AA (100 μM), NADPH (1 mM) and test compounds at 500nM in a 1ml microsomal 
incubation buffer (0.12 M potassium phosphate buffer containing 5mM magnesium chloride). 
Each compound had three replications (n=3). Vehicle group was used as control to calculate the 
percentage of eicosanoids formation rates. HET0016 (250 nM) was the positive control. Incubates 
without NADPH were the negative control. Reaction was started by adding NADPH to the 
incubates and was carried out at 37°C in a shaking water bath for 20 min. Reaction was stopped 
by placing tubes on ice, followed by adding 12.5 μl 20-HETE-d6 as internal standard. Microsomal 
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incubations were extracted with 3 ml ethyl ether, dried down under nitrogen gas and reconstituted 
in 125 μl 80:20 methanol: deionized H2O for analysis. 20-HETE formation was quantified using a 
validated UPLC-MS/MS assay and normalized by vehicle group (Miller et al. 2009).  
3.2.2.1.2 Chromatographic Analysis 
An Acquity ultra performance LC autosampler (Waters, Milford, MA) was used to separate 
HETEs, EETs, and DiHETs on a UPLC BEH C18, 1.7 μm (2.1 × 100 mm) reversed-phase column 
(Waters, Milford, MA) protected by a guard column (2.1 × 5 mm; Waters, Milford, MA). Column 
temperature was maintained at 55° C. Mobile phases consisted of 0.005% acetic acid, 5% 
acetonitrile in deionized water (A) and 0.005% acetic acid in acetonitrile (B). The flow rate was 
0.5 ml/min. The initial mixture of mobile phase was 65: 35 of A: B. Mobile phase B increased at 
0.4 minutes after injection from 35% to 70% in a linear gradient over 4 minutes, and again 
increased to 95% over 0.5 minutes where it remained for 0.3 minutes. This was followed by a 
linear return to initial conditions over 0.1 minutes with a 1.5 minutes pre-equilibration period prior 
to the next sample run. Total run time was 6.4 minutes for each injection. Injection volumes were 
7.5μl. Mass spectrometric analysis was carried out using a TSQ Quantum Ultra (Thermo Fisher 
Scientific, San Jose, CA) triple quadrupole mass spectrometer using heated electrospray ionization 
(HESI). Mass spectrometer was operated in negative selective reaction monitoring (SRM) mode. 
Quantitation of HETEs, EETs, and DiHETs by SRM was performed by monitoring their m/z 
transitions listed in Table 3.1. Analytical data were acquired and analyzed using Xcaliber 3.0 data 
system (ThermoFinnigan, San Jose, CA). 
Table 3.1 Analytical parameters of eicosanoids 
Compound Precursor-product (m/z) Collision energy (V) Retention time (min) 
20-HETE 455.3-165.0 27 2.68 
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3.2.2.1.3 Data analysis  
Screening data were presented as % of control. No statistical test was performed. 
3.2.2.2 Potency assessment  
To test the in vitro potency, stock solution (10 mM) was serial diluted into 12 
concentrations (0.1-50000 nM). Each concentration has three replicates. Incubations were 
performed with compounds of different concentrations in HLM or RLM (300 μg/ml) with AA 
(100 μM) and NADPH (1 mM). IC50 values were derived from the concentration-response curve 
by fitting nonlinear regression Y=100/(1+10^((LogIC50-X)×HillSlope))).  
3.2.2.3 Selectivity assessment  
Other eicosanoids from AA metabolism pathways including 15-, 12-HETEs, 8,9-, 11,12-, 
14,15-EETs, and 5,6-, 8,9-, 11,12-, 14,15-DiHETs were quantified by UPLC-MS/MS 
simultaneously (Table 3.1). Selectivity of CYP4 over EETs and DiHETs was presented as CYP450 
activity by calculating the total formation rates of three EETs and four DiHETs and presented as 
% of control. IC50 values for EETs and DiHETs formation were not obtained due to lack of 
inhibitory activity within the concentrations tested.   
15-HETE 268.0-116.2 20 2.08 
12-HETE 309.1-163.3 20 3.41 
8,9-EET 286.3-254.3 18 2.87 
11,12-EET 286.1-254.2 18 2.29 
14,15-EET 286.2-254.4 20 2.91 
5,6-DiHET 286.3-254.3 20 2.32 
8,9-DiHET 244.1-150.3 26 2.42 
11,12-DiHET 286.2-126.2 14 2.44 
14,15-DiHET 242.1-96.2 26 3.20 
20-HETE-d6 242.2-150.2 20 2.51 
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3.2.2.4 Metabolic stability assay 
3.2.2.4.1 Incubation conditions 
Metabolic stability assays were conducted in HLM as previously described (Chapter 2). In 
brief, HLM (0.5 mg/ml), test compounds (1 μM), and NADPH (1.3 mM) were incubated in 
microsomal incubation buffer. Reaction was started by adding NADPH and was carried out at 
37°C in a shaking water bath for 60 min. A 50 μl aliquot of incubates was removed at 0, 15, 30, 
45, 60 min and reaction was stopped by adding aliquot into 200 μl ice-cold acetonitrile. After 
centrifugation at 14000×g for 5 min, 200 μl supernatant was removed for UPLC-MS/MS analysis.  
3.2.2.4.2 Chromatographic analysis  
Detailed information on chromatographic analysis is presented in Chapter 2. The liquid 
chromatographic analysis can be found in section 2.2.2.4. The transitions for mass spectrometric 
analysis are listed in section 2.2.2.5, Table 2.1.   
3.2.2.4.3 Data analysis 
Using the t = 0 peak area as 100%, the percentage remaining at each time point was 
calculated. In vitro half-life is calculated based on the assumption of compound metabolism 
following first-order kinetics. The log percentage remaining verses incubation time was plotted, 
and the slope was calculated (Equation 3.1.1). The half-life was calculated according to Equation 
3.1.2. The equation for in vitro intrinsic clearance is shown in equation (3.1.3-3.1.4). Estimates of 
in vivo PK parameters can be obtained by in vitro-in vivo extrapolation (IVIVE) by equation 
(3.1.5-3.1.6). MPPGL is a scaling factor that represents the microsomal protein per gram of liver 
(40 mg/g). Liver weight is 20 g/kg of body weight.  
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Elimination rate constant (k) =  −𝑠𝑙𝑜𝑝𝑒 (Equation 3.1.1) 
Half − life (𝑇1/2)  =  
0.693
𝑘




) =  
𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 (𝜇𝑙)
𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑖𝑛 𝑡ℎ𝑒 𝑖𝑛𝑐𝑢𝑏𝑎𝑡𝑖𝑜𝑛 (𝑚𝑔)
 (Equation 3.1.3) 
𝐼𝑛 𝑣𝑖𝑡𝑟𝑜 intrinsic clearance (𝐶𝐿𝑖𝑛 𝑣𝑖𝑡𝑟𝑜,𝑖𝑛𝑡)(
𝜇𝑙/𝑚𝑖𝑛
𝑚𝑔 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
) =  
𝑉×0.693
𝑇1/2
 (Equation 3.1.4) 
𝐼𝑛 𝑣𝑖𝑣𝑜 intrinsic clearance (𝐶𝐿𝑖𝑛 𝑣𝑖𝑣𝑜,𝑖𝑛𝑡) =  𝐶𝐿𝑖𝑛 𝑣𝑖𝑡𝑟𝑜,𝑖𝑛𝑡 × 𝑀𝑃𝑃𝐺𝐿 × 𝑙𝑖𝑣𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (Equation 
3.1.5) 
ℎ𝑒𝑝𝑎𝑡𝑖𝑐 𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 (𝐶𝐿𝐻) =   
𝐶𝐿𝑖𝑛 𝑣𝑖𝑣𝑜,𝑖𝑛𝑡×𝑄𝐻×𝑓𝑢
𝐶𝐿𝑖𝑛 𝑣𝑖𝑣𝑜,𝑖𝑛𝑡+𝑓𝑢×𝑄𝐻
 (Equation 3.1.6) 
3.2.2.5 CYP inhibition assay  
3.2.2.5.1 Incubation conditions 
CYP cocktail assay was performed as described in Chapter 2. In brief, incubations 
contained 20, 2.0, 40, 5, and 2µM of phenacetin, diclofenac, S-mephenytoin, dextromethorphan, 
and midazolam, respectively; 0.1 mg protein/ml of human liver microsomes; and 1 mM NADPH 
in 500 ul potassium phosphate buffer (pH 7.4, 3 mM MgCl2). The incubation was performed at 37 
˚C for 10 min. The reactions were terminated by adding 12.5ul ice-cold internal standard mixtures 
(Table 2.2). The samples were extracted with 1.5 ml diethyl ether, dried down under nitrogen gas, 
and reconstituted in 125 μl mobile phase for analysis. 
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3.2.2.5.2 Chromatographic analysis 
Chromatographic analysis was performed according to the method developed in Chapter 
2. Detailed liquid chromatography method is provided in section 2.2.2.4. The mass spectrometric 
conditions for metabolites quantification are presented in section 2.2.2.5, Table 2.2. 
3.2.2.5.3 Data analysis 
DMSO was used as vehicle control. Formation rates were presented as % of vehicle 
control. 
3.2.2.6 Solubility assay 
Aqueous solubility was measured by Dr. Lawrence Vernetti at Drug Discovery Institute, 
University of Pittsburgh. A stock DMSO solution of the test compound was serial diluted to 
produce a range of concentrations. The final solutions were incubated in 0.01 M phosphate 
buffered saline (pH 7.4) for 2hr at 37 ˚C. The absorbance at 620 nm was read for each sample at 
the end of the incubation period. Data are presented as mean ± std.  
3.2.2.7 MDCK-MDR1 assay 
Madin-Darby Canine Kidney (MDCK)-MDR1 assay was performed by Absorption 
Systems (Exton, PA) (Absorption Systems 2020). In brief, MDCK-MDR1 cells were grown to 
confluence on microporous membranes. Compound (5 µM) was added to the apical side to 
measure the apical to basolateral (A to B) transport or to basolateral well to measure basolateral to 
apical (B to A) transport and incubated at 37˚C with 5% CO2 in a humidified incubator. Samples 
were collected from both apical and basolateral wells at 120 min (n=3) and then analyzed using 
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𝑑𝑡⁄  is the rate 
of permeability, C0 is the initial concentration in the donor compartment, and A is the surface area. 
The efflux ratio (ER) was calculated as ER = 
𝑃𝑎𝑝𝑝𝐵−𝐴
𝑃𝑎𝑝𝑝𝐴−𝐵
.  A PappA-B ≥ 3.0 × 10
-6 cm/s and ER < 3.0 
is classified as high BBB penetration potential. A PappA-B ≥ 3.0 × 10
-6 cm/s and 3.0 ≤ ER < 10 is 
classified as moderate BBB penetration potential. A PappA-B ≥ 3.0 × 10
-6 cm/s and ER ≥ 10 or 
PappA-B < 3.0 × 10
-6 cm/s is classified as low BBB penetration potential.  
3.2.2.8 In vitro safety pharmacology profiling 
In vitro safety pharmacology evaluation was conducted by Eurofins Discovery in a 
SafetyScreen44, Cerep Panel (Celle-Lévescault, France) (Eurofins Discovery 2020). In brief, 
compound (10 µM) was tested for 38 binding assays including receptors, ion channels, transporters 
and six enzyme inhibition and uptake assays. The targets are primarily associated with well-
described cardiovascular, CNS side effects, and arachidonic acid metabolic enzymes COX1, 
COX2, etc. Compound binding was calculated as a % inhibition of the binding of a radioactively 
labeled ligand specific for each target. Compound enzyme inhibition was calculated as % of 
inhibition of control enzyme activity. An inhibition or stimulation greater than 50% is considered 
a significant effect for the test compound. An inhibition or stimulation between 25% - 50% is 
considered as a weak to moderate effect. An inhibition or stimulation of less than 25% is not 
considered significant (Eurofins Discovery 2020).  
 80 
3.2.2.9 Statistical analysis  
Data analysis for each assay is provided within each method section. One-way ANOVA 
was carried out and corrected with Bonferroni as post-hoc test. Values that are statistically 
significant are designated by asterisks (*, p < 0.05). 
3.3 Results 
3.3.1 Physicochemical property evaluation   
Several physicochemical properties are important for CNS drug design. Lipophilicity, 
calculated as the logarithm of octanol/water partition coefficient (clogP); number of rotatable 
bonds (NRB); number of hydrogen-bond donors (HBD); number of hydrogen-bond acceptors 
(HBA); polar surface area (PSA) and molecular weight (MW) are important attributes for small 
molecules (Rankovic 2015). Compounds with physicochemical properties of MW ≤ 450, logP ≤ 
3.5, PSA ≤ 70, HBD ≤ 3, HBA ≤ 7, NRB ≤ 5 are more likely to penetrate BBB (Pajouhesh et al. 
2005). All compounds evaluated were designed to have physicochemical properties within the 
range seen in CNS drugs, suggesting compounds may have a high probability of BBB penetration 
via passive diffusion (Pajouhesh et al. 2005).   
 
3.3.2 Hit identification through in vitro screening 
The initial goal was to identify novel scaffolds that exhibit 20-HETE formation inhibitory 
activity in HLM by screening a small library of compounds. Pyrazole derivative, 5-(4-
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butoxyphenyl)-1H-pyrazole (compound 24, Fig 1.2) was reported as a 20-HETE formation 
inhibitor in 2003. This compound has an IC50 value of 23 nM against 20-HETE formation in human 
kidney microsomes, good selectivity against other CYP enzymes and improved stability in an 
acidic environment compared to HET0016 (Nakamura et al. 2003). The replacement of the N-
hydroxyformamidine by the pyrazole led to a more stable compound without affecting the potency. 
Therefore, 5-(4-butoxyphenyl)-1H-pyrazole (compound 24) was viewed as a good starting point 
for novel compound development. The structure of compound 24 can be segmented into three 
sections, the right-hand side pyrazole, the middle section benzene ring, and the left-hand side 
butane chain (Fig. 3.3). Compound 24 is a potent 20-HETE formation inhibitor and has three 
possible sections for structure changes to generate new compounds. 
 
Figure 3.3 Compound 24 and possible positions for structure changes 
We screened a small early exploratory library of 20 novel compounds designed with 
various and diverse moieties as replacements for the moieties seen in the three possible positions 
of compound 24 that could be altered. Compounds were screened for 20-HETE formation 
inhibition at 250 nM in HLM, rCYP4F2, and RLM (Tang 2016). Our early objective was to 
identify potent leads quickly. Therefore, a concentration of 250 nM, 7-fold higher than the IC50 of 
HET0016 in HKM (35 nM), would seem like a reasonable starting point to achieve this objective. 
The amount of 20-HETE formation was used as a surrogate for compound activity. Ideal 
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compounds should display 20-HETE inhibition in HLM and exhibit inhibition in rCYP4F2, which 
confirms the target engagement of CYP4F2. Compounds that showed the greatest inhibition in 20-
HETE formation in HLM were selected as compounds of interest for further evaluation.  
Through the initial screen, we identified UPMP010 and UPMP019 as hit compounds 
(Tang 2016). Both UPMP010 and UPMP019 showed the greatest 20-HETE inhibition in HLM 
during screening at 250 nM (Table 3.2). They also demonstrated that the inhibitory effect was 
mediated by the inhibition of CYP4F2 in the rCYP4F2 microsomal system. Both compounds 
showed good in vitro potency in HLM (UPMP010: IC50 = 443 nM; UPMP019, IC50 = 187 nM.  
The difference between UPMP010 and UPMP019 was the link position of the pyrazole 
group with the phenyl pyridine moiety present in these compounds. Based on the potency in HLM, 
linking the phenyl piperidine moiety at the 4-position of the pyrazole appeared to lead to a 2-fold 
improvement in the inhibition of 20-HETE formation.  
Table 3.2 In vitro screening and potency evaluation of UPMP010 and UPMP019  
Compound Structure 











-b - - 23 ± 12a 
HET0016 
 
7.80 ± 2.72 1.70 ± 0.37 9.50 ± 2.60 8.9 ± 2.7a 
UPMP010 
 
46.4 ± 5.93 69.6 ± 3.15 86.5 ± 1.92 443 
UPMP019  18.7 ± 2.00 44.3 ± 1.22 - 187 
Number of replicate = 3/compound 
a The IC50 value was obtained from human kidney microsome. 
b “-” represents data not available.  
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3.3.3 Characterization of properties for hit compounds  
Properties including solubility, selectivity, and metabolic stability were assessed for 
UPMP010 and UPMP019. Both compounds displayed strong inhibition against the ω-
hydroxylase pathway (Fig. 3.4). There was a dose-dependent inhibition towards 20-HETE 
formation in HLM. Both compounds did not show inhibition towards the epoxygenase pathway in 
HLM within the range of concentrations tested. The estimated IC50 values for EETs/DiHETs 
formation were greater than 10 and 50 µM for UPMP010 and UPMP019, respectively.  
Both compounds had reasonable solubility. UPMP010 had kinetic solubility > 600 µM, 
and UPMP019 had solubility of 121 µM (Table 3.3). Both compounds were slowly metabolized 
in HLM. UPMP010 had 91.6% parent compound remaining at 30 min. UPMP019 did not show 
disappearance of the parent compound at 30 min (Fig. 3.5). 




IC50 (nM) in HLM 
% compound 
remain in HLM 






24 23a 35 333 - 
HET0016 11.5 4.0 163 2.8 µM 
UPMP010 443 91 > 600  > 50 µM 
UPMP019 187 100 121  > 10 µM 
a The IC50 of compound 24 was measured in human kidney microsome. 
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Figure 3.4 Selectivity of 20-HETE formation inhibition versus EETs/DiHETs formation 
inhibition for UPMP010 and UPMP019 
The formation rates of 20-HETE, EETs and DiHETs were used to represent CYP450 
activity. The formation rates are presented as percent of the control of the vehicle group. 
UPMP010 and UPMP019 inhibit 20-HETE formation in a concentration-dependent manner. Both 
compounds did not inhibit EETs and DiHETs formation.  
 
 
Figure 3.5 Metabolic stability for compound 24, UPMP010, and UPMP019  
UPMP010 and UPMP019 were slowly metabolized in HLM. HLM incubation of 
UPMP010 and UPMP019 had 91.4 ± 11.0% and 100 ± 1.73% remaining at 30 min, respectively. 
One-way ANOVA was performed to compare the remaining parent compound at 30 min between 
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UPMP010, UPMP019 and compound 24. The remaining compound of UPMP010 and UPMP019 
was significantly greater than compound 24 of 35.1 ± 5.66%. 
 
To summarize, in the initial screening, we identified two compounds UPMP010 and 
UPMP019, with good 20-HETE inhibitory activity, large selectivity window against the 
epoxygenase pathway, good solubility, and low phase I metabolism. Therefore, UPMP010 and 
UPMP019 were chosen as hit compounds for further optimization to generate more analogs.  
An updated screening concentration was set at 500 nM. This concentration would increase 
the potential candidate pool, allowing us to select and study structurally different compounds to 
understand the structural need for 20-HETE formation inhibition. For the evaluation and 
advancement of novel UPMP010 and UPMP019 derivatives, the criteria for Tier 2 - in vitro 
screening were a greater than 50% inhibition of 20-HETE formation (< 50% 20-HETE remaining) 
in HLM and a greater than or equal to 40% inhibition of 20-HETE formation (≤ 60% 20-HETE 
remaining) in RLM. The criteria were set for both HLM and RLM, which would allow us to 
develop molecules in a preclinical animal model in rats. Compounds that meet both HLM and 
RLM criteria would be advanced to Tier 3 selected assays to generate data that could help 
understand how structure changes could affect selected properties. In Tier 3, the criteria for 
potency, solubility, selectivity, metabolic stability, BBB permeability, and in vitro safety 
pharmacology for derivatives are presented in Table 3.4. The potency should be less than or equal 
to 100 nM in HLM. Although an IC50 less than compound 24 is desired, we viewed that compounds 
with good biopharmaceutical and drug-like properties with a slightly higher IC50 would also be 
attractive for in vivo development. Thus, a 100 nM for potency was deemed an acceptable cut-off 
value. The solubility for compounds to advance should be greater than or equal to 400 µM. A high 
solubility would allow the flexibility in designing dosage form and the dosage required to achieve 
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desired concentration in the systemic circulation. The selectivity of 20-HETE versus EETs, or the 
selectivity of CYP4 inhibition versus other drug-metabolizing CYP isoforms should be greater 
than 100-fold. This would allow a wide therapeutic window, where increasing the dose of the 
inhibitor will not affect EETs formation or affect drug metabolism by other CYP isoforms. For 
metabolic stability, the remaining parent compound at 30 min should be greater than or equal to 
80%. This cut-off value was chosen to identify stable compounds (T1/2 > 90 min) with a low in 
vitro clearance. For BBB permeability assessed in MDCK-MDR1 cell lines, the PappA-B should 
be greater than 3×10-6 cm/s, and ER should be less than 10. Compounds that meet these criteria 
are predicted to have moderate to high brain penetration. Lastly, the in vitro safety pharmacology 
criteria were inhibition or stimulation less than 50% at 10 µM in the transporters, ion channels, 
and enzymes tested in the Cerep Safetyscreen44 Panel. This cut-off value would identify 
compounds that may have effect on receptors, ion channels, or enzymes that could potentially lead 
to undesired side effects. A greater than 50% inhibition or stimulation would require further 
investigation for IC50 determination for that specific target.  
Table 3.4 Criteria for Tier 1-3 to evaluate compound  
Drug-like property Criteria 
Physicochemical properties 
MW ≤ 450, cLogP ≤ 3.5, TPSA ≤ 70, HBD ≤ 3, HBA ≤ 
7, NRB ≤ 5 
Screening 
% of inhibition > 50% in HLM, % of inhibition > 40% in 
RLM 
Solubility ≥ 400 µM 
Potency IC50 ≤ 100 nM in HLM 
Selectivity IC50 for EETs/DiHETs ≥ 100-fold IC50 for 20-HETE  
Metabolic stability HLM stability ≥ 80% at 30 min 
CYP inhibition 
IC50 for CYP isoforms ≥ 100-fold IC50 for 20-HETE;  
Or IC50 for CYP isoforms > 1000 nM 
BBB permeability PappA-B>3×10-6 cm/s, ER < 3 or 3 < ER < 10 
In vitro safety pharmacology 
(CEREP panel) 
Inhibition (or stimulation) < 50% at 10 µM  
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3.3.4 Lead optimization  
3.3.4.1 Potency evaluation of UPMP010 and UPMP019 derivatives 
After confirmation of the selectivity, metabolic stability, and solubility of UPMP010 and 
UPMP019, we conducted in vitro evaluation for synthesized derivatives of both compounds. 
In a small subset of derivatives in which the phenyl is directly linked to piperidine and 
when there is a single simple non-halogen substitution on the phenyl group, we observed a trend 
that seems to suggest that linking the piperidine moiety at the 4-position of the pyrazole increases 
20-HETE formation inhibition compared to linking at the 5-position (Table 3.5). This trend seemed 
to be consistent with the finding that UPMP019 had a stronger inhibitory activity than UPMP010.  
Table 3.5 CYP4 inhibition of analogs with single substituion on benzene  
 












010 - 443 019 - 187 
027 4-OMe 143 031 4-OMe 73.4 
028 3-OMe 194 029 3-OMe 169 
041 2-OMe >500a 042 2-OMe >500 
037 4-COOMe >500 038 4-COOMe >500 
039 3-COOMe >500 040 3-COOMe >500 
046 4-Me 111 047 4-Me 78.8 
081 3-Me 177.8 077 3-Me 111.5 
080 2-Me >500 078 2-Me 647 
049 4-ethylsulfonyl 107 048 4-ethylsulfonyl 80.3 








062 4-acetamide 173 072 4-acetamide 45.8 
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The data presented in Table 3.5 for simple non-halogen derivatives of UPMP010 and 
UPMP019 suggested that the 4-methoxy derivatives (UPMP027, IC50 = 143 nM; UPMP031, IC50 
= 73.4 nM) were ~3 and ~2.5-fold more potent compared to UPMP010 and UPMP019. Moving 
methoxy to 3-position on the phenyl (UPMP028, IC50 = 194 nM; UPMP029, IC50 = 169 nM) led 
to ~1.4 to ~ 2.3-fold less active compounds compared to 4-methyloxyl derivatives, but they had 
improved activities compared to hit compounds UPMP010 and UPMP019. When the methoxy 
group was at the 2-position on the phenyl, this let to UPMP041 and UPMP042 that were markedly 
less active (IC50 > 500 nM). We found 4-methyl derivatives (UPMP046, IC50 = 111 nM; 
UPMP047, IC50 = 73.4 nM) to have comparable activity to UPMP027 and UPMP031. A similar 
trend of decrease in activity was seen when moving methyl group from 4- to 3-, and 2-position on 
benzene (UPMP081, UPMP077 and UPMP080, UPMP078). An interesting result was that 
substitution with methyl acetate moiety (UPMP037, UPMP039, UPMP038, and UPMP040) 
negated CYP4 inhibitory activity in HLM. In vitro screening in rCYP4F2 suggested UPMP037, 
UPMP039, UPMP038, and UPMP040 have inhibitory activity in rCYP4F2 and followed the 
trend of 4-position > 3-position (data not shown here). The loss of activity in HLM could be 
attributed to the hydrolysis of methyl acetate by esterase in the HLM, whereas rCYP4F2 is a 
purified system with no esterase in presence, leaving compounds intact. In this small set of 
derivatives of UPMP010 and UPMP019, we found that para- substitution induced the greatest 
activity improvement followed by meta-, whereas ortho- substitution was less tolerated. Other 
derivatives with substituents at 4-position such as ethylsulfonyl (UPMP049, IC50 = 107 nM; 
UPMP048, IC50 = 80.3 nM) and acetamide (UPMP062, IC50 = 107 nM; UPMP072, IC50 = 45.8 
nM) resulted in a more than ~1.8- to ~2.5-fold improved activity. Methoxymethyl (UPMP051 and 
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UPMP054) and N-methylacetamide (UPMP061 and UPMP060) substitutions did not result in a 
clear improvement in potency. In this set of derivatives, the potency data seemed to suggest that 
4-phenyl-1-(1H-pyrazole-4-yl)piperidine derivatives had better 20-HETE formation inhibition 
compared to 4-phenyl-1-(1H-pyrazol-5-yl)piperidine derivatives. Small simple substitutions at 4- 
and 3-position on the phenyl group are tolerated compared to 2-position. Among these derivatives, 
the acetamide derivative (UPMP072) demonstrated the strongest inhibition against CYP4 
enzymes.  
Evaluation of compounds with halogen modifications on the benzene ring of UPMP010 
and UPMP019 is shown in Table 3.6. In this subset of compounds, based on the screening data, 
halogen substitution appeared to be tolerated. Fluorine at the ortho- position did not seem to affect 
the inhibitory activity. 2-F derivative UPMP083 (IC50 = 235 nM) has a comparable activity to 
UPMP019 (IC50 = 187 nM). Derivatives with chloro substitution at 4- and 3- position showed 
similar percent of 20-HETE formation inhibition compared to derivatives with fluoro substitution 
at 2-, 3- and 4- position. In this subset of halogen-monosubstituted derivatives, based on the 
screening data, it appeared that the 4-phenyl-1-(1H-pyrazol-4-yl)piperidine derivatives were more 
potent.  










% of inhibition 
in HLM 
071 4-F 66 070 4-F 80 
074 3-F 67 075 3-F 80 
079 2-F 47 083 2-F 77 
085 4-Cl 60 086 4-Cl 74 
- - - 084 3-Cl 77 
a Screening results were used for the comparison of inhibitory activity.  
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We also evaluated derivatives with double substitution on the phenyl group of UPMP010 
and UPMP019 (Table 3.7). The 3-F, 4-OMe derivative (UPMP068, IC50 = 49.5 nM) showed a 
~1.5-fold improvement in activity compared to 4-OMe derivative (UPMP031, IC50 = 73.4 nM). 
The 2-F, 4-OMe derivative (UPMP073, IC50 = 82.1 nM) had comparable activity to UPMP031. 
In this subset of derivatives with two substitutions on the phenyl group, the screening data 
suggested that the 4-phenyl-1-(1H-pyrazol-4-yl)piperidine derivatives and the 4-phenyl-1-(1H-
pyrazol-5-yl)piperidine derivatives had comparable activity against 20-HETE formation.  














076 3-F,4-OMe 92 068 3-F, 4-OMe 95 
082 2-F, 4-OMe 88 073 2-F, 4-OMe 92 
097 3-F, 5-OMe 61 096 3-F, 5-OMe 77 
098 3-OMe, 4-F 55 099 3-OMe, 4-F 61 
091 3-Cl, 4-OMe 83 088 3-Cl, 4-OMe 88 








a Screening results were used for the comparison of inhibitory activity.  
 












010 - 443 019 - 187 
021 R1 = CH2 149 022 R2 = CH2 49.6 
013 R1 = O >500
a 043 R2 = O 215 
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056 R1 = S >500 057 R2 = S 98.1 
059 R1 = O=S=O >500 058 R2 = O=S=O >500 
a A > 500 nM was assigned to compounds that showed less than 50% inhibition in HLM.  
 
Evaluation of compounds with a linker between the piperidine and benzene moieties is 
presented in Table 3.8. When the phenyl group in UPMP010 and UPMP019 was extended by a 
methylene group, an improved potency was observed (UPMP021, IC50 = 149 nM; UPMP022, 
IC50 =49.6 nM). In this small set of derivatives shown in Table 3.8, we observed that when the 
linker was -S- (UPMP056), -O- (UPMP013), or -O=S=O (UPMP059) on derivatives with 1H-
pyrazol-5-yl-piperidine core, there was a loss of activity compared to hit UPMP010. Comparing 
derivatives with 1H-pyrazol-4-yl-piperidine core, it appeared that the potency showed a trend of -
C- > -O- > -S- > -O=S=O (UPMP022, IC50 = 49.6nM; UPMP057, IC50 = 98.1 nM; UPMP043, 
IC50 = 215 nM; UPMP058, IC50 > 500 nM).  
So far, after potency evaluation, several compounds with great 20-HETE formation 
inhibition were identified, including UPMP072 (IC50 = 45.8 nM), UPMP068 (IC50 = 49.5 nM), 
and UPMP022 (IC50 = 49.6 nM).  
UPMP072 contains an amide group that we suspected might subject to hydrolysis. 
Although active, UPMP072 had low metabolic stability in HLM (section 3.3.5.3). Derivatives of 
UPMP072 with amide groups and amide isosteres that might have reduced tendency for hydrolysis 
were synthesized and evaluated for potency to test whether these analogs could maintain the strong 
inhibitory activity of UPMP072. The microsomal stability was also evaluated to see if analogs 
exhibited slow turnover in HLM (section 3.3.5.3).  
Comparison of UPMP124 to UPMP072 suggested that introducing a cyclic amide ring 
(UPMP124, IC50 = 53.6 nM) led to a compound with similar potency of UPMP072 (Table 3.9). 
Based on screening results, UPMP101, UPMP102, and UPMP125 all showed similar percent of 
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inhibition compared to UPMP072. Extending the distance between benzene and the cyclic amide 
group substituent of UPMP124 led to UPMP107 (IC50 = 54.2 nM) with comparable activity to 
UPMP072. Comparing UPMP105, UPMP106 to UPMP101, UPMP102, the addition of fluoro 
at 3-position of benzene did not seem to provide an improvement in activity. Similarly, when 
comparing UPMP135, UPMP136 to UPMP107, UPMP108, the addition of fluoro at 2-position 
of benzene did not show improvement in 20-HETE percent of inhibition in HLM. Based on the 
screening results, 1,1,1-trifluoropropan-2-amine (UPMP130) seemed to maintain the 20-HETE 
formation inhibitory activity, and 4-cyclopropyl sulfonamide (UPMP140) seemed to have less 
activity in HLM. We also evaluated the hypothesized active moiety of UPMP072, 4-NH2 
(UPMP131), which showed a slight reduction in inhibition of 20-HETE formation. Additionally, 
we also evaluated nitro derivatives UPMP137 and UPMP138, the methanesulfonamide and 
pyrrolidinesulfonamide derivatives (UPMP139, UPMP109, and UPMP120) (Table 3.9). Except 
for UPMP120, these derivatives appeared to show less inhibition of 20-HETE formation compared 
to UPMP072.  
For derivatives with a sulfone moiety, it appears that the sulfone position and if the sulfone 
is a part of a ring, affects the inhibitory activity (UPMP113, UPMP126, and UPMP134) (Table 
3.10). Further potency evaluation is needed to reach a solid conclusion. 















R1 =  
60.0 072 




R1 =  
82.6 101 
R1 =  
83.6 
106 
R1 = , 
R3 = F 
74.5 105 
R1 = , 
R3 = F 
83.1 
108 
R1 =  
79.4 107 
R1 =  
91.6 
120 
R1 =  
63.1 109 
R1 =  
81.3 
125 
R1 =  
79.0 124 
R1 =  
76.1 
136 R1 = ,  
R2 = F 
80.4 135 R1 = ,  
R2 = F 
90.3 
- - - 130 
R1 =  
86.1 
- - - 131 R1 = NH2 67.3 
138 
R1 =  
21.9 137 
R1 =   
43.5 
- - - 139 
R1 =  
30.5 
- - - 140 
R1 =  
68.7 
a Not all compounds with 4-phenyl-1-(1H-pyrazol-5-yl)piperidine core were synthesized. 
b R2 = H and R3 = H when R2 and R3 are not defined in the table.  
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- - - 113 
R1 =  
34.8 
- - - 134 




- - - 126 




a Not all compounds with 4-phenyl-1-(1H-pyrazol-5-yl)piperidine core were synthesized. 
b R2 = H and R3 = H when R2 and R3 are not defined in the table.  
 
Evaluation of derivatives with a linker between piperidine and substituted benzene moieties 
is presented in Table 3.11. Derivatives with 3-OMe (UPMP069), or 4-pyrrolidone (UPMP133), 
while keeping the CH2 linker had comparable percent of inhibition for 20-HETE formation in 
HLM compared to UPMP022. Derivative (UPMP103) with 4-OMe seemed to be less active 
compared to UPMP022. When using -S- as the linker, introducing R4 substituents (UPMP094, 
UPMP100, UPMP104, UPMP106) seemed to maintain the inhibition of 20-HETE formation 
compared to UPMP022. In this set of derivatives, 4-Cl derivative (UPMP117, IC50 = 17.3 nM) 
and 4-CH3 derivative (UPMP142, IC50 = 24.0 nM) led to a 2.8- and 2- fold increase in potency 
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compare to the top activities (e.g. UPMP072, IC50 = 45.8 nM; UPMP022, IC50 = 49.6 nM), 
respectively.   















021 R1 = CH2  022 R3 = CH2 77.3 
- - - 103 
R3 = CH2, R4 = 4-
OMe 
59.8 
- - - 069 
R3 = CH2, R4 = 3-
OMe 
71.0 
- - - 142 




R1 = CH2, R2 = 3-
CH3 
35.3 118 
R3 = CH2, R4 = 3-
CH3 
61.3 
- - - 117 R3 = CH2, R4 = 4-Cl 93.0 
115 
R1 = CH2, R2 = 3-
Cl 
40.4 114 R3 = CH2, R4 = 3-Cl 67.0 
- - - 133 








- - - 100 R3 = S, R4 = 3-OMe 84.4 
- - - 104 R3= S, R4 = 4-OMe 85.7 
- - - 094 R3 = S, R4 = 4-F 84.8 
- - - 116 R3= S, R4 = 2-F 77.3 
a Not all compounds with 4-phenyl-1-(1H-pyrazol-5-yl)piperidine core were synthesized. 
b R2 = H when R2 is not defined in the table.  
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3.3.4.2 Species difference in inhibitory activity  
Given the species difference in enzymes responsible for 20-HETE formation between 
rodents and humans, we also assessed CYP4 inhibitory activity in RLM. Based on the screening 
data, we observed large differences in 20-HETE formation inhibition between HLM and RLM 
(Appendix A Table 1 - 6). Based on the screening data, small single non-halogen substituents on 
benzene such as 3-OMe (UPMP029), 3-Me (UPMP077), 3-COOMe (UPMP040) appeared to 
have better inhibitory activity when compared to derivatives with the same substitutions on 4-
position (UPMP031, UPMP047, UPMP038) (Appendix Table 1). It appeared that double 
substitutions with -OMe, -F, or -Cl (UPMP068, UPMP073, UPMP099, UPMP088) showed a 
trend of improvement in the 20-HETE formation inhibition when comparing to single non-halogen 
small substitution (Appendix Table 3). When extending the phenyl group, UPMP022 did not seem 
to improve 20-HETE inhibitory activity in RLM compared to UPMP019 (Appendix Table 4). 
However, the 4-methyl derivative (UPMP142) and 4-chloro derivative (UPMP117) showed 
increased 20-HETE formation inhibition in RLM. The above findings are interim and preliminary 
based on screening data. IC50 evaluation in RLM may provide a better understanding of structural 
requirements for compounds’ potency improvement.  
Among some of the potent compounds presented in Table 3.12, there was an approximately 
5- to 14-fold difference in potency between different species. For example, UPMP107 was 13-
fold less potent in RLM compared to HLM (IC50 =54.2 nM in HLM; IC50 =723 nM in RLM). 
UPMP072 was ~ 5-fold less potent in RLM than in HLM.To summarize, in Tier 2 single 
concentration screening, we screened 143 compounds in three microsomal systems. Among these 
compounds, 76 compounds showed greater than 50% 20-HETE formation inhibition in HLM, 28 
compounds showed greater than 40% 20-HETE formation inhibition in RLM. These compounds 
 97 
of interest would be advanced to Tier 3 in vitro evaluation. We evaluated the potency for 40 novel 
molecules and obtained preliminary SAR traits. Based on the available data, it appeared that (1) 
the (1H-pyrazole-4-yl)piperidine core seemed to provide improved 20-HETE formation inhibitory 
activity compared to (1H-pyrazole-5-yl)piperidine core when single small substitution is present 
at the phenyl group that directly attached to the piperidine group; (2) Double substitutions on 
phenyl group seems to induce an improvement in 20-HETE formation inhibition when the phenyl 
group directly connected to the piperidine group; (3) Single substitution on the phenyl group on 
para- position and meta- position were tolerated in a small subset of derivatives. When fluorine 
was at the ortho- position, the activity seemed to be preserved comparing to other substitution at 
ortho-position in compounds with benzene moiety directly attached to the piperidine group; (4) 
Extending the piperidine connection of the phenyl group via a methylene or a S link may provide 
additional active compounds for development. A portion of the SAR traits was based on single 
concentration screening and a small amount of IC50 data. Generation of additional IC50 values for 
compounds of interest will help further evaluate the SAR to support lead optimization.  
 Based on the potency in HLM, a list of 14 compounds that met the criteria of IC50 ≤ 100 
nM in HLM were identified. Based on the potency in HLM, a ranking of novel chemical entities 
was derived (Table 3.12). The fourteen compounds were ranked as top compounds to be assessed 
in the other in vitro assays. 
Table 3.12 Top ranked novel compounds based on IC50 in HLM 
Compound 
(UPMP) 
IC50 (nM) in HLM IC50 (nM) in RLM 
117 17.3 120 
142 24.0 - 
072 45.8 240 
105 47.4 >500 
068 49.5 337 
022 49.6 >500 
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124 53.6 570 
107 54.2 723 
031 73.4 >500 
047 78.8 >500 
048 80.3 >500 
073 82.1 - 
057 98.1 >500 
060 101 - 
 
3.3.5 Characterization of properties for top ranked compounds 
3.3.5.1 Selectivity  
Through the tiered screening and potency evaluation, compounds with IC50 as low as 17.3 
nM against CYP4 enzymes were identified. The selectivity of 20-HETE versus EETs and DiHETs 
was studied next. The UPLC-MS/MS method allowed us to quantify 8,9-, 11,12-, 14,15- EET; 5,6-
, 8,9-, 11,12-, 14,15-DiHET and 20-HETE simultaneously. The formation of EETs and DiHETs 
was used as a surrogate index for epoxygenase activity. As compound concentration increased, 
compounds inhibited 20-HETE formation in a concentration-dependent manner. Formation of 
EETs and DiHETs were not affected until reaching high concentrations (Fig.3.6). Therefore, all 
the top compounds that were evaluated had IC50 for EETs and DiHETs > 10,000 nM, which were 
≥ 100-fold IC50 for 20-HETE inhibition, meeting the selectivity criteria. 
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Figure 3.6 Selectivity of 20-HETE versus EETs and DiHETs for top ranked compounds 
Effects of novel top ranked compounds on the formation of 20-HETE versus EETs and 
DiHETs in HLM. Results are expressed as percent of control and are mean ± std (n=3). Compounds 
inhibited 20-HETE concentration-dependently. Compounds either did not show inhibition for 
epoxygenases or inhibited EETs and DiHETs with IC50 values greater than 100-fold of IC50 values 
for 20-HETE.  
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3.3.5.2 Solubility  
Kinetic solubility was evaluated for the top ranked compounds (Table 3.13). Compound 
UPMP072, UPMP022, UPMP107, and UPMP060 met the solubility criteria of > 400 µM. 
UPMP068 had a solubility of 35.4 µM, which is approximately 700-fold higher than its IC50 in 
HLM. The rest of the compounds had solubilities that were 1000-fold higher than their respective 
IC50 values for 20-HETE inhibition in HLM, giving a wide window to increase the dose without 
insolubility concern if they were to be prepared as an IV formulation to be evaluated in animal 
studies.  
3.3.5.3 Metabolic stability and preliminary prediction of human clearance 
Metabolic stability of compounds was evaluated in HLM at a concentration of 1 µM. Time-
courses of substrate disappearance is shown in Fig 3.7. In vitro t1/2 and in vitro intrinsic clearance 
(CLint, in vitro) were derived from the natural logarithmic transformed data by fitting linear regression. 
Most of the top ranked compounds were slowly metabolized throughout the 60-min incubation 
period comparing to benchmark compound 24. We found that the novel compounds had prolonged 
in vitro t1/2 compared to positive controls (HET0016, t1/2 = 6.10 min; compound 24, t1/2 = 19.6 min) 
(Table 3.13). Novel 20-HETE formation inhibitors had 5.2- to 130-fold prolonged t1/2. Among the 
novel compounds, approximately 100% of UPMP048 and UPMP068 remained after incubation 
with HLM over 60 min test period. The t1/2 values were not estimated due to slow metabolism 
(Table 3.13). UPMP060 and UPMP072 were quickly metabolized and did not meet the metabolic 
stability criteria. The fast metabolism of UPMP060 and UPMP072 might be attributed to the 
hydrolysis of the amide group as disappearance of compounds in NADPH-free incubation in HLM 
was observed (Table 3.14). Human in vivo intrinsic clearance (CLint, in vivo) was calculated 
according to Equation 3.1.5 and presented in Table 3.13. Hepatic clearance was not predicted due 
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to unknown plasma protein binding. Among the 12 evaluated top ranked compounds, all met 
metabolic stability criteria except UPMP060 and UPMP072. 
 
Figure 3.7 Metabolic stability of top ranked compounds in HLM. 
Compounds were incubated in HLM, data are presented as percent of control and are mean 
± std. Compound 24 (red) was metabolized quickly in HLM (t1/2 = 19.5 min). There was 35.1% 
remaining compound at 30 min. UPMP060 (orange) and UPMP072 (pink) were quickly 
metabolized in HLM. The remaining amounts were 23.8 and 23.0%, respectively. Other top ranked 
compounds (black) had greater than 80% remaining compounds at 30 min. 
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IVIVE of clearance MDCK-MDR1 
In vitro t1/2 
(min) 
CLint, in vitro 
(µl/min/mg protein) 







HET0016 163 6.10 227 182 - - - 
24 333 19.5 71.1 56.8 - - - 
UPMP117 117 200 5.19 6.94 44.3 40.0 0.902 
UPMP142 71 - - - 77.4 70.3 0.908 
UPMP072 482 9.99a 139 111 - - - 
UPMP105 353 - - - - - - 
UPMP068 35.4 NMa NM - - - - 
UPMP022 505 152 9.09 7.27 62.8 60.1 0.957 
UPMP124 74 796 1.74 1.74 22.2 46.9 2.12 
UPMP107 >600 267 6.94 5.19 5.16 41.6 8.06 
UPMP031 35 226 6.12 4.90 32.0 25.7 0.803 
UPMP047 85 248 5.60 4.48 - - - 
UPMP048 244 NM NM - - - - 
UPMP073 - 144 9.64 7.71 47.8 32.1 0.672 
UPMP057 96 109 12.8 10.2 - - - 
UPMP060 >600 14.8 b 93.6 74.9 18.4 40.2 2.18 
a Not metabolized in HLM for the duration of 60 min.  
b The compound was assumed to be hydrolyzed in incubation without NADPH. 
22e
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Metabolic stability (% of control) 
NADPH-dependent NADPH-free Boiled microsome 
UPMP060 UPMP072 UPMP060 UPMP072 UPMP060 UPMP072 
0 100 100 100 100.0 100 100 
15 53.9 35.3 39.2 44.1 159 97 
30 23.8 23 16.9 24.0 106 101 
45 12.2 9 6.93 5.83 103 - 
60 6.92 6 11.3 4.27 106 105 
CLint, in vitro 
(µl/min/mg 
protein) 
119 139 79.0 125 - - 
3.3.5.4 MDCK-MDR1 and BBB permeability  
To our knowledge, previous reports on 20-HETE formation inhibitors did not disclose BBB 
permeability. To develop 20-HETE formation inhibitors as neuroprotective agents that work in the 
brain, early in vitro evaluation of BBB penetration is of critical importance. Among the compounds 
that were evaluated for MDCK-MDR1 permeability, PappA-B varied from 5.16 to 77.4 × 10
-6 cm/s, 
suggesting high apical to basolateral passive permeability and brain uptake potential (Table 3.13). 
The ratio of PappA-B/PappB-A (ER) was used as an index of P-gp mediated efflux across MDCK 
cells transfected with the human mdr1 gene that expresses P-gp. The ER for the compounds ranged 
between 0.803 – 8.06. Overall, among top ranked compounds that were tested, they all exhibited 
moderate to high BBB penetration in the MDCK-MDR1 assay. These compounds might have good 
BBB permeability in vivo. 
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3.3.5.5 CYP inhibition and DDI potential  
We also tested the analogs for inhibition against five drug metabolizing CYP enzymes. A 
greater than 50% percent of control suggests an IC50 for a CYP isoform > 100-fold of IC50 for 20-
HETE formation, yielding at least a 100-fold selectivity window. UPMP117 abolished CYP2C19 
activity at 2000nM (Table 3.15). UPMP068 inhibited CYP2C19 activity by 89% at 1000 nM. 
Inhibition of CYP enzymes was less than 50% for UPMP107 and UPMP124. Therefore, 
UPMP107 and UPMP124 met the CYP inhibition criteria.  
Table 3.15 CYP inhibition for NCEs 
compound a 
% of control 
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
UPMP117 102±16.7 74.8±14.6 1.05±0.34 56.3±11.6 121±8.06 
UPMP068 94.2±7.65 49.4±2.13 11.2±2.78 98.5±3.47 119±12.5 
UPMP022 85.4±25.1 102±6.75 44.4±43.1 65.7±10.2 111±6.07 
UPMP124 101±8.50 70.6±4.98 71.3±8.01 97.2±3.71 94.2±6.37 
UPMP107 82.0±9.57 51.3±6.70 83.4±6.76 106±15.5 92.3±5.56 
a Compound were tested at concentrations of UPMP117: 2000 nM; UPMP068: 1000nM; 
UPMP022:5000nM; UPMP107: 5000 nM; UPMP124: 5000 nM. 
3.3.5.6 In vitro safety pharmacology 
The use of in vitro safety pharmacology profiling is an important tool to identify potential 
adverse effects and reduce safety-related attrition early in drug discovery. A panel of 44 known 
human pharmacological targets was used to evaluate UPMP107 and UPMP124 at 10 µM (Table 
3.16). The targets included well-described cardiovascular or CNS targets such as 5-HT receptors, 
hERG, ion channels, and enzymes such as COX. UPMP107 did not show a greater than 50% 
inhibition or stimulation on GPCRs, kinases, ion channels, transporters or enzymes in the panel. 
Initial safety pharmacology evaluation suggested that UPMP124 had a 78% inhibition on the L-
type Ca2+ channel. A followed-up IC50 evaluation showed a lack of dose-dependent inhibition, 
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suggesting a lack of inhibition on the L-type Ca2+ channel (Table 3.17). Therefore, UPMP107 and 
UPMP124 met the in vitro safety pharmacology criteria of <50% inhibition at 10 µM. 
Table 3.16 In vitro safety pharmacology results of UPMP107 and UPMP124 
Assay 
% Inhibition of control specific 
binding 
UPMP107 UPMP124 
A2A (h) (agonist radioligand) -9 1 
alpha 1A (h) (antagonist radioligand) 24 -3 
alpha 2A (h) (antagonist radioligand) -5 2 
beta 1 (h) (agonist radioligand) -3 -3 
beta 2 (h) (antagonist radioligand) -6 -2 
BZD (central) (agonist radioligand) -10 -22 
CB1 (h) (agonist radioligand) -12 1 
CB2 (h) (agonist radioligand) -4 -6 
CCK1 (CCKA) (h) (agonist radioligand) -16 2 
D1 (h) (antagonist radioligand) 2 2 
D2S (h) (agonist radioligand) 3 -7 
ETA (h) (agonist radioligand) 5 -2 
NMDA (antagonist radioligand) 0 -3 
H1 (h) (antagonist radioligand) -6 2 
H2 (h) (antagonist radioligand) -21 -10 
MAO-A (antagonist radioligand) 6 14 
M1 (h) (antagonist radioligand) 10 2 
M2 (h) (antagonist radioligand) 21 -6 
M3 (h) (antagonist radioligand) -2 -10 
N neuronal alpha 4beta 2 (h) (agonist radioligand) 10 9 
delta (DOP) (h) (agonist radioligand) -2 0 
kappa (h) (KOP) (agonist radioligand) 2 -4 
mu (MOP) (h) (agonist radioligand) 2 1 
5-HT1A (h) (agonist radioligand) -8 -3 
5-HT1B (h) (antagonist radioligand) -6 -4 
5-HT2A (h) (agonist radioligand) -7 -4 
5-HT2B (h) (agonist radioligand) -21 20 
5-HT3 (h) (antagonist radioligand) -4 7 
GR (h) (agonist radioligand) 2 5 
AR (agonist radioligand) 2 4 
V1a (vh) (agonist radioligand) 9 -3 
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Ca2+ channel (L, dihydropyridine site) (antagonist 
radioligand) -15 78 
Potassium Channel hERG (human)- [3H] Dofetilide -3 0 
KV channel (antagonist radioligand) 1 -5 
Na+ channel (site 2) (antagonist radioligand) 17 16 
norepinephrine transporter (h) (antagonist radioligand) -4 -1 
dopamine transporter (h) (antagonist radioligand) -2 0 
5-HT transporter (h) (antagonist radioligand) 6 -8 
   
Assay % Inhibition of control values 
COX1(h) 8 -29 
COX2(h) 28 25 
PDE3A (h) 1 -3 
PDE4D2 (h) -15 -8 
Lck kinase (h) 1 -13 
acetylcholinesterase (h) -7 5 
 
Table 3.17 UPMP124 binding to Ca2+ channel   
Test concentration (M) 
% inhibition of control 
specific binding 
% of control specific binding 
(mean) 
1.37 × 10-8 6 93.5 
4.12 × 10-8 3 97.1 
1.23 × 10-7 -7 106.9 
3.70 × 10-7 1 99.4 
1.11 × 10-6 4 96.4 
3.33 × 10-6 1 99.1 
1.00 × 10-5 -3 102.7 
3.00 × 10-5 11 88.5 
1.37 × 10-8 8 91.5 
4.12 × 10-8 -6 106.2 
1.23 × 10-7 -1 101.1 
3.70 × 10-7 3 97.4 
1.11 × 10-6 29 71.1 
3.33 × 10-6 -1 100.7 
1.00 × 10-5 -5 104.5 
3.00 × 10-5 10 89.7 
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It should be noted that while other compounds with more potent 20-HETE formation 
inhibition were identified (e.g. UPMP117, IC50 = 17.3 nM; UPMP072, IC50 = 45.8 nM; 
UPMP068, IC50 = 49.5 nM; UPMP022, IC50 = 49.6 nM), each possessed unfavorable attributes 
compared to UPMP107. Specifically, UPMP117, UPMP068, and UPMP022 had liability in CYP 
inhibition. UPMP072 was markedly less stable in HLM, with a t1/2 value of 9.99 min. Additionally, 
hydrolysis of UPMP072 will produce an aniline group which may be subject to chemical oxidation 
reactions (Bruns et al. 2012).  
The decision process of selecting UPMP107 as the preclinical candidate is presented in 
Fig.3.8. In Tier 2, we screened 143 compounds. Among these compounds, 76 of them displayed ≥ 
50% inhibition in HLM that would be advanced for potency evaluation. We completed potency 
evaluation for 40 compounds in HLM. Among them, 14 compounds had IC50 ≤ 100 nM in HLM. 
The 14 compounds are the top ranked compounds presented in Table 3.12. Since we would like to 
evaluate the efficacy of novel molecules in rats that express different 20-HETE formation enzymes, 
compounds with good 20-HETE formation inhibition in RLM would be preferable. Of the 14 
compounds, 7 compounds (UPMP072, UPMP105, UPMP022, UPMP031, UPMP047, 
UPMP048, and UPMP057 were excluded from the preclinical candidate pool because of low 20-
HETE inhibition in RLM in the single concentration screening assay. Among the seven 
compounds remained, UPMP117, UPMP142, UPMP068, UPMP124, and UPMP073 had 
solubility less than 400 µM and were excluded from further consideration. This led to two 
compounds for further evaluation. The quick metabolism of UPMP060 in HLM made it an 
unfavorable candidate. Among all the compounds evaluated, UPMP107 met all prespecified in 
vitro property criteria and therefore became the preclinical candidate that would be advanced to in 
vivo evaluation. 
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To summarize, by following the multi-tiered evaluation approach of evaluating potency 
and other characteristics including solubility, selectivity, metabolic stability, BBB permeability, 
CYP inhibition, and in vitro safety pharmacology, we reported the identification of UPMP107 as 
a novel preclinical candidate that target CYP4 enzymes to inhibit 20-HETE formation. This novel 
compound was selected to be evaluated in animal studies.
 
 
Figure 3.8 Decision tree to narrow down the preclincial candidate pool 
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The decision tree illustrates the process of UPMP107 being selected as a preclinical 
candidate. In Tier 2, 143 compounds were screened. 76 compounds inhibited 20-HETE formation 
≥ 50% in HLM and were advanced for potency evaluation. Among the 76 compounds, we tested 
IC50 for 40 compounds in HLM, 14 compounds showed IC50 ≤ 100 nM. They were the 14 top 
ranked compounds present in Table 3.12. Among them, 7 compounds showed poor 20-HETE 
formation inhibition in RLM in screening assay and were excluded from the preclinical candidate 
pool. Among the 7 compounds that were evaluated for solubility, UPMP107 and UPMP060 had 
≥ 400 µM kinetic solubility. UPMP107 also met metabolic stability, CYP inhibition, BBB 
permeability, and Cerep in vitro safety pharmacology criteria. Therefore, UPMP107 was selected 
as the preclinical candidate for in vivo evaluation.  
3.4 Discussion and conclusions 
The CYP4 enzymes, responsible for the activation of numerous eicosanoids signaling 
pathways, represent an important therapeutic target in multiple disease areas, such as hypertension, 
stroke, and cancers. However, exploiting CYP4 as a drug target is yet to be achieved. In this study, 
we showed that UPMP107 is a novel CYP4 inhibitor with strong potency against 20-HETE 
formation in both human and rat liver microsomes and good physicochemical properties. 
UPMP107 was selective, with a greater than 900-fold selectivity window for 20-HETE formation 
inhibition vs. EETs and DiHETs formation inhibition. UPMP107 was highly soluble. 
Furthermore, in contrast to the rapid in vitro metabolism of HET0016, UPMP107 was 
metabolically stable in HLM. UPMP107 was further characterized as having a low potential for 
DDIs and good BBB penetration potential. 
One of the challenges for structure-based drug design for 20-HETE formation inhibitors is 
the absence of CYP4F2 or CYP4A11 protein structural information. Computational protein 3D 
structure prediction such as homology modeling has been frequently applied in drug discovery 
projects to determine protein structure from amino acid sequence based on a template (Cavasotto 
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et al. 2009). CYP4 enzymes catalyze fatty acid hydroxylation at terminal ω-carbon or internal sites 
(Fer et al. 2008). The unique feature of CYP4 structure is the presence of an ester bond between 
the heme and the carboxyl group of glutamic acid in helix I (LeBrun et al. 2002, Joyce et al. 2004, 
Hsu et al. 2017). Hydroxylation of endogenous CYP4F2 substrate vitamin K1 was investigated by 
a CYP4F2 homology model and shed light on the active residues including Phe124, Phe327, 
Glu328, Val368, and Leu504 in vitamin K1 binding to the inner pocket of CYP4F2 (Li et al. 2018). 
CYP4B1 has also been successfully utilized to generate CYP4Z1, CYP4A22 homology models 
(Xu et al. 2017, Durairaj et al. 2019). Considering rat CYP4B1 has 45% sequence identity with 
human CYP4F2 and specifically ω-hydroxylate short-chain saturate alkanes, the structural 
inferences that can be made about CYP4F2 are limited (Fisher et al. 1998). Nonetheless, the 
availability of a homology model may provide insight on the active sites to help design compounds 
and study the binding of the compounds.  
We observed a large species difference in CYP4 inhibitory activity across the compounds 
that had been screened. Among the 143 screened compounds, 76 met the screening criteria of > 
50% inhibition in HLM and 26 met the screening criteria of > 40% inhibition in RLM. The large 
interspecies difference is not unexpected but poses a challenge in developing novel 20-HETE 
formation inhibitors. The difference in compound activity could be due to (1) different isoforms 
catalyze the formation of 20-HETE in rats and humans. CYP4A1, 4A2, 4A3, 4A8, 4F1, and 4F4 
in rats; CYP4A11, 4F2, 4F3B in human are 20-HETE-synthesizing enzymes (Powell et al. 1998, 
Nguyen et al. 1999, Hoch et al. 2000, Kalsotra et al. 2002); (2) even if the isoforms are same across 
species, the differences in CYP protein primary sequence will lead to different substrate specificity; 
and (3) CYP isoform expression levels may be different in rodents and humans (Boobis et al. 1990, 
Eagling et al. 1998, Martignoni et al. 2006).  
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Novel compounds showed either greater inhibition in HLM compared to rCYP4F2 or 
greater inhibition in rCYP4F2. This could likely be explained by that CYP4F2 is not the sole 
enzyme for 20-HETE synthesis and the expression and function of the isoforms are unknown. To 
date, CYP4A11 and CYP4F2 are still considered two major enzymes that underlie 20-HETE 
formation. CYP4A11 has the strongest catalytic activity of 15.6 nmol/min/nmol P450, but the 
affinity for arachidonic acid is relatively low with Km value of 228 µM. Although CYP4F2 has a 
lower 20-HETE formation rate of 6.8 nmol/min/nmol P450, it has a high affinity to arachidonic 
acid (Km=24 µM) (Powell et al. 1998). Several other CYP isoforms also possess 20-HETE 
formation activity, including CYP4F3B, CYP4F11, and CYP2U1 (Lasker et al. 2000, Chuang et 
al. 2004, Fer et al. 2008, Tang et al. 2010). CYP4F3B also has a high affinity to the substrate (Km 
= 22 uM) (Christmas et al. 2001). The total amount of CYP4F protein level has a large variability 
in human liver microsomes, as estimated to be 18 – 128 pmol/mg liver microsomal protein (Tang 
et al. 2010). Due to the high homology of CYP4F2, CYP4F3B, CYP4F11 and CYP4F12, the 
absolute amount of each enzyme in the liver is unknown (Edson et al. 2013). The expression, 
catalytic activity of enzymes responsible for 20-HETE formation may vary in HLM from batch to 
batch. The affinity of enzymes and compounds is unknown. Compounds that showed greater 
inhibition in HLM than CYP4F2 might bind to several enzymes that can form 20-HETE in HLM.   
We observed induction in 20-HETE formation for several compounds such as UPMP13 
and UPMP132. The induction of 20-HETE could be an artifact and should be confirmed with 
repeated potency tests. Another explanation might be related to CYP enzyme activation. CYP3A4 
has been studied extensively with respect to enzyme activation with different substrates, such as 
CYP3A4-catalyzed phenanthrene in the presence of 7,8-benzoflavone. In the presence of CYP3A4 
substrate 7,8-benzoflavone, phenanthrene metabolism showed an increased Vmax without affecting 
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Km, and phenanthrene didn’t increase Km of 7,8- benzoflavone metabolism, while decreasing its 
Vmax, indicating more than one molecule could bind to CYP3A4 active sites simultaneously. 
Phenanthrene and 7,8- benzoflavone serve as each other’s effector of metabolism. 7,8-
benzoflavone stimulates phenanthrene metabolism by 15.7-fold, while phenanthrene is a partial 
inhibitor of 7,8-benzoflavone metabolism. The unchanged Km values suggested that phenanthrene 
and 7,8-benzoflavone could not displace each other from the active site (Korzekwa et al. 1998). 
There are at least two or possibly three active sites within CYP3A4 (Hosea et al. 2000). This 
atypical kinetics was also observed for other CYP enzymes and substrates such as dapsone 
activation of CYP2C9-mediated metabolism (Korzekwa et al. 1998, Matthew Hutzler et al. 2003, 
Blobaum et al. 2013). When coincubating dapsone with flurbiprofen, the CYP2C9-mediated 
flurbiprofen 4’-hydroxylation had a decrease in Km and an increase in Vmax. The decreased spectral 
binding constant from 14.1 to 2.1 µM also suggested that the presence of dapsone increased the 
affinity of flurbiprofen for CYP2C9.(Matthew Hutzler et al. 2003). This kinetic evidence 
suggested that both effector (dapsone) and substrate (flurbiprofen) may be present in the active 
site simultaneously, supporting a two-site binding model of CYP450-mediated metabolism 
(Hutzler et al. 2001). By studying dapsone and its nine analogs, a sulfone group in direct 
association with two benzene rings with para- electron-donating groups were found to be the 
structural requirements to be an efficient activator of CYP2C9 (Hutzler et al. 2002). The increase 
in 20-HETE formation in the presence of a test compound could suggest a possibility of 
arachidonic acid binding to the CYP4F2 active site in the presence of a test compound. The test 
compound might cause arachidonic acid to bind more efficiently or in a more productive 
orientation that leads to increased catalytic activity of 20-HETE formation. Incubation needs to be 
repeated to confirm the finding of compounds that exhibited an increase in 20-HETE formation. 
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Additional experiments to obtain Vmax and Km of arachidonic acid ω-hydroxylation by 
coincubating arachidonic acid and compound of interest at various concentrations and analysis of 
Eadie-Hofstee plots would support the effect of compound on CYP4F2-mediated arachidonic acid 
activation.  
The human brain is a sophisticated organ with the protection of blood-brain barrier (BBB), 
enabling selective access of molecules. Designing compounds that can penetrate the protection 
system to achieve optimal exposure at the site of action is an utmost challenge in CNS drug 
development. Physicochemical properties such as lipophilicity, hydrogen bonding potential, and 
size have been identified as important requirements for penetrating the BBB (Janicka et al. 2020). 
Lipophilicity is an important property that is related to permeability, solubility, and protein 
binding. Higher lipophilicity (LogP) is usually associated with increased plasma and tissue 
binding, and increased passive permeability for molecules containing ionizable groups (Gleeson 
2008, Reichel 2009). An analysis of 3000 diverse GlaxoSmithKine compounds found a negative 
correlation between LogP and fraction of unbound in the brain (ƒu,b), suggesting higher free drug 
concentrations in the brain might be obtained by lowering LogP to achieve higher efficacy 
(Gleeson 2008). Based on the free-drug assumption that only unbound drugs are able to cross the 
BBB to produce a therapeutic effect, compounds with higher lipophilicity are not favorable as they 
might be highly protein bond and are less likely to penetrate the BBB. However, drugs that are 
highly protein bond such as imipramine and desimirpamine have high concentrations in the brain 
(Lin et al. 1987). In fact, 15 most prescribed CNS drugs have ƒu,b < 5% (Liu et al. 2014). The 
possible mechanisms include 1) conformational change of protein when interacting with capillary 
walls may free the drug molecule from a drug-protein complex; 2) binding with protein may induce 
protein-mediated transport to enhance BBB penetration; and 3) capillary endothelium in some 
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regions is more permeable (Wanat 2020). The calculated LogP for 107 is 1.90, within the optimal 
cLogP range of 1 – 3 that provides a balance between the hydrophilicity and lipophilicity and to 
reduce the chances of poor solubility, high metabolism and increases the possibility of passive 
permeation across BBB. Hydrogen bond descriptors were also found to be critical CNS 
differentiators. Increased H-bonding potential is associated with lower passive permeability 
(Veber et al. 2002). Marketed CNS drugs have 2.12 hydrogen bond acceptors and 1.5 hydrogen 
bond donors on average (Pajouhesh et al. 2005). UPMP107 has 1 hydrogen bond donor and 2 
hydrogen bond acceptors, meeting the physicochemical properties seen in CNS positive drugs. 
BBB permeability and active transport are recognized determinants of drug exposure in the 
brain. Currently, high-throughput permeability assays are generally employed in human colon 
carcinoma (Caco-2), MDCK, or human bladder carcinoma (ECV304)) cell lines (Morofuji et al. 
2020). Although these cells are not derived from the brain, the tight junctions enable in vitro in 
vivo permeability correlation (Puscas et al. 2019). The ABC efflux transporter P-gp, encoded by 
MDR1, is a key transporter that recognizes a wide array of structural types of compounds and 
actively transport drugs out of brain capillary endothelial cells. MDCK-MDR1, a canine renal 
epithelial model transfected with the human MDR1 gene, is generally used as a cell-based 
surrogate for BBB penetration (Hellinger et al. 2012). In addition to P-gp, other efflux transporters 
such as breast cancer resistance protein (BCRP), multidrug resistance proteins (MRPs) are also 
expressed at the BBB. A recent study of BBB transporter protein abundance in 30 postmortem 
adults showed a ranking of BCRP > P-gp for efflux transporters (Billington et al. 2019). Although 
compounds found to be P-gp substrates in rodents are also likely to be substrates in higher species, 
there is a more than two-fold difference in protein abundance such as P-gp and MRP4 between 
humans and Sprague-Dawley rats (Syvanen et al. 2009, Hoshi et al. 2013). Therefore, when 
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interpreting the result from the MDCK-MDR1 assay, the lack of expression of other relevant BBB 
transport proteins and species difference should be considered. Nonetheless, UPMP107 has PappA-
B of 5.16 × 10
-6 cm/s and an ER of 8.06, suggesting that UPMP107 might have good brain 
penetration in vivo.  
In vitro metabolic stability is routinely examined to exclude compounds with potentially 
high clearance. We utilized substrate depletion method to determine in vitro metabolism in human 
liver microsomes as it provides the most convenient and affordable way to study CYP-mediated 
metabolism and is not confounded by other metabolic processes or transporter uptakes (Jia et al. 
2007). Phase II metabolism can be tested by addition of UDP-glucuronyltransferases to 
microsomes. There could be an underprediction of clearance when using human liver microsomes 
to measure phase I metabolism given that microsomes do not contain organelles or transporters 
like hepatocytes and phase II metabolism not being studied. An average 9-fold underprediction of 
in vivo clearance was reported when using HLM (Chiba et al. 2009). Efforts have been made to 
reduce the systemic underprediction via applying a multiplicative correction factor (Poulin et al. 
2013). In vitro-in vivo extrapolation is commonly used to estimate human hepatic clearance. 
Microsomes can be used to determine an in vitro intrinsic clearance (CLint, in vitro) and then scaled 
by microsomal protein content and liver weight to an in vivo intrinsic clearance (CLint, in vivo) that 
can be used to calculate hepatic clearance using a well-stirred model  (Houston 1994, Riley et al. 
2005, Obach 2011). Our attempt to predict human hepatic clearance is preliminary. The calculation 
of CLint, in vitro did not account for the fraction of unbound in the incubation (ƒuinc). Hepatic 
clearance was not estimated due to a lack of information in plasma protein binding. As promising 
leads are discovered, obtaining information on metabolism and elimination pathways is critical. 
Clearance in multiple animal species is also required to perform human clearance prediction with 
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high confidence (Caldwell et al. 2004, Lombardo et al. 2013). We observed several compounds 
such as UPMP048 and UPMP068 exhibited low turnovers in HLM. Although achieving a low 
clearance is commonly the goal when designing new compounds, the low clearance in HLM also 
presents a challenge in predicting accurate in vivo clearance. A couple of methodologies were 
proposed to overcome the challenge of low clearance including measuring metabolite formation, 
coculture hepatocyte systems, and hepatocyte relay method to improve the accuracy of in vitro 
clearance measurement (Di et al. 2015). 
Inhibition of a CYP enzyme can cause potential drug-drug interaction that may lead to 
failure in clinical development due to serious side effects. Among all CYP isoforms, CYP1A2, 
2C9, 2C19, 2D6, and 3A4 take up 8.9%, 12.8%, 6.8%, 20%, and 30.2% of the total CYP450 in 
the liver, but are responsible for the metabolism of 95% marketed drugs (Zanger et al. 2013, 
Spaggiari et al. 2014). In vitro DDI studies using human liver microsomes indicated a lack of 
potential of UPMP107 to directly inhibit CYP1A2, 2C19, 2D6, 2C8, and 3A4 at a concentration 
of 5000 nM, but UPMP107 inhibited CYP2C9 activity by 48.7%, barely passing the prespecified 
CYP inhibition selectivity criteria. This fast screening results at a single concentration serve as 
preliminary information to preclude compounds that have CYP inhibition liabilities. Further study 
is needed to obtain an IC50 value for each isoform to draw a solid conclusion.  
Our study has several limitations that are worth noting. First, some of the SAR findings 
were derived from screening data. The SAR exploration is interim and preliminary and warrants 
additional IC50 evaluation for pairs of compounds to extract well-defined patterns. Second, we did 
not test compound activity in human brain microsomes due to the commercial unavailability of the 
materials and the need for large quantities of microsomes for screening and IC50 determination. 
Third, prediction of human clearance is an initial attempt, more information on the metabolism 
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mechanism, metabolism pathways, protein binding is needed to improve the prediction accuracy. 
Fourth, we did not obtain IC50 values for compounds that showed inhibition of drug metabolizing 
CYP activities, considering the goal was to exclude compounds with liabilities at this stage. And 
finally, a P-gp inhibitor in the MDCK-MDR1 assay would confirm the role of P-gp in transporting 
UPMP107. Ideally, a comprehensive evaluation should be performed for all promising compounds 
so that from a medicinal chemistry perspective, lead compounds can be optimized based on 
selectivity, stability, permeability, or toxicology results. Nonetheless, the goal of identifying a 
preclinical candidate with favorable attributes is completed in this body of work.   
In conclusion, this study is the first to report the discovery of a novel CYP4 inhibitor, 
UPMP107, that reduce 20-HETE formation in vitro. The advantages of this novel compound 
include high metabolic stability, low in vitro clearance, strong potency, wide selectivity window, 
and in vitro BBB penetration. These favorable characteristics are intended to improve the 
druggability of UPMP107 to support its development as a highly promising preclinical candidate 
to be proceeded to in vivo evaluation.  
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4.0 Pharmacokinetics and Pharmacodynamics of a Novel 20-HETE Formation Inhibitor 
UPMP107 in Pediatric Rats  
4.1 Introduction  
Out-of-hospital cardiac arrest (OHCA) remains an unresolved public health emergency.  
The estimated number of children that experience OHCA is more than 5000 each year in the United 
States (Topjian Alexis et al. 2019). Although cardiopulmonary resuscitation (CPR) and prompt 
defibrillation are two effective treatments, the reported survival to hospital discharge in children 
of 6.4% to 10.2% from 2005 – 2013 is low (Atkins et al. 2009, Perkins et al. 2015, Fink et al. 
2016). Post-cardiac arrest brain injury remains the main cause of morbidity and mortality in 
children after admission to ICU following OHCA (Topjian Alexis et al. 2019). Neurological 
sequelae associated with hypoxic-ischemic brain injury (HIBI) after cardiac arrest impede 
pediatric OHCA survivors to return to daily living and school performance due to high risk of 
physical, cognitive, and emotional disabilities (Chiota et al. 2011). 
Cerebral perfusion after cardiac arrest was identified by the International Committee on 
Resuscitation as an important target to prevent secondary brain injury (Nolan et al. 2008). A recent 
literature review suggested that flow promotion and vasodilatory therapies are the two promising 
classes of agents for improving cerebral perfusion to increase cerebral blood flow (CBF) (Li 2019). 
Although multiple experimental treatments are available and several therapies have been tested in 
clinical studies, no therapies other than therapeutic hypothermia have been reported to show 
beneficial effects on neurological outcomes. (Geocadin et al. 2008). Therefore, there is a critical 
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need to discover and develop novel compounds as CBF-directed treatment to ameliorate secondary 
brain injury after cardiac arrest. 
20-hydroxyeicosatetraenoic acid (20-HETE) is an important vasoconstrictive mediator in 
regulating CBF (Attwell et al. 2010). 20-HETE is produced by cytochrome P450 family 4 (CYP4) 
enzymes. Specifically, CYP4A11, 4F2, and 4F3B have been recognized to transform arachidonic 
acid (AA) into 20-HETE in humans (Powell et al. 1998, Harmon et al. 2006). Growing evidence 
has implicated the role of 20-HETE in the pathogenesis of post-cardiac arrest HIBI. Preclinical 
animal studies support the beneficial effect of inhibition of 20-HETE formation on CBF and 
neurological outcomes in pediatric rat and piglet cardiac arrest models (Shaik et al. 2015, Zhu et 
al. 2015). Despite the therapeutic potential in 20-HETE formation inhibition, developing chemical 
inhibitors of CYP4 enzymes to inhibit 20-HETE formation has been discouraged by potency, 
physicochemical properties, or pharmacokinetic (PK) liabilities.  
N-Hydroxy-N′-(4-n-butyl-2-methylphenyl)formamidine (HET0016) is a potent inhibitor 
of 20-HETE formation enzymes. It has been widely employed in preclinical studies as a 
pharmacologic agent to study the role of 20-HETE formation in various disease models such as 
cardiac arrest and ischemic stroke (Poloyac et al. 2006, Shaik et al. 2015). Limitations of HET0016 
including poor aqueous solubility, instability under an acidic environment, rapid metabolism, and 
a narrow selectivity window have rendered it an undesirable preclinical compound for clinical 
development and have complicated the interpretation of its dose-response relationship in 
preclinical studies (Mu et al. 2008). Therefore, developing novel inhibitors that can prevail in these 
aspects is in crucial need.   
Ongoing efforts have focused on overcoming the challenges mentioned above for 
developing CNS-targeted 20-HETE formation inhibitors. Cheminformatics, medicinal chemistry, 
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and sensitive bioanalytical methods were utilized to set up tiers of evaluation to facilitate the 
discovery of novel derivatives of a new series of 20-HETE formation inhibitors. UPMP107 has 
been identified as a novel potent CYP4 inhibitor through a battery of in vitro evaluation. Previous 
studies have shown that UPMP107 exhibits a high degree of selectivity in 20-HETE formation 
inhibition. The IC50 values for 20-HETE formation inhibition in human liver microsome (HLM) 
and rat liver microsome (RLM) are 0.0542 µM and 0.723 µM, respectively. The IC50 values for 
epoxyeicosatrienoic acids (EETs) and dihydroxyeeicosatrienoic acid (DiHETs) formation are > 50 
µM in HLM. The inhibition towards CYP1A2, 2C9, 2C19, 2D6, and 3A4 had IC50 values > 5 µM. 
Additionally, UPMP107 in vitro intrinsic clearance (Clint,in vitro = 5.19 µl/min/mg protein) in HLM 
is 43 fold lower compared to HET0016 (227 µl/min/mg protein). UPMP107 has a kinetic 
solubility > 600 µM and a PappA-B = 5.16 × 10-6 cm/s, ER = 8.06 in MDCK-MDR1 assay, 
suggesting a good BBB penetration potential. UPMP107 met the key drug-like characteristics and 
warrant further in vivo studies for assessment of pharmacokinetics and central target engagement. 
On the strength of the favorable attributes of UPMP107 observed from the in vitro studies, 
the goal of this study was to evaluate the pharmacokinetics and pharmacodynamics of UPMP107 
in vivo. The purpose includes (1) study the pharmacologic effect of 20-HETE inhibition of 
UPMP107; (2) evaluate UPMP107 plasma PK; and (3) evaluate UPMP107 brain PK. In this 
present study, we used a developed and validated UPLC-MS/MS method to quantify UPMP107 
and 20-HETE concentrations in the plasma and brain. The results from this study will provide a 
foundation to help design future animal studies. 
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4.2 Materials and Methods  
4.2.1 Materials 
Arachidonic acid, 20-HETE, 20-HETE-d6, and HET0016 were purchased from Cayman 
Chemicals (Ann Arbor, MI). N-(4-Butyl-2-methylphenyl)acetamide (SMIP004) was purchased 
from Millipore Sigma (Burlington, MA). Organic solvents including acetonitrile, methanol, and 
acetic acid were purchased from ThermoFisher Scientific Co. (Pittsburgh, PA).  
4.2.2 Animals  
Postnatal day (PND) 16-18 Sprague-Dawley male rats (bodyweight 28-42g) were obtained 
from Envigo (Denver, PA). Upon arrival, the animals were maintained on a 12-hour light/dark 
cycle and were given free access to pellets and water. All animal procedures were approved by the 
Institutional Animal Care and Use Committee of the University of Pittsburgh. 
4.2.3 Chemicals and formulation  
UPMP107 was designed and synthesized in the laboratory of Dr. Lee McDermott (School 
of Pharmacy, University of Pittsburgh). UPMP107 was formulated in hydroxypropyl-β-
cyclodextrin (HPβCD) (Mu et al. 2008). Briefly, 1.5mg of UPMP107 powder was added to 1ml 
of 15% HPβCD. The solution was agitated at 450 rpm under room temperature for 48 hours on a 
Titer Plate Shaker (Lab – Line Instruments, Inc., Melrose Park, IL). At the end of the agitation, 
the samples were aliquoted and lyophilized to complete dryness with a Freezone 6 Lyopholizer 
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(Labcono Inc., Kansas City, MO). Samples were reconstituted on the day of animal experiments 
with phosphate-buffered saline (PBS) and filtered using Millipore 0.45 µm, 13 mm PVDF Syringe 
Filters (Fisher Scientific, Pittsburgh, PA) before intravenous administration to animals.  
4.2.4 Single dose pharmacokinetic study  
This study was an open, parallel-group experimental design. Rats were randomly assigned 
to the vehicle or UPMP107 groups. Rats were anesthetized with 3% isoflurane in conjunction with 
50/50 N2O/O2 in a Plexiglas chamber until unconscious. Femoral artery and venous catheters were 
placed with a 50-gauge connected to 10-gauge polyethylene tubing. Mean arterial blood pressure 
(MAP) and heart rate were monitored through the arterial catheter. Arterial blood gases were 
measured at baseline. Rectal temperature was continuously monitored and maintained at 37˚C by 
a heated water blanket system. UPMP107 was administered as a single intravenous (IV) dose. A 
single IV bolus of UPMP107 at either 5, 10, and 20 mg/kg was administered (n=8/group). The 
doses were selected to achieve plasma concentrations of 50-, 100-, and 200-fold of IC50 of 
UPMP107 based on previous plasma concentrations observed in postnatal day 17 rats. Plasma 
sampling time points were at 0, 5, 30, 60, 120, 240, 360, and 480 min after dosing (Table 4.1). The 
sampling scheme is considered long enough to capture the entire time course of UPMP107 based 
on pilot in vivo study in postnatal day 17 rats, where we observed the half-life was approximately 
60 min.  A blood volume of 50 µl was collected at each time point. Blood samples were collected 
via the arterial line for time points before 60 min and collected through the tail vein for time points 
after 60 min. The last blood sample was collected through cardiac puncture right before perfusing 
the brain. Blood samples were collected in heparinized Eppendorf tubes. Within 5min of blood 
collection, plasma was collected by centrifuging at 1000g for 10 min. Rats were euthanized by 
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exsanguination during brain perfusion after the last blood sample at 480 min.  Mixed brain tissue 
(whole left or right hemisphere) was harvested at 480 min. Plasma and brain samples were stored 
at -80˚C until analysis. 
 




0 5 30 60 120 240 360 480 
1 x x x x    x 
2  x   x x x x 
3 x x x x    x 
4  x   x x x x 
5 x x x x    x 
6  x   x x x x 
7 x x x x    x 
8  x   x x x x 
 
4.2.5 Brain distribution study  
A separate cohort of animals received UPMP107 3 mg/kg and 20 mg/kg single IV 
injection. Animals were sacrificed at multiple time-points at 60, 180, 360, 540, or 720 min to 
collect blood and mixed brain tissues (n= 4/time point). The selection of sampling time points was 
exploratory. We hypothesized the PK of UPMP107 drives the PD effect, and a prolonged 20-
HETE formation inhibitory effect is expected due to its relatively long in vitro t1/2 of 267 min. The 
first time point 60 min would capture the early distribution of UPMP107 into the brain. The last 
time point was at 720 min for 3 mg/kg. The last time point was updated to 540 min for 20 mg/kg 
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based on the emerged plasma PK data from 3 mg/kg. A detailed sampling scheme is presented in 
Table 4.2.   
Table 4.2 Blood and brain samples collection scheme for UPMP107 brain distribution 
study at dose level of 3 and 20 mg/kg 
Rat 
Time (min) 
60 180 360 540 or 720 
1 x x x x 
2 x x x x 
3 x x x x 
4 x x x x 
 
4.2.6 Plasma and brain sample preparation  
20-HETE and UPMP107 concentrations were determined using solid phase extraction as 
previously described. Briefly, brain tissue samples were homogenized in 0.12 M potassium 
phosphate buffer containing 5mM magnesium chloride and 0.113 mM butylated hydroxytoluene 
(BHT) and centrifuged at 10,000 rpm for 30 min. The supernatant was collected, 7.5 ng of 20-
HETE-d6 and 7.5 ng of SMIP004 were added to the supernatant as internal standards. The samples 
were extracted using HLB solid phase extraction cartridges (Oasis, Waters, Milford, MA). 
Similarly, plasma samples were added to 1ml of the buffer, and internal standards were added to 
the solution for extraction. Columns were washed with three 1ml of 5% methanol and were eluted 
with 100% methanol. The eluent was dried down under nitrogen gas at 37˚C and reconstituted in 
125ul of 80:20 methanol: deionized water.  
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4.2.7 Quantification of UPMP107 and 20-HETE 
Plasma and brain concentrations of UPMP107 and 20-HETE were determined using a 
validated UPLC-MS/MS method described in Chapter 2. Briefly, analysis of 20-HETE was carried 
out using a UPLC BEH C18, 1.7 μm (2.1 × 100 mm) reversed-phase column (Waters, Milford, 
MA). Mobile phase consisted of 0.005% acetic acid, 5% acetonitrile in deionized water (A) and 
0.005% acetic acid in acetonitrile (B). The flow rate for mobile phases was 0.5 ml/min. The initial 
mixture of mobile phase was 65:35 of A and B. Mobile phase B increased at 0.4 minutes after 
injection from 35% to 70% in a linear gradient over 4 minutes, and again increased to 95% over 
0.5 minutes where it remained for 0.3 minutes. This was followed by a linear return to initial 
conditions over 0.1 minutes with a 1.5 minutes pre-equilibration period prior to the next sample 
run. The total run time was 6.4 minutes for each injection. Injection volumes were 7.5μl. 
Separation of UPMP107 was conducted using the above methods with a slight 
modification in the gradient. The initial mixture of mobile phase was 80:20 of A: B. Mobile phase 
B increased at 2 min from 20% to 70% in a linear gradient over 2 min and maintained at this 
condition for 1.5 min. This is followed by a 1.5 minutes pre-equilibration before the next injection. 
Total run time was 5.5 min and injection volumes were 7.5μl. 
Mass spectrometric analysis detail can be found in Table 2.3. In brief, the analysis was 
performed using a TSQ Quantum Ultra (Thermo Fisher Scientific, San Jose, CA, USA) triple 
quadrupole mass spectrometer coupled with heated electrospray ionization operated in negative 
selective reaction monitoring mode for 20-HETE and positive selective reaction monitoring mode 
for UPMP107. Unit resolutions at both Q1 and Q3 were set at 0.70 full-width at half-maximum. 
Quantitation by selective reaction monitoring analysis on 20-HETE and UPMP107 was performed 
by monitoring their m/z transitions (20-HETE: m/z 325.3 → 251, collision energy: 20 V; 
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UPMP107: m/z 325.3 → 240.3, collision energy: 17 V). Scan time was set at 0.01 seconds and 
collision gas pressure was set at 1.3 mTorr. Analytical data were acquired and analyzed using 
Xcalibur software version 2.0.6 (Thermo Finnigan, San Jose, CA, USA). The linearity range for 
UPMP107 was 12.5 – 1500 pg on column, and the linearity range for 20-HETE was 6.25 – 10,000 
pg on column.  
4.2.8 Pharmacokinetic analysis  
PK parameters were analyzed by two methods. Noncompartmental analysis (NCA) was 
performed for naïve pooled data on the average plasma concentrations using R 4.0.3 (package: 
PKNCA). Briefly, the terminal phase of the plasma concentration-time curve was fitted by linear 
regression of data points to obtain the slope of the terminal phase (λz). The area under the 
concentration-time curve from time zero to infinity (AUC0-∞) was determined using the trapezoidal 
method plus the extrapolated area. The extrapolated area was determined by dividing the last 
measurable concentration at 480 min by λz. Other pharmacokinetic parameters included 
elimination half-life (T1/2), the observed maximum concentration (Cmax), the mean residence time 
(MRT), total body clearance (CL = dose/AUC0-∞), and volume of distribution at steady state (Vss 
= MRT×CL). 
An animal population PK model was developed using the nonlinear mixed effect modeling 
software NONMEM 7.4.3 (ICON Development Solutions, Ellicott City, MD, USA). R 4.0.3 was 
used for dataset preparation and graphical display. One- or two-compartment structural model with 
linear or nonlinear elimination were evaluated to describe UPMP107 plasma concentrations. 
Initial parameter estimates were obtained from NCA results. Individual PK parameters were 
assumed to follow a log-normal distribution with the mean (θ: typical value) and variance (ω2: 
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interindividual variability). Additive, constant coefficient of variation (CCV), and additive plus 
CCV residual error models were tested. The first-order conditional estimation with interaction 
(FOCE-I) algorithm was used throughout model development process. Model selection and 
comparison was based on successful convergence of the minimization process, Akaike information 
criterion (AIC), and goodness-of-fit plots (GOF) including observed concentrations versus 
individual predicted concentrations (IPRED), observed concentrations versus population predicted 
concentrations (PRED), individual conditional weighted residuals (IWRES) versus IPRED, and 
conditional weighted residuals (CWRES) versus time. The predictive performance was also 
evaluated by visual predictive checks (VPC). VPC was performed with 500 runs. For the final 
model, nonparametric bootstrapping (n = 1,000) was performed to check model stability and to 
obtain the confidence intervals (CI) for the model parameters. 
4.2.9 Statistical analysis  
Animal baseline physiology parameters were summarized by descriptive statistics and 
expressed as mean and standard deviation (SD). The Welch-Satterthwaite t-test was used to 
compare the differences between the control group and the treated group. NCA obtained PK 
parameters were summarized as population means for different dosage groups. No statistical 
analysis was performed due to the naïve pooling method. Dose proportionality was evaluated by 
two methods. An analysis of variance (ANOVA) was performed on dose normalized Cmax to 
evaluate the dose proportionality between different dosage groups. The test was performed at a 
level of α equals 0.05. The p-value of the ANOVA test was interpreted in only an exploratory 
manner. No post-hoc test was conducted. A p-value > 0.05 suggests the acceptance of dose 
proportionality. Dose proportionality was also assessed using a power model expressed in 
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Equation 4.1.1, which transformed to linear regression (Equation 4.1.2) after taking natural 
logarithm transformation. Dose proportionality is measured by the estimate and confidence 
interval of β (Equation 4.1.3). A β equals 1 indicates perfect dose proportionality, suggesting 
doubling the dose equals doubling the exposure. If β equals 0, it implies the response is 
independent of the dose. Dose proportionality was accepted when the 90% CI for β lies completely 
within the critical region defined in Equation 4.1.3, where r is the ratio of the highest to the lowest 
administered dose, θL = 0.8 and θH = 1.25 (Smith et al. 2000).  
𝑦 =  𝑒𝑎 × 𝑑𝑜𝑠𝑒𝛽 × 𝑒𝜀 (Equation 4.1.1) 




 ≤  β ≤ 1 +  
ln 𝜃𝐻
ln 𝑟
 (Equation 4.1.3) 
4.3 Results  
4.3.1 Animal baseline physiology  
Sixty-eight PND17 male rats were included in the study, with a mean weight of 35.1 g (28 
– 44.7g). In the brain distribution study, 16 rats were dosed at 3 mg/kg UPMP107, 16 rats were 
dosed for 20 mg/kg UPMP107, each time point comprised of 4 rats. Four rats were treated with 
vehicle. In the single dose pharmacokinetic study, 8 rats were dosed with UPMP107 for each 
dosage group, and 8 rats were administered with vehicle. No adverse effects were observed in 
animals treated with UPMP107. A summary of blood gases at 5 min after UPMP107 IV injection 
and physiological parameters are listed in Table 4.3 for rats in the single dose pharmacokinetic 
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study. At 5 min after compound injection, all physiological parameters were within normal range. 
No differences were observed between UPMP107 and the vehicle group.  
Table 4.3 Baseline physiological variables and blood gas of animals 
 UPMP107  
(Mean ± SD) 
Vehicle  
(Mean ± SD) 
Weight (g) 35.1 ± 4.64 38.3 ± 2.83 
Temperature (˚C) 37.0 ± 0.23 37.2 ± 0.01 
Heart rate (bpm) 364 ± 74.9 375 ± 21.2 
MAP (mmHg) 48.7 ± 5.41 47.5 ± 10.6 
pH 7.36 ± 0.07 7.36 ± 0.07 
pCO2 (mmHg) 42.6 ± 6.68 43.1 ± 3.39 
pO2 (mmHg) 215 ± 28.2 259 ± 10.7 
HCO3
- (mmol/L) 23.9 ± 1.79 22.7 ± 1.56 
Actual base excess  -1.47 ± 2.25 -2.65 ± 2.47 
 
4.3.2 Analytical results  
Chromatographs of UPMP107, 20-HETE, and internal standards are displayed in Figure 
4.1. The R2 of standard curves was ≥ 0.99. The linearity ranged from 12.5 to 1500 pg on column. 
The predicted QC deviation was ≤ 13.3% of the nominal values. Based on the performance of 
standard curves and QC samples, the assay of UPMP107 was accurate, precise, and reproducible. 
Formulated UPMP107 was dissolved in PBS and the concentration was measured by UPLC-
MS/MS method before animal experiments to ensure the correct amount was administered.  
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Figure 4.1 Chromatograms in plasma samples 
The chromatograms are (A) blank, (B) UPMP107, (C) SMIP004, (D) 20-HETE, and (E) 
20-HETE-d6. Tissues and plasma samples underwent solid-phase extraction followed by UPLC-
MS/MS analysis for 20-HETE and UPMP107 as described in the Materials and methods section. 
The UPLC-MS/MS method allows for subsequent analysis of 20-HETE and UPMP107.  
4.3.3 Noncompartmental analysis results 
Concentration-time profiles of UPMP107 following IV administration of 5, 10, and 20 
mg/kg (n=8/group) are illustrated in Fig. 4.2. Mean (S.E.) plasma concentrations were presented 
in Table 4.4. Plasma concentrations were detectable up to 8 hours post-injection.  
NCA was performed on mean plasma concentrations for each dosage group. The PK 
parameters determined by NCA are summarized in Table 4.5. Following IV administration of 
UPMP107, plasma concentrations declined rapidly in a biexponential fashion indicating 
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UPMP107 was rapidly distributed upon dosing. Within 30 min after cessation of intravenous 
administration, plasma levels of UPMP107 declined 74-89% from Cmax.  
The systemic clearance (CL) values for UPMP107 ranged from 13.7 to 20.1 ml/min/kg. 
As the dose increased from 5 to 10 mg/kg, CL values decreased by approximately 32%. As the 
dose increased from 10 to 20 mg/kg, CL values maintained relatively the same with a slight 3% 
increase.  
 The volume of distribution ranged from 415 – 734 ml/kg. The Vss values for UPMP107 
were approximately 6-11 fold greater than the plasma volume and are similar to the total body 
water in rats. Similar to CL, Vss showed a 43% decrease when the dose increased from 5 to 10 
mg/kg and a 17% increase from 10 to 20 mg/kg.  
Elimination half-life and mean residence time were short. The t1/2 and MRT were relatively 
consistent across different dose levels. Elimination half-life ranged from 21.1 to 25.3 min and 
MRT ranged from 30.4 to 36.5 min.  
Since NCA was performed on mean plasma concentrations, therefore, the individual 
concentrations did not contribute to the interpretation of UPMP107 pharmacokinetics. Hence, 
NCA might not accurately analyze the PK parameters, and there was a need to use a population 
approach to incorporate all individual concentrations that would adequately describe UPMP107 
PK in plasma.  
Table 4.4 UPMP107 mean plasma concentrations after IV administration at 5, 10, and 20 
mg/kg 
Time 
Mean plasma concentrations (pg/µl) 
5 mg/kg 10 mg/kg  20mg/kg  
Mean  SE Mean SE Mean SE 
0 25446 2919 36054 994 61604 23776 
5 5048 466 21039 2714 33319 5027 
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30 1906 366 9036 2587 16280 2652 
60 1095 83.3 2188 116 8572 2116 
120 102 14.2 479 92.6 795 230 
240 29.9 8.72 41.4 11.0 70.2 48.2 
360 28.4 17.8 14.5 2.54 24.8 21.3 
480 10.7 2.86 5.95 1.41 9.03 3.46 
 
 
Figure 4.2 Plasma concentration-time profile following UPMP107 IV administration of 5, 10, 
and 20 mg/kg 
Data are presented as individual concentrations in (A) cartesian and (B) semilogarithmic 
scale, and as mean concentrations in (C) cartesian and (D) semilogarithmic scale 
 
Table 4.5 NCA results of UPMP107 following a single IV administration at dose of 5, 10, 
and 20 mg/kg 
PK parameter a 5mg/kg 10mg/kg 20mg/kg 
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(n = 8) (n = 8) (n = 8) 
AUCinf (ng*min/ul) 248.4 732.5 1,425 
AUMCinf (ng*min2/ul) 9,056 22,279 49,179 
MRTinf (min) 36.46 30.41 34.52 
Kel (min-1) 0.02742 0.03288 0.02897 
T1/2 (min) 25.27 21.08 23.92 
CL (ml/min/kg) 20.13 13.65 14.04 
Vss (ml/kg)  734.1 415.2 484.6 
a Standard deviation are not reported since PK parameters calculation was based on mean plasma 
concentrations. 
4.3.4 Dose proportionality  
The dose-proportionality following a single dose of UPMP107 was evaluated for Cmax and 
AUC0-∞. Cmax increased in a proportion less than the increment in dose. As the dose increase in a 
ratio of 1: 2: 4, Cmax increased in the ratio of 1: 1.4: 2.4. On the contrary, AUC0-∞ increased in a 
proportion greater than the increment in dose. As dose increased, AUC0-∞ increased in a ratio of 1: 
2.9: 5.7.  
One-way ANOVA was performed to evaluate dose proportionality on dose normalized 
Cmax. After IV administration, there was a borderline significant (p = 0.049) dose effect for Cmax, 
indicating Cmax increase in a dose-dependent manner. Since p-value is less than 0.05, the null 
hypothesis was not rejected, suggesting a lack of dose proportionality in Cmax. One-way ANOVA 
was not performed on AUC0-∞ due to limited sample size.  
In addition, dose proportionality was evaluated by the power model. The linear regressions 
of individual ln(Cmax) versus ln(dose) and ln(AUC0-∞) versus ln(dose) with 90% confidence 
interval (90% CI) are presented in Fig. 4.3. The slopes (90% CI) for Cmax and AUC0-∞ were 0.60 
(0.32 - 0.88) and 1.26 (0.17 - 2.35), respectively. The slope for AUC exhibited a wide 90%CI, 
suggesting a high variability. The β values for AUC and Cmax did not fall within the equivalent 
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limit of (0.84, 1.16) calculated by Equation 4.1.3 using r = 20/5, θL = 0.8 and θH = 1.25. Based on 
the results of β estimates, UPMP107 AUC0-∞ increased more than expected by dose 
proportionality, while Cmax increased less than expected by dose proportionality. A two-fold 
increase in dose leads to a 0.6-fold increase in Cmax and a 1.26-fold increase in AUC0-∞, 
respectively. The results of the power model analysis are presented in Table 4.6. The results from 
the power model analysis are consistent with the one-way ANOVA analysis on dose-normalized 
PK parameters, suggesting a lack of dose proportionality for Cmax. 
 
Figure 4.3 Regression plots of UPMP107 for (A) AUC0-∞ and (B) Cmax 
The circles are observed AUC0-∞ and Cmax values. The solid lines are the fitted line based 
on the power model. The dashed lines are the 90% CI.  
 
Table 4.6 Dose proportionality results for Cmax and AUC0-∞ based on power model 
Parameters β 90% CI Acceptance range  
Cmax 0.6016 (0.3222, 0.8811) (0.8390, 1.1610) 
AUC0-∞ 1.2595 (0.1685, 2.3505) (0.8390, 1.1610) 
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4.3.5 Brain distribution and pharmacological effect on brain 20-HETE  
A total number of 36 rats were included in the experiment, 32 rats were treated with 
UPMP107, 4 rats were treated with vehicle. Brain concentrations of UPMP107 and 20-HETE 
were measured at 60, 180, 360, 540, or 720 minutes after UPMP107 single IV administration (n 
= 4 per time point). As shown in Fig. 4.4, UPMP107 was able to penetrate BBB rapidly and 
exhibited the same biphasic decline as plasma concentrations. The B/P ratios at each time point 
are presented in Table 4.7. The B:P ratios in both dosage groups showed high variability. At 3 
mg/kg, B/P ratios ranged from 0.7 – 2.2 within the experiment duration. The B/P ratios increased 
as the time increased from 60 min to 720 min, suggesting it may take longer than 180 min to reach 
equilibrium between brain and plasma. At 20 mg/kg, B/P ratios were lower, ranging from 0.1 – 
0.8. The B/P ratios also increased in a similar trend, suggesting B/P ratios after 180 min might be 
more representative of steady-state B/P ratios.  
 
Figure 4.4 Plasma and brain concentration-time profiles of UPMP107 following IV 
administration 
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A single dose of (A) 20 mg/kg and (B) 3 mg/kg of UPMP107 was administered to male 
PND17 SD rats. Symbols and error bars represent means and standard deviation (n =4 per time 
point). 
 
To explore the response-time courses of 20-HETE inhibition, the drug effect was plotted 
against time for the two dosage groups. At 3 mg/kg, there was an initial 84% reduction of brain 
20-HETE levels at 60 min, the inhibitory effect gradually declined and 20-HETE returned to 
baseline level at 360 min. In the 20 mg/kg group, there was an initial 76% reduction in brain 20-
HETE levels at 60 min and the inhibition effect maintained at 60% until 540 min.  





Time (min) 60 180 360 720 
Mean ± SD 0.70 ± 0.33 1.13 ± 0.47 2.20 ± 1.02 1.55 ± 1.13 
20 mg/kg 
Time (min) 60 180 360 540 
Mean ± SD 0.10 ± 0.02 0.51 ± 0.26 0.53 ± 0.17 0.78 ± 0.26 
n = 4/time point 
 
Figure 4.5 Brain 20-HETE levels after UPMP107 administration at 3 and 20 mg/kg 
Brain 20-HETE concentrations are expressed in % of control. Intravenous administration 
of 3 mg/kg UPMP107 inhibited 20-HETE for a short duration. The brain 20-HETE levels returned 
to control value at 360min. A higher dose at 20 mg/kg maintained the 20-HETE inhibitory effect 
throughout the experiment duration.  
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4.3.6 Population PK model  
A total of 27 rats with 117 observations were included to build the pop PK model. Several 
linear and nonlinear compartmental PK models were evaluated to describe UPMP107 plasma 
concentrations. Based on the AIC and GOF plots, a two-compartment model with nonlinear 
elimination and a combined residual error model was selected as the final model that best described 
the data. The system comprised compartment 1 (central compartment) and compartment 2 
(peripheral compartment). The differential equations describing the system are given in Equations 
4.2.1 – 4.2.2. X1, X2 are the drug amount in the central and peripheral compartments, and k12, k21 
are the first-order distribution rate constants. Vmax is the maximum enzyme catalytic velocity; Km 
is the concentration of substrate that reaches half Vmax.  
𝑑𝑋1
𝑑𝑡
= −𝑘12𝑋1 + 𝑘21𝑋2 −  
𝑉𝑚𝑎𝑥 × 𝑋1
𝐾𝑀 ×𝑉1+𝑋1
  (Equation 4.2.1) 
𝑑𝑋2
𝑑𝑡
= −𝑘21𝑋2 + 𝑘12𝑋1 (Equation 4.2.2) 
The GOF plots and the results of visual predictive checks (VPC) are displayed in Fig 4.6 
and 4.7, respectively. The predicted and observed concentrations are overall in good agreement. 
The individual fitted plots of observed versus predicted values are presented in Appendix A 
Figure 1. The model underestimated the observed concentration at later time points and 
overestimated concentrations at earlier time points (Fig. 4.6D). The VPC results suggest the 
model adequately predicts the observed concentrations with regards to the median and the spread 
of the data (Fig. 4.7). 
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Figure 4.6 Goodness-of-fit plots of the final model 
In the (A) observed concentration versus population predicted concentration and (B) 
observed concentration versus individual predicted concentration, the data were evenly 
distributed around the line of identity. The red lines indicate the linear regression fit and the 
black line represent the line of identity. In the (C) individual weighted residuals (IWRES) versus 
individual predicted concentrations and the (D) conditional weighted residuals (CWRES) versus 




Figure 4.7 Visual predictive check of UPMP107 plasma concentrations versus time 
The blue circles indicate the observations. The solid red line represents the median of the 
simulations, the red dashed lines represent the 5th and 95th percentiles of the observed data. The 
shaded regions represent the 95% confidence intervals of the 5th, 50th, and 95th percentiles from 
the predicted data. Overall, the plot demonstrates that the model predictions captures much of the 
observed UPMP107 concentrations within the 5th and 95th percentiles of the simulated values (n 
= 500).  
 
The point estimates for the model parameters of the final model, the nonparametric 
bootstrap median and confidence interval for the model parameters are listed in Table 4.8. Overall, 
the estimated Vmax is 0.0212 mg/min, Km is 21.6 mg/L, V1 is 0.00994 L for the volume of 
distribution for the central compartment, V2 is 0.0166 L for the peripheral compartment, and Q is 
0.0027 L/min for intercompartment clearance. The interindividual variability (IIV) could only be 
estimated for V1 and Q and were dropped for the other PK parameters. No covariates were 
evaluated for the animal popPK model. The bootstrap results from 1000 runs confirmed the 
stability of the final model and 51.4% of the bootstrapping runs were minimized successfully. The 
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median values were close to the parameter estimates from the original dataset with low relative 
biases. 
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Table 4.8 Parameter estimates of the final popPK model from the original dataset and from 1000 bootstrap replicates 
 Nonparametric bootstrap 
Parameter Unit Estimate  RSE (%) Shrinkage (%) Bootstrap median (2.5th – 97.5th PTa) Relative bias (%) 
V1 L 0.00994 8.97  0.009808 (0.008423 – 0.01125) -1.33 
Km mg/L 21.6 28.0  20.8 (11.3 – 69.5) -3.58 
Vmax mg/min 0.0212 21.1  0.0206 (0.0132 – 0.0581)  -2.70 
V2 L 0.0166 11.0  0.0168 (0.0143 – 0.0197)  1.40 
Q L/min 0.0027  33.6  0.0026 (0.00155 – 0.00516) -3.86 
Interindividual variability      
IIV (V1) CV% 7.77 254 76.2 9.8 (0.155 – 24.4) 11.7 
IIV (Q) CV% 234 48.1 31.0 129 (78.0 - 549) 28.7 
Residual variability     
Proportional CV% 27.7 21.3 6.63 26.1 (20.3 – 31.8)  -5.69 
Additive mg/L 15.6 24.5 6.63 15.4 (12.8 – 18.5)  -1.39 
aPT: percentile.  
bRelative bias: = (bootstrap median -final model estimate)/final model estimate × 100. 
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4.4 Discussion and conclusions 
We report for the first time that that UPMP107 penetrates the blood-brain barrier and 
exhibits a quick onset of brain 20-HETE inhibition in pediatric rats. We observe a biphasic decline 
of plasma and brain concentrations after UPMP107 intravenous administration. This study is the 
first attempt to investigate UPMP107 plasma pharmacokinetics, brain pharmacokinetics, and 
efficacy. The findings will provide knowledge for designing future PK and PD studies in animals.  
UPMP107 showed rapid brain penetration. After IV administration, UPMP107 quickly 
distributes throughout the body, evidenced by the fast decline of plasma concentrations (Fig. 4.2). 
Maximum brain concentrations were observed at 1 hour after administration (Fig. 4.4). A shorter 
brain Tmax could not be precluded due to the first brain sample being collected at 1 hour post-
injection. The chemical properties for UPMP107, including molecular weight < 350, clogP ≤ 5, 
number of H-bond donor < 3, number of H-bond acceptor < 7, are favorable attributes seen in 
marketed drugs with passive CNS penetration (Pajouhesh et al. 2005). Previous in vitro MDCK-
MDR1 BBB permeability assay showed that UPMP107 has high permeability from apical to 
basolateral. We observed an influence of dose on the brain-to-plasma ratio (B/P). A higher B/P 
ratio under a lower dose of 3 mg/kg and a lower B/P ratio in the 20 mg/kg group at different time 
points was found. The decreasing B/P ratios with dose might be a sign of dose-dependent brain 
penetration. Since the B/P ratios were calculated by single-point ratios of brain and plasma 
concentrations, this finding should be validated by additional studies and the B/P ratios should be 
calculated by ratios of AUCbrain/AUCplasma. The role of P-glycoprotein in UPMP107 brain 
penetration should also be investigated as it is of great significance in further development.  
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Despite the short plasma half-life of UPMP107, inhibition of brain 20-HETE 
concentrations remained for a prolonged duration. The onset of 20-HETE inhibition was fast. The 
response was the strongest at 1 h post-injection in both dosage groups. Unlike the gradual decline 
of the 20-HETE inhibition observed in the 3 mg/kg group, a saturation of the response was 
observed at 20 mg/kg (Fig. 4.5). The absence of post-peak decline of the inhibitory response in the 
20 mg/kg group may be explained by the sampling time not being long enough to capture the entire 
time course of the PD response. From a pharmacodynamic perspective, the short half-life does not 
necessarily require a continuous infusion to maintain the 20-HETE inhibitory activity. In-depth 
knowledge of the compound transfer to and from the CYP4 enzymes, the affinity for CYP4, and 
target turnover are important information to help study the onset, intensity, and duration of the 
pharmacological response of 20-HETE inhibition (Gabrielsson et al. 2019). The dose-response-
time data from this study and data generated from future studies can be used together with the 
application of mathematical models for dose-response-time analysis to elucidate the possible 
mechanisms of pharmacodynamic responses. 
A good correlation between the estimated plasma PK parameters by NCA and popPK 
analysis was observed. PopPK predicted volume of distribution (Vd) and NCA estimated Vd is in 
close agreement. NCA derived Vss ranged from 415 – 734 ml/kg. The V1 and V2 obtained from 
popPK analysis were 9.94 ml and 16.6 ml, respectively (Table 4.8). For a two-compartment IV 
bolus model, Vss can be calculated using Equation 4.3. A Vss value of 664 ml/kg was obtained after 
normalizing the body weight, which is consistent with the NCA results. For Sprague-Dawley rats, 
the blood volume is 64 ml/kg and the total body water volume is 668 ml/kg (Davies et al. 1993). 
The Vss of UPMP107 is approximately equal to the volume of total body water. UPMP107 is 
distributed to the peripheral compartment as evidenced by the rapid brain distribution (Fig. 4.4) 
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and high intercompartment clearance (Q = 67.5 ml/min/kg). The popPK estimated intrinsic 
clearance (CLint) can be calculated from Equation 4.4. The CLint value of 24.5 ml/min/kg is slightly 
higher than the clearance calculated from NCA (13.7 – 20.1 ml/min/kg). Nevertheless, UPMP107 
has a low clearance as the value is lower than the hepatic blood flow of 55.0 ml/min/kg in rats (De 
Buck et al. 2007). 
𝑉𝑠𝑠 =  𝑉1 +  𝑉2 (Equation 4.3) 
𝐶𝐿𝑖𝑛𝑡 =  
𝑉𝑚𝑎𝑥
𝐾𝑀
 (Equation 4.4) 
UPMP107 has a short biological half-life of 21.7 ± 1.97 minutes. Prior in vitro study 
suggested UPMP107 has a low in vitro intrinsic clearance of 5.19 µl/min/mg of protein in human 
liver microsomes (HLM). Comparing to UPMP107, HET0016 has a 44-fold higher in vitro CLint 
of 227 µl/min/mg of protein in HLM. The short biological half-life was somewhat unexpected 
considering the low in vitro CLint of UPMP107. The underestimation of in vivo clearance has 
several explanations. First, conventional in vitro - in vivo extrapolation (IVIVE) could lead to a ≥ 
10-fold underestimation of hepatic CLint (Chiba et al. 2009). Next, the investigation of UPMP107 
metabolism pathways are insufficient. The measurement of in vitro metabolic stability was carried 
out in HLM, where there could be species difference in enzyme affinity and activity in 
metabolizing UPMP107 between human and rodents. Metabolic stability in HLM system using 
co-factor NADPH overlooked phase II metabolism by UDP-glucuronosyltransferases (UGT). To 
study if phase II enzymes are involved in metabolizing UPMP107, uridine-5′-diphospho-α-D-
glucuronic acid (UDPGA) could be used as the co-factor in HLM. Recently, we studied 107 phase 
II metabolism in both human and rat S9 fraction., and UPMP107 was not metabolized throughout 
the incubation period, suggesting phase II metabolism is likely not involved in the elimination of 
UPMP107. Finally, there could be extrahepatic metabolism in tissues such as kidney, or renal 
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elimination that could contribute to the clearance of UPMP107. Nevertheless, in vivo results 
should always take precedence over in vitro results (Jia et al. 2007). 
Previous pharmacokinetic study in adult Sprague-Dawley rats showed that HET0016 has 
a half-life of 39.6 ± 20.0 minutes, with a clearance of 57.4 ± 14.8 ml/min/kg and a volume of 
distribution of 2400 ml/kg (Mu, Klamerus et al. 2008). To amend the difference in PK due to age 
and body size, we studied HET0016 PK in PND17 rats (data not shown here). The HET0016 CL 
and Vss in pediatric rats were lower compared to adult rats with values of 7.21 ml/min/kg and 444 
ml/kg, respectively. The half-life was similar to that in adults with a value of 42.7 ± 2.4 minutes. 
UPMP107 has a higher CL and a similar Vss compared to HET0016 in PND17 rats. Although the 
half-lives of HET0016 and UPMP107 are similar, the advantages of UPMP107 over HET0016 is 
a higher solubility and a wider selectivity window that enables a large window for dose increment.   
We were unable to conclude a dose-linearity for UPMP107 in the range of 5 – 20 mg/kg 
using various statistical methods. Dose linearity is an important PK assessment during drug 
development. A linear PK suggests dose proportionality, indicating the PK parameters such as 
Tmax, T1/2, CL, Vss, and MRT should remain constant regardless of the dose levels. If dose 
proportionality is not seen, an escalation to higher dose levels may saturate a metabolic or 
elimination pathway that would lead to an upswing of concentrations or exposures (Walker 2004). 
We observed that UPMP107 AUC0-∞ exhibited a more than dose-proportional increase as dose 
increases, and Cmax exhibited a less than dose-proportional increase. In the ANOVA analysis, the 
p-value for Cmax was at borderline significance. The slope of Cmax and AUC did not fall in the 
acceptance range. The nonlinear elimination resulted a better fit evidenced by a 3-unit drop in AIC 
value. In future studies, serial plasma sampling would allow AUC calculation for each animals to 
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increase the sample size for statistical analysis and to further evaluate the dose-linearity of 
UPMP107.  
The current study had some limitations that are worth mentioning. First, the failure to 
conclude dose-linearity was based on a small number of dose levels. Studies are needed with more 
dose levels and full serial plasma sampling in order to collect adequate information to evaluate the 
dose proportionality. Next, we did not measure drug concentration in different brain regions due 
to the limited amount of brain samples that could be harvested from a pediatric rat. Drug 
distribution into and within the brain is governed by multiple factors such as plasma protein 
binding, uptake and efflux transporters, and blood flow; and compounds do not distribute evenly 
across different brain regions (Alavijeh et al. 2005). The target of the action, CYP4 enzymes, are 
expressed in the neocortex, entorhinal cortex, hippocampus, thalamus, and hypothalamus. CYP4 
is also expressed in cerebral vasculature such as endothelial cells, vascular smooth muscle cells, 
and glial limiting membrane of pial arteries and penetrating arterioles (Gonzalez-Fernandez et al. 
2020). Future studies of measuring protein-unbound drug concentrations in different brain regions 
are needed to bring light to the pharmacokinetics and pharmacodynamics of 20-HETE inhibitors 
in the central nervous system.  
In summary, CNS drug development has long been hindered by the inadequate 
consideration of CNS pharmacokinetics and pharmacodynamics. Understanding the plasma PK, 
neuro PK, and neuro PD are of great importance to help inform CNS drug discovery and 
development. This study generated important pharmacokinetic and pharmacodynamic information 
for UPMP107. UPMP107 exhibited a biphasic plasma concentration-time profile after IV 
administration. It has a low clearance and an intermediate volume of distribution with a relatively 
short half-life. We reported for the first time that UPMP107 has a rapid distribution into brain 
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tissues and exhibited brain target engagement where brain 20-HETE levels were reduced. These 
data are of great importance for future preclinical PK/PD study design.   
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5.0 Population Pharmacokinetics of Propofol in ICU patients  
5.1 Introduction  
Patients in intensive care units (ICU) often require sedatives and analgesics to manage pain, 
reduce stress, improve mechanical ventilation synchronization, and keep them comfortable but 
rousable (Sessler et al. 2008, Hughes et al. 2012, Reade et al. 2014). Propofol and benzodiazepines 
are commonly used for ICU sedation. Benzodiazepine sedatives are associated with longer 
duration of the first episode of delirium, longer duration on mechanical ventilation, longer ICU 
and hospital stay, increased risk of delirium, and increased mortality (Pisani et al. 2009, Fraser et 
al. 2013, Lonardo et al. 2014, Zaal et al. 2015). In the current guideline, it is recommended to avoid 
benzodiazepines for sedation in the ICU, and propofol is recommended over benzodiazepines for 
mechanically ventilated patients (Devlin et al. 2018).  
Propofol (2,6-diisopropylphenol) is a short-acting anesthetic frequently used for induction 
and maintenance of general anesthesia or sedation. Propofol has a large volume of distribution of 
5.8 L/kg due to its high lipophilicity, a high clearance of 3.2 L/h/kg. The terminal half-life ranges 
from  4 - 7 h, and may increase up to 1 – 3 days after a 10-day infusion (FDA 2017, Folino. 2020). 
. Due to its rapid onset of action and quick recovery, it is usually given by an i.v. injection of a 
bolus dose followed by continuous infusion. Several population pharmacokinetic (popPK) and 
pharmacodynamic (PD) models have been developed to describe propofol in different populations 
such as children, burnt, underweight, obese or ICU (Barr et al. 2001, Yamashita et al. 2010, Park 
et al. 2018). Usually, propofol pharmacokinetics (PK) can be best described with two-or three-
compartment models. Some popPK models have been programmed in target-controlled infusion 
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(TCI) devices to achieve user-defined plasma or effect-site concentration for optimum 
effectiveness and safety (Eleveld et al. 2018, García Guzzo et al. 2020).  
Critical illness such as sepsis can have a significant influence on physiology and organ 
function such as sepsis-induced liver hypoperfusion and increase in α-1 glycoprotein that will 
affect drug disposition (De Paepe et al. 2002). The PK of propofol in ICU patients differs 
significantly from the PK of propofol in healthy subjects (Schüttler et al. 1985, Shafer et al. 1988). 
Furthermore, there is a large variability in the time to emergence and extubation in ICU patients 
that were given propofol (Barr et al. 2001). Therefore, propofol PK and PD in ICU patients needs 
further investigation.  
The purpose of this study is to characterize the pharmacokinetics of propofol and identify 
covariates that significantly influence the PK parameters in a diverse ICU population available to 
us. The characterization of the PK profile and identification of potential factors can be used to 
better individualize the propofol doses to meet the sedation needs in the critically ill patients. 
5.2 Methods 
5.2.1 Analysis population 
The population for this analysis consisted of propofol-treated ICU patients. Detailed 
information on study conduct, including analytical methodology can be found in the paper 
published by Masica et al. (Masica et al. 2007).  In brief, adult patients who required the use of 
propofol were included in the analysis. Propofol dosing was managed according to clinical 
guidelines. Nurses adjusted doses based on physician-ordered clinical sedation targets to reach 
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these goals. Doses were adjusted by titrating propofol infusion rates and based on patient weight 
(propofol: µg/kg/min). Drug doses were recorded each morning. Sedation levels were measured 
twice daily by study personnel using Richmond Agitation-Sedation Scale (RASS). Blood samples 
(~5 ml) were collected twice daily concurrent with RASS measurements according to the protocol. 
The exact date and time were recorded and were used for the analysis. Blood samples were 
collected up to 48 hr after the cessation of the infusion. 
5.2.2 Bioanalytical assay  
Blood samples were collected in EDTA tubes. Samples were centrifuged and plasma were 
collected and stored in -80˚C freezer until analyzed for propofol using a validated HPLC assay 
with fluorescence detection (Plummer 1987).  In brief, The linearity range for the calibration curve 
was 10-1000 ng/ml (Masica et al. 2007).  
5.2.3 Data handling  
A time-ordered dataset of doses and concentrations was constructed from raw data. The 
data were checked for inaccuracies by investigating any observations that did not reasonably agree 
with the dosing records. Inaccuracies were identified and corrected when possible. Start and end 
times for the infusions were only available for the dose around which plasma samples were drawn. 
According to the protocol, propofol dose entry was recorded every 1 hour. When a dose entry had 
both dose and infusion start time, we assumed the dose was infused at the entered time and used 
the actual start and end time for infusion duration calculation. When an entry had infusion start 
time < 1 h from the previous infusion, but no dose was recorded, we assumed there was no dose 
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infused at that start time. When an entry had infusion start time > 1 h from the previous infusion 
and had a dose recorded, we calculated the actual infusion duration based on the entered time. For 
dose entries before the last measured plasma concentrations that was recorded as 0, but followed 
with non-zero dose, we assumed the dose was stopped for 1 h. For doses entries before the last 
measured plasma concentrations that was recorded as 0, and followed with zero doses, we assumed 
the propofol treatment was stopped for that subject. All other infusions were assumed to have been 
infused for 1h.  
For propofol concentrations, suspected outliers were tested and excluded. Concentrations 
were initially fitted with one compartment model, observations with |CWRES| > 6.0 or |WRES| > 
6.0 were considered as influential samples (Quartino et al. 2016, Li et al. 2020). Cook’s distance 
> 4/n were also used to identify suspected outliers. Data for each subject were fit with and without 
the suspected outlier. If the PK profile was altered significantly (>20% change in the PK parameter 
estimate) and an improvement in the fit was seen in the remaining samples for that patient, the 
observation was determined as a significant outlier and was excluded from the analysis.  
5.2.4 Statistical methods  
All data preparation and presentation were performed using R 4.0.3. The data were 
analyzed using nonlinear mixed effect modeling software NONMEM 7.4.3 (ICON Development 
Solutions, Ellicott City, MD, USA). First order conditional estimation with interaction method 
(FOCE-I) was used throughout the model building process.  
Selection of non-nested models was based on Akaike information criterion (AIC) and 
goodness-of-fit (GOF) plots. A lower number in AIC would support the selection of a model. To 
compared nested models, a minimum value of objective function value (OFV; -2 × log-likelihood) 
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was pursued. The change in OFV follows an asymptotical χ2 distribution. A greater than 3.84 
decrease in OFV was considered a statistically significant improvement (α = 0.05, degrees of 
freedom [dƒ] =1).  
The model was assessed by examination of the following: (1) scatterplot of measured 
concentrations versus population predicted concentrations; (2) scatterplot of measured 
concentrations versus individual predicted concentrations; (3) scatterplot of  individual weighted 
residuals versus individual predicted concentrations; (4) scatterplot of conditional weighted 
residuals versus time since last dose; (5) changes in the estimates of interindividual and residual 
variability; and (4) the precision of the parameter estimates measured by the percent standard error 
of the mean (RSE%= standard error/parameter estimate × 100%) 
5.2.5 Population pharmacokinetic analysis  
The procedure for popPK model development follows structural model development, error 
model evaluation, covariate evaluation, model refinement, and final model evaluation.  
5.2.5.1 Structural model development 
5.2.5.1.1 Compartmental model 
Original plasma concentrations or natural logarithmic transformed concentrations were 
fitted with either one-, two-, and three compartmental models with zero order input and first order 
elimination from the central compartment.  
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5.2.5.1.2 Interindividual variability 
Interindividual variability (IIV) of PK parameters were assumed to be log-normal 
distributed and were modeled using an exponential error model given by equation 5.1 where 𝑋𝑗 is  
the true value of the 𝑋 parameter in the jth individual, ?̃?𝑗 is the typical value of parameter 𝑋 in the 
jth individual, and 𝜂𝑗
𝑥is the variability that is normally distributed with a mean of 0 and a variance 
of ω2 (η~(0, ω2)). The estimates are presented as percent coefficient of variation (%CV). For IIV, 
several forms of variance-covariance matrix structure were explored. 




5.2.5.1.3 Residual variability 
 
Residual variability was described using an additive model (Equation 5.2.1), constant 
coefficient of variation (CCV) model (Equation 5.2.2), additive plus CCV model (Equation 5.2.3), 
or log error model (Equation 5.2.4). 𝐶𝑝𝑖𝑗  represents the measured 𝑖th concentration in the 𝑗th 
subject, 𝐶𝑝𝑖𝑗  represents the predicted 𝑖 th concentration in the 𝑗 th subject, 𝜀𝑖𝑗  is the random 
variable which represents the difference between the measured and the predicted 𝑖 th serum 
concentration in the 𝑗th subject. 𝜀𝑖𝑗 is normally distributed with a mean of 0 and variance of σ
2 and 
represents additive, proportional, additive and proportional, and log error in equations 5.2.1-5.2.4, 
respectively.  
𝐶𝑝𝑖𝑗 = 𝐶?̂?𝑖𝑗 + 𝜀𝑖𝑗 (5.2.1) 
𝐶𝑝𝑖𝑗 = 𝐶?̂?𝑖𝑗 × (1 + 𝜀𝑖𝑗) (5.2.2) 
𝐶𝑝𝑖𝑗 = 𝐶?̂?𝑖𝑗 × (1 + 𝜀1𝑖𝑗) + 𝜀2𝑖𝑗 (5.2.3) 
𝑙𝑜𝑔𝐶𝑝𝑖𝑗 = 𝑙𝑜𝑔𝐶?̂?𝑖𝑗 + 𝜀𝑖𝑗 (5.2.4) 
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5.2.5.2 Covariate model development 
After an adequate structural model was identified, individual Bayesian estimates of the PK 
parameters were generated. Diagnostic plots of parameters versus covariates were generated and 
evaluated for observable trends. If large numbers of patients had missing values for a covariate, 
the covariate was not evaluated.  
The covariates were prespecified based on clinical significance and literature reports. For 
continuous covariates such as age and body weight, the relationship between the typical value of 
a parameter and a continuous covariate was evaluated either linear, exponential or power model in 
equations 5.3.1 – 5.3.3. For dichotomous and categorical covariates, the relationship between the 
typical value of a parameter and a covariate was evaluated with either additive or proportional 
model in equations 5.3.4 – 5.3.5. 
Linear: 𝑋?̃? = 𝜃𝑋
𝑖𝑛𝑡 + 𝜃𝑋
𝐶𝑂𝑉 × (𝐶𝑂𝑉𝑗 − 𝐶𝑂𝑉̅̅ ̅̅ ̅̅ ) (5.3.1) 
Exponential: 𝑋?̃? = 𝜃𝑋
𝑖𝑛𝑡 × 𝑒𝜃𝑋
𝐶𝑂𝑉∙(𝐶𝑂𝑉𝑗−𝐶𝑂𝑉̅̅ ̅̅ ̅̅ ) (5.3.2) 
Power: 𝑋?̃? = 𝜃𝑋




Additive: 𝑋?̃? = 𝜃𝑋 + 𝜃𝑋
𝐶𝑂𝑉 × 𝐶𝑂𝑉𝑗 (5.3.4) 
Proportional: 𝑋?̃? = 𝜃𝑋 × (1 + 𝜃𝑋
𝐶𝑂𝑉 × 𝐶𝑂𝑉𝑗) (5.3.5) 
Where:  
𝑋?̃? : estimated typical parameter value in the 𝑗th subject;  
𝐶𝑂𝑉𝑗: measured value of a covariate in the 𝑗th subject; 
𝐶𝑂𝑉̅̅ ̅̅ ̅̅ : median value of a covariate in the 𝑗th subject;  
𝜃𝑋
𝑖𝑛𝑡: estimated parameter population mean for subjects with the median value of a covariate 
𝜃𝑋
𝐶𝑂𝑉: linear: change in parameter value per unit change in a covariate  
exponential: change in log parameter value per unit change in a covariate  
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power: change in log parameter value per unit change in log covariate  
proportional: the increase or decrease in 𝜃𝑋 for subjects with 𝐶𝑂𝑉𝑗 = 1 
𝜃𝑋: estimated parameter population mean for subjects with 𝐶𝑂𝑉𝑗 = 0 
 
Stepwise forward inclusion and backward elimination was used for covariate model 
development. At least a 3.84 decrease in OFV (α = 0.05, dƒ = 1) needed to be achieved for 
covariates to be considered significant. The covariate that contributes to the most significant 
reduction in OFV was added to the structural model. The forward inclusion was repeated until no 
further covariates produce additional significant changes in the OFV. This model was considered 
the full model. Each covariate was then removed from the model using backward elimination 
method. A covariate was considered significant if it contributed at least a 10.84 increase in the 
OFV (α = 0.001, dƒ = 1) when removed from the model. This process was repeated until all 
remaining covariates were significant.  
The final model including all significant covariate was then evaluated by visual predictive 
check (VPC) and bootstrap, where patients were randomly sampled with replacement, and the 
parameter estimates from actual analysis and bootstrap results were compared to evaluate the 
robustness of the model. 
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5.3 Results  
5.3.1 Patient characteristics  
A total of 119 subjects were included in the analysis. The demographic profiles of subjects 
are summarized in Table 5.1 and 5.2. Frequency distribution histograms for the continuous 
demographic characteristics are provided in Fig. 5.1. These plots demonstrated that there was a 
wide distribution of baseline demographic characters. The overall population used to develop the 
population PK model had a slightly larger number of males than females. Most patients were White 
(87.4%). The median age was 54 years and ranged from 19 to 91 years. The median weight was 
87.9 kg and ranged from 34.5 to 272 kg.  
Table 5.1 Demographic characteristics of the analysis population (continuous variables) 
Demographics Mean Median (min – max) 
Age (yr) 53 54 (19 - 91)  
Weight (kg) 94.2 87.9 (34.50 - 272) 
Height (cm) 172.1 172.7 (142.2 – 205.7) 
BMI (kg/m2) 31.6 28.4 (12.3 - 84.3) 
Bilirubin (mg/dl) 2.31 1.20 (0.3 – 39.3) 
Creatinine (mg/dl) 1.79 1.30 (0.38 – 9.36) 
 
Table 5.2 Demographic characteristics of the analysis population (catogorical variables) 
 Number of individuals Percent (%) 
Sex    
Male 68 57.1 
Female 51 42.9 
Race   
White  104 87.4 
Black  15 12.6 
Hepatic SOFA score    
0 81 68.1 
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1 15 12.6 
2 17 14.3 
3 5 4.20 
4 1 0.840 
Cardiovascular SOFA score   
0 27 22.7 
1 47 39.5 
2 3 2.52 
3 22 18.5 
4 20 16.8 
ICU type    
Medical  79 66.4 
Surgical  40 33.6 
 
 
Figure 5.1 Frequency distribution histograms of continuous demographics variables for the 
analysis population 
Histograms show a wide distribution in baseline weight, age, height, BMI, creatinine and 
bilirubin levels among included subjects.  
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5.3.2 Sample description and outlier analysis 
A total of 253 PK samples were available from 119 subjects before removing the outliers. 
The observed plasma concentration (DV) versus time since last dose (TSLD) was presented in Fig. 
5.2. An iterative process was taken to identify outliers in the initial structural model. Individual fit 
was examined for each patient with and without the outlier. A total of 19 observation records were 
deleted from the population PK analysis for the following reasons: patients with missing dosing 
histories (n = 2); unreasonable concentrations that exceed the upper limit of propofol plasma 
concentration usually observed in the literature (10,000 ng/ml) (n = 3); relatively high propofol 
concentrations based on individual dosing profiles and concentration-time trajectories that are not 
plausible (n = 14) (Table5.3). Following the deletion of these data, a total of 234 propofol 
concentrations from 116 subjects were available for the development of the population PK model. 
Most of the PK samples were sparse. Number of samples per patient and distribution of sampling 
time are presented in Table 5.4 and Figure 5.3.  
 
Figure 5.2 DV versus TSLD  
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(A) Observed concentration (DV) versus time since last dose (TSLD) and (B) natural logarithm 
transformed DV versus TSLD. Three concentrations were greater than 20-fold than the reported 
upper limit (10,000 ng/ml) of propofol plasma concentration.  
 
Table 5.3 Summary of outliers that were removed from the dataset 
Samples excluded Patients excluded Reason for exclusion 
3 0 
Extremely high concentration values > 200,000 
ng/ml 
2 1 No dosing information 
14 2 
Relatively high concentration values that were not 
plausible based on the dosing information 
 
 
Figure 5.3 Frequency distribution histrogram of time since last dose (TSLD) for all 
concentrations 
 
Table 5.4 Distribution of the number of PK samples per patient 
Number of samples per patient Number of patients  Percent (%) 
1 41 35.3  
2 47 40.5 
3 17 14.7 
4 7 6.03 
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5 4 3.45 
 
5.3.3 Structural pharmacokinetic model  
A two-compartment model with zero-order intravenous infusion and first-order linear 
elimination was fit to the sparse PK data. The model parameters contained CL, V1, Q, and V2. 
Interindividual variability of CL, V1, Q, and V2 was described using an exponential error model. 
A combined additive and CCV error model was used to describe the residual variability.  
The results indicated that the model was able to support the estimation of all parameters 
except the interindividual variability (IIV) of the central volume of distribution (V1). Specifically, 
the variance for V1 interindividual variability was close to zero (0.00198) with a precision (%RSE) 
of 5707%. The removal of IIV(V1) improved the parameter estimation for CL, V1, and Q typical 
values where the %RSE changed from 35%, 156%, and 27% to 24%, 32%, and 17% respectively. 
Therefore, the IIV of V1 was removed and the model was re-evaluated. Population parameter 
estimates and precisions (%RSE) are provided in Table 5.5 for the structural model. The model 
parameters were within reasonable precision (%RSE < 50%) except for V1 and additive 
component of the residual error. The GOF plots suggested that there was a slight underprediction 
for high concentrations and at early time points (Fig. 5.4). One or three-compartment models were 
also tested to see if there were improvements in the model fit. One compartment model 
underpredicted concentrations to a larger degree and the sparse data were not able to support a 
more complex three compartment model. The covariances were also estimated in NONMEM to 
improve the fit of the model. There was a high degree of correlation between CL and Q as shown 
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in Table 5.6. The process of structural model development and model selection are presented in 
Appendix B Table 8. 
 
Figure 5.4 Goodness-of-fit plots for the structural model 
(A) Observed propofol concentration (DV) vs. population predicted concentration (PRED); (B) 
Observed propofol concentration vs. individual predicted concentration (IPRED); (C) Conditional 
weighted residuals (CWRES) vs. population predictions and (D) conditional weighted residuals 
vs. time. The black lines in (A) and (B) represent the line of unity. The solid black lines in (C) and 
(D) represent y = 0. The red line is the smoothing line. 
 
Table 5.5 Parameter estimates of the base structural model  
Parameter Unit Estimate  RSE (%) Shrinkage 
(%) 
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CL L/h 53.7 20.5  
V1 L 32.2 53.1  
Q L/h 240 20.6  
V2 L 6860 17.8  
Interindividual variability    
IIV (CL) CV% 208 26.0 50.8 
IIV (Q) CV% 112 43.4 34.6 
IIV (V2) CV% 214 17.4 44.0 
Residual variability   
Proportional CV% 42.8 14.8 29.3 
Additive mg/L 14.3 101 29.3 
RSE: relative standard error; V1: volume of distribution of central compartment; Q: 
intercompartment clearance; V2: volume of distribution of peripheral compartment; IIV: 
interindividual variability.  
 
Table 5.6 Correlation matrix for the PK parameter estimates from the structural model 
 CL  Q  V2 
CL 1.00   
Q 0.753 1.00  
V2 0 0 1.00 
 
5.3.4 Forward selection of covariates 
There were 234 records from 116 subjects in the dataset used for the covariate modeling 
development. Univariate linear regression was performed to explore the relationship between PK 
parameters and covariates. The univariate plots of CL versus covariates, V2 versus covariates, and 
Q versus covariates are provided in Fig. 5.5-5.7. The significant relationship based on univariate 
regression were sex with CL; weight, BMI, and hepatic SOFA score with V2; weight and sex with 
Q. Age, and creatinine were reported to be significant covariates in the literature, so we tested the 
statistical significance for the addition of these covariates as well. Since more than 10% of the 
subjects were missing bilirubin measurement, it was not included in the covariate assessment. 
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The abovementioned covariates were included by forward selection. During the first step 
of forward selection, the most significant relationship was between sex and CL and was therefore 
added to the base model. During the second step of forward selection, the effect hepatic SOFA 
score at enrollment on V2 was most significant and was therefore added to the model. During the 
third step of forward selection, the most significant covariate from this step was the relationship 
between BMI and V2 and was therefore added to the model. During the fourth step, there was no 
significant covariate that demonstrated a relationship with PK parameters. Summaries of 
covariates being tested during each step, the functional form, and the statistical significance are 




Figure 5.5 Univariate plots of various covariates versus propofol CL 
The line inside the boxplots represents the median, the upper and lower limits of the box 
are the 75th and 25th percentiles. The upper and lower error bars indicate the 95th and 5th percentiles. 





Figure 5.6 Univariate plots of various covariates versus propofol V2 
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Figure 5.7 Univariate plots of various covariates versus propofol Q 
 
Table 5.7 Step one covariate selection for CL, V2, and Q 




1a Sex on CLa Exponential  -6.82 
1b Age on CL Power   -3.25 
1c Weight on CL Exponential  -5.09 
1d BMI on CL Exponential  -2.78 
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1f Creatinine on CL  Additive  -0.49 
1g SOFA liver on CL Proportional  -3.07 
    
1h Sex on V2 Exponential   -3.66 
1i Age on V2 Additive  -1.70 
1j Weight on V2 Power  -6.02 
1k BMI on V2 Exponential  -6.16 
1l Creatinine on V2 Additive -1.94 
1m SOFA liver on V2 additive -4.99 
1n Sex on Q Additive  -2.42 
1o Age on Q Power  0 
1p Weight on Q Exponential  -5.62 
1q BMI on Q Exponential  -4.70 
1r Creatinine on Q Additive  0 
1s SOFA liver on Q Additive  -0.61 
a The grey shaded covariate is the most significant covariate found in the step 
 
Table 5.8 Step two covariate selection for CL, V2, and Q 
Model Parameter added   Functional form ΔOFV 
Base Sex on CL  0 
2a Age on CL Additive   2.32 
2b Weight on CL Power   -0.13 
2c BMI on CL Power  -1.64 
2d Creatinine on CL  Additive  0.03 
2f SOFA liver on CL Additive  -0.22 
2g Sex on V2 Exponential   0.87 
2h Age on V2 Additive  -0.53 
2i Weight on V2 Exponential    -2.12 
2j BMI on V2 Power  -4.58 
2k Creatinine on V2 Additive 0.37 
2l SOFA liver on V2 additive -5.67 
2m Sex on Q Exponential   0.93 
2n Age on Q Additive 0.02 
2o Weight on Q Exponential  -1.40 
2p BMI on Q Exponential  -1.48 
2q Creatinine on Q Additive  -0.01 
2r SOFA liver on Q Additive  3.68 
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Table 5.9 Step three covariate selection for CL, V2, and Q 
Model Parameter added   Functional form ΔOFV 
Base Sex on CL, SOFA on V2  0 
3a Age on CL Power    2.65 
3b Weight on CL Power   -0.20 
3c BMI on CL Power  -0.36 
3d Creatinine on CL  Additive  0.15 
3e SOFA liver on CL Additive  -0.66 
3f Sex on V2 Exponential   -0.21 
3g Age on V2 Exponential   -0.03 
3h Weight on V2 Power     -1.70 
3i BMI on V2 Power  -3.88 
3j Creatinine on V2 Additive -0.13 
3k Sex on Q Exponential   -0.03 
3l Age on Q Additive -0.01 
3m Weight on Q Power  -0.73 
3n BMI on Q Exponential  -1.57 
3o Creatinine on Q Additive  0.24 
3p SOFA liver on Q Proportional   0.08 
 
Table 5.10 Step four covariate selection for CL, V2, and Q 
Model Parameter added   Functional form ΔOFV 
Base Sex on CL, SOFA on V2, BMI on V2  0 
4a Age on CL Additive     0 
4b Weight on CL Power   -0.20 
4c BMI on CL Power  -0.36 
4d Creatinine on CL  Additive  -0.33 
4e SOFA liver on CL Additive  -0.22 
4f Sex on V2 Exponential   0 
4g Age on V2 Exponential   -0.05 
4h Weight on V2 Power     -0.98 
4i Creatinine on V2 Additive 0 
4j Sex on Q Exponential   -0.11 
4k Age on Q Additive 0 
4l Weight on Q Exponential   -3.14 
4m BMI on Q Exponential  1.29 
4n Creatinine on Q Additive  0 
4o SOFA liver on Q Proportional   -0.12 
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In summary, after forward selection, the covariate sex, hepatic SOFA score, and BMI were 
found to be significant predictors for propofol CL and V2. The equations for CL and V2 are 
provided in Equations 5.4.1-5.4.3. 
TVCLj (L/h) = 20.6 × e
1.08×SEX (5.4.1) 
If SOFA ≤ 3, TVV2j (L) = 8150 × (BMI/29.27)
0.984 (5.4.2) 
If SOFA ≥ 4, TVV2j (L) = 8150 × (BMI/29.27)
 0.984 – 1630 × SOFA (5.4.3) 
TVXj = the typical value of the X
th parameter for the jth subject.  
SEX = indicator variable in the jth subject with a value of 1 for male and 0 for female.  
SOFA = hepatic SOFA score ranged from 0 – 4.  
BMI = body mass index calculated as body weight in kilograms divided by height in meters. 
5.3.5 Evaluation of the full model  
Population mean parameter estimates and precision from the full model are provided in 
Table 5.11. The addition of covariates decreased interindividual variability on CL and V2. The 
addition of SEX explained CL variability by 45%. The addition of hepatic SOFA score and BMI 
explained V2 variability by 8%. Figure 5.8 shows the GOF plots for the full model. There was a 
slightly better agreement between the population predicted and individual predicted concentrations 
versus observed concentrations than previously observed with the base structural model. Further 
attempts were made to estimate the IIV for V1, however, the data could not support the estimation 
of this parameter. The plot of individual weighted residual error versus individual predicted 
concentrations did not reveal observable biases across the predicted concentrations.   
The results of the full model showed that the precision of V1 was large (RSE %= 282). The 
effect of sex, hepatic SOFA, and BMI on CL and V2 was reasonably estimated with RSE% ranging 
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from 45% to 54%. The additive residual error also estimated with large uncertainty (RSE% = 
119%).  
 
Figure 5.8 Goodness-of-fit plots for the full model 
(A) Observed propofol concentration (DV) vs. population predicted concentration (PRED); (B) 
Observed propofol concentration vs. individual predicted concentration (IPRED); (C) Conditional 
weighted residuals (CWRES) vs. population predictions and (D) conditional weighted residuals 
vs. time. The black lines in (A) and (B) represent the line of unity. The solid black lines in (C) and 
(D) represent y = 0. The red line is the smoothing line. 
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Table 5.11 Parameter estimates of the full popPK model replicates 
Parameter Unit Estimate  RSE (%) Shrinkage (%) 
CL L/h 20.7 59.9  
V1 L 27.4 282  
Q L/h 280 53.2  
V2 L 8160 38.2  
SEX on CL  1.08 44.9  
SOFA on V2  -1640 46.4  
BMI on V2  0.984 54.2  
Interindividual variability    
IIV (CL) CV% 163 95.4 39.3 
IIV (Q) CV% 120 36.4 39.7 
IIV (V2) CV% 206 23.6 13.5 
Residual variability   
Proportional CV% 41.8 16.1 27.1 
Additive mg/L 13.7 119 27.1 
 
5.3.6 Backward elimination of covariates  
Stepwise backward elimination was performed. The effects of BMI on V2, hepatic SOFA 
on V2, and sex on CL were removed from the model in a stepwise fashion. Details of each step of 
backward elimination process are provided in Table 5.12. The covariate of BMI on V2, hepatic 
SOFA score at enrollment on V2, and sex on CL were removed from the full multivariate model 
(p > 0.01).  
Table 5.12 Backward elimination of covariates 
Model Parameter added ΔOFV p-value 
Full  Sex on CL, SOFA on V2, BMI on V2 0  
5a -BMI on V2 3.75 0.053 
5b -SOFA on V2 4.85 0.028 
5c -Sex on CL 3.66 0.056 
5d -Sex on CL, -BMI on V2 3.85 0.050 
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5e -Sex on CL, -SOFA on V2 4.89 0.027 
5f -Sex on CL, -BMI on V2, -SOFA on V2 7.30 0.0069 
 
5.3.7 Final model  
The population mean parameter estimates and precisions of the final model are provided 
in Table 5.13. The precision for V1 and additive residual error were greater than 50%, but the 
remaining parameters were estimated with acceptable precision. Given the lack of covariates 
identified through the backward elimination, this is the best model that was fitted to the sparse 
data.  
 
Figure 5.9 Visual predictive check of the final model 
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The blue dots represent the observed data. The solid red line indicates the 50th percentile 
of the simulated data. The red dashed lines indicate the 5th and 95th percentiles of the observed 
data. The shaded areas represent 95% confidence intervals of the simulated 50th percentile and 5th 
and 95th percentiles. Overall, the plot demonstrates that the model predictions captures much of 
the observed concentrations within the 5th and 95th percentiles of the simulated values (n = 500).  
 
No model misspecification was detected from the VPC (Fig.5.9). The bootstrap results 
from 1000 runs confirmed the stability of the final model and 79.7% of the bootstrapping runs 
were minimized successfully. Median values of the parameters obtained from bootstrap datasets 
(n=1000) are displayed in Table 5.13. For CL, Q, and V2 the mean estimates from the original 
dataset are close to the median value of estimates from the bootstrap analysis, suggesting the mean 
estimates from the final model are relatively unbiased. The relative biases for V1 was high (-
28.3%), suggesting the mean estimate of V1 is somewhat biased. The frequency histograms of the 
mean PK parameter estimate distribution histograms from the bootstrap analyses are shown in 
Appendix Fig 2.  
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Table 5.13 Parameter estimates of the final popPK model from the original dataset and from 1000 bootsrap replicates 
 Nonparametric bootstrap 
Parameter Unit Estimate  RSE (%) Shrinkage (%) Bootstrap median (2.5th – 97.5th PTa) Relative bias (%) 
CL L/h 53.7 20.5  44.8 (26.1 – 80.1) -16.6 
V1 L 32.2 53.1  23.1 (11.3 – 68.7) -28.3 
Q L/h 240 20.6  262 (117– 372)  9.17 
V2 L 6860 17.8  8102 (3846 – 10382)  18.1 
Interindividual variability      
IIV (CL) CV% 208 26.0 50.8 172 (58.6 – 350) -20.9 
IIV (Q) CV% 112 43.4 34.6 119 (56.4 – 224) 5.88 
IIV (V2) CV% 214 17.4 44.0 211 (123 – 313) -1.42 
Residual variability     
Proportional CV% 42.8 14.8 29.3 41.5 (35.5 – 47.0) -3.13 
Additive mg/L 14.3 101 29.3 14.0 (4.87 – 23.1) -2.14 
aPT: percentile. 
bRelative bias: = (bootstrap median -final model estimate)/final model estimate × 100.  
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5.4 Discussion and conclusions  
The objective of this project was to develop a population pharmacokinetic model to 
describe the pharmacokinetics of propofol in a heterogeneous ICU population.  The final model 
that best fit the data was a two-compartment model with zero-order infusion and linear elimination. 
There was high degree of variability in CL, V2, and Q in this ICU population.  Further development 
of the model was performed to understand the influence of demographics, covariates on the 
pharmacokinetics of propofol in this target population. Hepatic SOFA score was a significant 
covariate on V2.  
The population mean clearance was estimated to be 53.7 L/h. This value is smaller than 
previously reported values in ICU patients that underwent long-term sedation (87.6 L/h, 12.4 
%CV) (Smuszkiewicz et al. 2016). In a multicenter popPK analysis, where 256 out of 270 subjects 
underwent surgery, the authors reported a CL of 86.4 L/h, 37.4 %CV (Schuttler et al. 2000).  . 
Distributive clearance (240 L/h) is larger compared to reported values in ICU patients ranging 
from 69 to 111 L/h (Smuszkiewicz et al. 2016, Blussé van Oud-Alblas et al. 2019). The population 
mean for central volume of distribution (V1) was 32.2 L and the estimated value for peripheral 
volume of distribution (V2) was quite large (6860 L). The large volume of distribution reported in 
critically ill patients ranged from 499 to 4850 L (Bailie et al. 1992, Frenkel et al. 1995, Barr et al. 
2001). The differences in clearance and volume of distribution seen in the current analysis 
compared to reported values have several explanations. First,  the sparse samples in our dataset 
pose a challenge in estimating clearance and volume of distribution for multi-compartmental 
drugs. For patients included in the study, their plasma samples were collected twice daily 
 176 
concurrent with sedation level measurements up to 48 hr after the cessation of the infusion. The 
design of the sampling time points was not optimal for clearance or volume of distribution 
estimation. Among the 234 available samples, 143 samples (59%) were collected during the 
infusion, which provides limited information for propofol elimination. The limited absolute 
number of samples per patient and the inconsistent sampling time could cause difficulty in 
predicting precise parameter values. The referenced studies contain rich PK data. Smuszkiewicz 
et al. included 393 propofol concentrations from 29 subjects and the multicenter popPK anlaysis 
by Schuttler et al. included 4112 concentrations from 270 subjects. (Schuttler et al. 2000, 
Smuszkiewicz et al. 2016).  With limited sampling strategies, optimization of sampling times are 
of particular importance (Sylvie Retout n.d.). Second, the less controlled study used in this analysis 
may preclude the ability to obtain accurate estimates as evidenced by the relatively large RSE% 
seen in V1. The effect of sample size and sampling time on variability in propofol PK parameters 
had been reported. There was an as large as 25-fold difference in central volume of distribution 
and a 2-fold difference in clearance between three studies when different numbers of samples and 
different sampling time points were used to derive the propofol pharmacokinetics (Reed 1999). In 
addition, the uncertainty in infusion duration may contribute to the large proportional residual 
error. 
A secondary objective of this analysis was to study if any patient factors could help explain 
the interindividual variability in propofol pharmacokinetic parameters. The current analysis did 
not identify significant covariates for PK parameters.  Common covariates that explain parameter 
variability usually include body weight and age for CL; body weight or BMI for volume of 
distribution (Sahinovic et al. 2018). In our analysis, we did not identify any covariates that 
significantly explained the variability in PK parameters. The lack of significant covariates on 
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propofol clearance and volume of distribution has also been reported in an ICU population that 
underwent long-term sedation (Smuszkiewicz et al. 2016). In the three-compartment model, the 
interindividual variability for V1, Q1, and V2 were not able to be estimated. The interindividual 
variability for CL, V1, and Q2 was 52.0%, 90.1%, and 249%, respectively. And, the authors 
reported none of the covariates were significant. The inability to identify covariates when there 
was a large variability in the parameter distribution could be contributed by the relatively large 
shrinkage values (> 30%). The possible relationships between covariates and parameters may be 
masked or falsely presented (Savic et al. 2009). Another explanation is the aforementioned 
difficulty in obtaining accurate parameter estimates, which could be due to the sampling scheme 
or data inaccuracies secondary to the study design. 
In conclusion, a population pharmacokinetic model was developed to describe propofol 
concentrations in a heterogeneous ICU population. A two-compartment model with zero-order 
infusion and first-order elimination best described the data. No covariates were found significant. 
The large interindividual variability within ICU patients requires individualized dosing based on 
the degree of sedation. Future studies with serial PK collections in this population would help to 
inform the model and improve parameter precision. 
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6.0 Summary and Future Directions 
The main objective of this thesis dissertation was to develop novel compounds that inhibit 
20-HETE formation, which aimed to improve cerebral blood flow to ameliorate secondary brain 
injury. This was achieved by 1) development and validation of bioanalytical assays to assist the 
evaluation of metabolic stability, CYP inhibition, and quantification of preclinical candidate of 
interest; 2) in vitro screening of over 140 compounds and evaluation of compounds by a multi-
tiered approach to select preclinical candidate UPMP107 that has best drug-like properties; and 3) 
in vivo efficacy and pharmacokinetics evaluation of UPMP107 in healthy pediatric rats. The 
secondary objective of this dissertation was to characterize the pharmacokinetics of propofol in a 
heterogeneous ICU population. This was achieved by 1) development of a structural population 
pharmacokinetic model and 2) exploration of covariates that could potentially explain to the 
variability of the propofol pharmacokinetic parameters. The key findings, clinical implications, 
and future directions are discussed in the following sections. 
6.1 Key research findings 
6.1.1 Development and validation of bioanalytical assays 
The development and validation of UPLC-MS/MS methods for metabolic stability, CYP 
inhibition, and quantification of UPMP107 are described in Chapter 2. The development of these 
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assays facilitated the evaluation of drug-like properties and measurement of preclinical candidate 
in biological samples. 
In the metabolic stability assay, we utilized the substrate disappearance method to evaluate 
in vitro metabolic stability in HLM. The substrate concentration was 1 µM to ensure linear 
reaction. The protein concentration was 0.5 mg/ml to minimize nonspecific binding. The 
incubation duration was 1 hour. This assay enables the assessment of in vitro clearance for novel 
compounds. The sample processing was simple and time efficient. The UPLC-MS/MS method 
developed for each compound had a short run time and was specific. This assay was developed to 
specifically support the work described in Chapter 3.  
To evaluate the in vitro drug-drug interaction, a CYP cocktail assay was developed. 
Phenacetin, diclofenac, S-mephenytoin, dextromethorphan, and midazolam were probe substrates 
for CYP1A2, 2C9, 2C19, 2D6, and 3A4, respectively. The protein concentration was 0.1 mg/ml. 
The concentrations of probe substrates were below their corresponding Km values to ensure the 
linear formation of metabolites. A UPLC-MS/MS method was developed to simultaneously 
quantify the five metabolites. The method had a short run-time and passed FDA bioanalytical 
method validation recommendations (FDA 2018). The method was developed to support the work 
in Chapter 3.  
We also reported the first UPLC-MS/MS method for the quantification of novel 20-HETE 
formation inhibitor UPMP107. The method was validated according to the FDA bioanalytical 
method validation guidance. The UPLC-MS/MS assay supported the quantification of UPMP107 
and 20-HETE under the same LC method, which improves the efficiency of sample processing 
and sample quantification. The method was developed to support the work described in Chapter 
4. 
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6.1.2 In vitro evaluation of novel 20-HETE formation inhibitors 
The objective of this chapter was to identify preclinical candidate that inhibit 20-HETE 
formation through preclinical evaluation of drug-like properties and other characteristics including 
potency, solubility, selectivity, metabolic stability, in vitro BBB permeability, CYP inhibition, and 
in vitro toxicity. The screening of entire library of compounds was carried out in three types of 
microsomes: HLM, RLM, and rCYP4F2. The formation rate of 20-HETE was used as an indicator 
to identify active compounds. The potency and selectivity of 20-HETE over EETs/DiHETs was 
evaluated in HLM. Quantification of an arachidonic acid metabolite panel including 10 metabolites 
were used to derive IC50 values for 20-HETE formation inhibition and selectivity of ω-hydroxylase 
versus epoxygenase. In vitro metabolic stability was evaluated by the previously developed 
metabolic stability assay. The calculated in vitro intrinsic clearance was used to derive human in 
vivo intrinsic clearance by IVIVE. Compounds were evaluated for in vitro drug-drug interaction 
based on the disappearance of the metabolites in the CYP cocktail assay. The solubility, BBB 
permeability, and in vitro safety pharmacology was also evaluated for selected compounds. Using 
the prespecified criteria for drug-like properties, 143 novel compounds were screened and 
evaluated according to the multi-tiered evaluation funnel (Fig. 3.2). The potential preclinical 
candidates were narrowed down based on whether the compound was able to fulfill the criteria. 
We reported that UPMP107 was found to be the preclinical candidate as a 20-HETE synthase 
inhibitor. It has a strong inhibitory activity (IC50 = 54.2 nM in HLM) and a greater than 100-fold 
selectivity window for CYP4 over other drug metabolizing enzymes. UPMP107 has a low in vitro 
intrinsic clearance of 6.94 µl/min/mg protein and is highly soluble (kinetic solubility > 600 µM). 
It has a good brain penetration in MDCK-MDR1 assay (PappA-B = 5.16 ×10
-6 cm/s, ER = 8.06). 
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And UPMP107 did not show > 50% inhibition or stimulation for a panel of 44 ion channels, 
enzymes, or transporters in the in vitro safety pharmacology evaluation.   
6.1.3 In vivo evaluation of novel 20-HETE formation inhibitor: UPMP107  
The novel finding of previous chapter that UPMP107 possesses strong potency and 
favorable drug-like properties prompted us to continue its in vivo development. The main objective 
of Chapter 4 was to investigate whether the previously selected preclinical candidate, compound 
UPMP107, can reduce brain 20-HETE levels in healthy pediatric rats. The secondary objective of 
this chapter was to study the plasma and brain pharmacokinetics of UPMP107. The main objective 
was achieved by assessing the levels of UPMP107 and 20-HETE in brain tissue after a single IV 
bolus dose. Compound and 20-HETE levels were measured by previously developed UPLC-
MS/MS method. We reported for the first time that UPMP107 penetrated into the brain and 
inhibited brain 20-HETE levels. The distribution of UPMP107 was rapid, and the brain 
concentrations decline in a biphasic pattern. The brain to blood ratios ranged from 0.7 to 2.2 for 3 
mg/kg group and 0.1 to 0.8 for 20 mg/kg group. At 20 mg/kg, the 20-HETE inhibitory effect lasted 
for 9 hr post-injection. In the single dose pharmacokinetics study, we observed UPMP107 
exhibited a biexponential decay of the pharmacokinetics profile after IV injection. It has a total 
clearance ranging from 13.7 – 20.1 ml/min/kg, a steady state volume of distribution ranging from 
415 - 734 ml/kg, and a half-life of 21.7 ± 1.97 min. This is the first in vivo study that demonstrated 
UPMP107 penetrated into brain tissue and produced a prolonged 20-HETE inhibitory effect in the 
Sprague Dawley rat brain. It is also the first in vivo study that showed UPMP107 has a low 
clearance, a volume of distribution that equals total body water, and a short half-life.  The PK 
information can help dose regimen estimation in the future UPMP107 pharmacokinetic study in 
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pediatric cardiac arrest rats. The nominal concentration-time data can be incorporated with future 
concentration time data from injured rats to study from how disease (cardiac arrest) or 
physiological parameter (body temperature) change induce a change in the pharmacokinetic of 
UPMP107. 
6.1.4 Population pharmacokinetics of propofol in ICU patients 
The objective of chapter 5 was to study the population pharmacokinetics of propofol in 
ICU patients and explore potential covariates that could explain the variability of propofol 
pharmacokinetic parameters. A population pharmacokinetics approach was used to evaluate 
propofol sparse concentrations. First-order conditional estimation with interaction method was 
used throughout the model development process. Structural model was compared by AIC and 
diagnostic plots. Stepwise forward selection and backward elimination were applied to evaluate 
the statistical significance of prespecified continuous and categorical covariates including age, 
body weight, BMI, height, creatinine, MAP, sex, race, hepatic SOFA score, renal SOFA score, 
cardiovascular SOFA score, history of liver failure, and history of moderate or severe liver disease. 
Final model was evaluated by visual predictive check (VPC) and bootstrap. A final model of two 
compartment, zero-order input, first-order elimination with a combined residual error model was 
found to best describe the data. For a lipophilic drug, typically total body weight is a significant 
covariate on volume. The failure to identify covariates on CL or V is somewhat unexpected due to 
the large inter-individual variability. The typical value of propofol clearance is 53.7 L/h and the 
typical values for volume of distribution are 32.2 L and 6860 L for central and peripheral 
compartment, respectively. The results suggested the population pharmacokinetic model was 
developed to describe the sparse propofol concentrations in a heterogeneous ICU population and 
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we did not find any covariates that could explain the interindividual variability in PK parameters. 
In the future, collection of serial plasma samples from this population would help improve the 
parameter estimate precision.  
6.2 Clinical implications 
The project of preclinical evaluation of novel 20-HETE formation inhibitors has a major 
strength in which studies were designed and performed to improve the translational success of 
novel compound to be developed as a treatment for secondary brain injury. Translational 
approaches were taken to help accelerate the move of basic research findings into therapeutics in 
the clinical research environment. 
The development of metabolic stability assay, CYP inhibition assay, and quantification for 
UPMP107 are essential for this drug development project. The LC-MS/MS methods are sensitive, 
specific, robust, and reproducible. These assays allowed us to measure in vitro intrinsic clearance, 
evaluate drug-drug interaction, and quantify the amount of preclinical candidate UPMP107 in 
biological samples presented in Chapter 3 and 4. These methods are the groundwork that allows 
the continuous support of lead optimization and in vivo testing of preclinical candidates. 
The identification of the preclinical candidate UPMP107 is a novel finding in this 
discovery and early development project. The advance of the project is in accordance with the drug 
development process, where a number of streamlined assessments were applied to identify 
molecules that would possess suitable characteristics for future drug development (Fig. 6.1). The 
target, 20-HETE has been identified as a potential therapeutic target as described in Chapter 1. 
Bioanalytical assays have been developed and validated as described in Chapter 2. Rigorous 
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advancement criteria as stated in Chapter 3 were prespecified for the hit generation, lead generation 
and optimization stages where compounds that meet the “Go” criteria were advanced to decrease 
the late stage failure rate in drug development. Hits (UPMP010 and UPMP019) were confirmed 
by repeated potency evaluation, assays confirmed the specificity and selectivity, druggability 
evaluation including solubility, stability, and BBB permeability was also confirmed. During lead 
optimization, preliminary SAR was explored, druggability was evaluated for compounds to ensure 
the selection of the optimized preclinical candidate (UPMP107). The wide selectivity window of 
compounds provides a favorable clinical implication. A wide therapeutic window, where 
increasing the dose will lead to greater efficacy of 20-HETE inhibition with minimum inhibitory 
effect for EETs enables a wide dose range selection. In vitro intrinsic clearance is also one of the 
important “Go” and “No Go” decisions for compound development. Specifically, we applied a 
translational approach of IVIVE to project human pharmacokinetic parameters from in vitro data. 
Although additional experiments are required to improve the accuracy of human PK parameter 
predictions, important human PK information was obtained for the first time, which could support 
first-in-human studies. The evaluation of BBB permeability at early drug development stage also 
has great clinical significance. The moderate brain penetration of UPMP107 from BBB 
permeability assay may be of clinical importance given that drug efflux by P-gp can reduce brain 
concentrations, and for drugs that have central activities, it may induce a treatment failure (Loscher 
et al. 2005). Therefore, it is vital to conduct further experiments to confirm if UPMP107 is a 
substrate of human P-gp thereby facilitating the design or interpretation of future clinical studies. 
In addition, the in vitro safety profiling of new chemical entities during early stages of drug 
development is an essential tool to predict clinical adverse effects. Collectively, the plausible 
mechanism of action of 20-HETE inhibition in recombinant CYP4F2 microsomes was validated; 
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a multi-tiered in vitro evaluation approach was implemented to evaluate drug-like properties and 
select compounds according to the prespecified rigorous criteria at early drug development, which 
enables the discovery of compounds that might have high probability of clinical success.  
 
Figure 6.1 Steps for early drug development 
Figure is adapted from Nature Review by Knowles et al. (Knowles et al. 2003).  
 
Preclinical pharmacokinetic evaluation can facilitate the early termination of weak 
candidates and can help identify lead candidates with favorable pharmacokinetics that are more 
likely to be efficacious and safe. The in vivo studies in this project provide preliminary evidence 
of pharmacokinetics and efficacy of UPMP107 in pediatric rats. The pharmacokinetic data from 
animals can be used to predict human pharmacokinetics. The prediction of human 
pharmacokinetics from animal pharmacokinetics or toxicokinetics data is of great clinical 
importance as the information such as no-observed-adverse-effect level (NOAEL) is useful in the 
design of the first-in-human study for a drug development program. Besides the naïve pooling 
approach to analyze the UPMP107 pharmacokinetic data by noncompartmental analysis, we also 
applied population pharmacokinetics principles and techniques to analyze the UPMP107 
pharmacokinetic data to facilitate the early drug development and translational research. The 
model is subject to continuous refinement and optimization as more data is collected to provide 
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insight in designing future animal studies, such as incorporating an effect-site compartment to 
assist the prediction of effect-site concentration (brain) under a specific dose. The developed model 
is also of great translational value when making the transition from nonclinical studies to first-in-
human clinical trials in facilitating allometric scaling across species, predict human exposure, and 
provide between-subject variabilities.  
In addition to new drug discovery, we also studied the PK of propofol in an ICU population. 
The goal was to develop a popPK/PD model and explore if there are any covariates that could 
explain the PK variability. The ultimate goal was to perform model-based simulation to study the 
association of various dosing regimens and sedation level in this population. The application of 
the population PK model to guide dose titrations to achieve required sedation levels has been 
reported. Population pharmacokinetic models have been programmed in target-controlled infusion 
(TCI) systems to help calculate required infusion rates to achieve desired plasma concentrations 
(Marsh et al. 1991, Schnider et al. 1998). We also observed large interindividual variability of 
propofol pharmacokinetics in ICU patients. However, no significant covariate for PK parameters 
was found. In our analysis, propofol peripheral volume of distribution was large, suggesting 
significant drug accumulation and saturation in the peripheral tissues.  
6.3 Future directions 
In this dissertation, we identified a preclinical candidate UPMP107 through a tiered 
screening and evaluation approach that showed good brain penetration and brain 20-HETE 
inhibition. We also developed a population pharmacokinetic model for propofol to describe 
propofol PK in ICU patients.  
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As the development of novel chemical entities is still at an early stage, a large body of 
additional work and analysis could to be performed in order to achieve the ultimate goal of 
developing a clinically relevant neuroprotective agent. We will primarily discuss the work that can 
contribute to this project from drug metabolism and pharmacokinetics perspective.  
6.3.1 Future work related to in vitro evaluation for novel compounds 
There are several enzymes that contribute to 20-HETE formation such as CYP4F2, 
CYP4A11, and CYP4F3B. As introduced previously, CYP4A11 has the highest catalytic activity 
for arachidonic acid, followed by CYP4F2, and CYP4F3B. The affinity of arachidonic acid to 
these enzymes were ranked as CYP4F2 > CYP4F3B > CYP4A11. CYP4F2 was recognized as the 
predominant enzyme for 20-HETE formation in an immunochemical analysis, where CYP4F2 
antibodies inhibited 93.4% of 20-HETE formation in hepatic microsomes. The specificity of novel 
compounds was evidenced by the inhibition of 20-HETE formation in recombinant CYP4F2 
microsomes. In the screening assay, we observed compounds that showed greater inhibition in 
HLM than in rCYP4F2, implying the potential involvement other CYP isoforms in forming 20-
HETE. Testing the inhibition of 20-HETE in recombinant CYP4A11 or CYP4F3B microsomes 
will elucidate the potential enzyme targets for novel compounds. 
As mentioned in Chapter 3, there are several limitations in the assays to evaluate the drug-
like properties. First, the metabolic stability assay can be tested in hepatocytes to measure the 
clearance contributed by both phase I, II enzymes, and transporters. Inhibition of other drug 
metabolizing CYP enzymes should be further confirmed by obtaining IC50 values. The role of P-
gp in UPMP107 brain penetration could be tested in the presence of a known P-gp inhibitor in the 
MDCK-MDR1 assay.  
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The inhibition mechanism and metabolism pathways for UPMP107 are unknown 
currently. The inhibition mechanism can be studied by performing incubation in three groups, 
including 1) 0 min pre-incubation group; 2) 30 min pre-incubation in the presence of NADPH; and 
3) 30 min pre-incubation in the absence of NADPH prior to the addition of substrate arachidonic 
acid. A ≥ 1.5-fold shift in the IC50 values between group 2 and 3 would suggest the compound is 
a time-dependent inhibitor (Grimm et al. 2009). A lack of IC50 difference between group 1, 2, and 
3 would suggest the compound is a reversible inhibitor. The identification of enzymes involved in 
metabolizing the molecule is of equal importance because elucidating the metabolism pathway 
helps predict the possible drug-drug interactions in humans. The enzymes involved in the 
metabolism of a novel molecule can be studied by CYP phenotyping in human liver microsomes 
or hepatocytes in the presence and absence of selective inhibitors for a specific CYP isoform (Jia 
et al. 2007). To improve the accuracy of human PK parameters projection, microsomal protein 
binding, blood to plasma ratio, and plasma protein binding are also important information that can 
be collected during in vitro evaluation. 
To continue finding compounds that are more potent and with better properties, it is 
important to evaluate a larger number of compounds in the in vitro assays. The trend observed not 
only in potency, but also in other properties such as metabolic stability and BBB permeability 
could provide information on optimizing novel compound structure.  
Aside from continuing evaluation of novel compounds’ properties, research interest also 
lies in elucidating the molecular mechanisms of novel compounds. Hippocampal slices subjected 
to oxygen-glucose deprivation could be treated with either novel compound or control. The cell 
viability, reactive oxygen species (ROS), and caspase-3 activity could be tested. If a higher 
neuronal survival, a decreased ROS, and lower caspase-3 activity were to be observed, a direct 
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neuronal protective effect would be positive finding in addition to the proposed effect of 
attenuating the fall of CBF caused by microvascular vasoconstriction. 
6.3.2 Future work related to in vivo evaluation of preclinical candidate: UPMP107  
Although the in vitro metabolic stability study suggested UPMP107 is slowly metabolized, 
the pharmacokinetic study of UPMP107 in pediatric rats suggested it has a short in vivo half-life. 
The short biological half-life of UPMP107 observed in vivo have several explanations including 
instability in plasma or extrahepatic metabolism. Compounds with functional groups such as 
esters, amides, lactones, lactams, carbamides, sulfonamides, and peptic mimetics are prone to 
hydrolysis in plasma (Di et al. 2005). Plasma instability can cause low levels of a compound in the 
systemic circulation. To test whether UPMP107 gets degraded in plasma, the disappearance of 
parent compound in rat or human plasma at different time points could be measured. Extrahepatic 
metabolism can be tested by incubating the compound in tissues such as the kidney microsomes 
and measure the disappearance of the parent compound. In addition, non-hepatic clearance in 
organs such as kidney could be one of the elimination pathways, which can be tested by measuring 
the amount of compound excreted in the urine samples.   
CYP4A enzyme expressions were found in various regions in the brain including 
neocortex, hippocampus, thalamus, hypothalamus, striatum and amygdala (Gonzalez-Fernandez 
et al. 2020). These regions were consistent with previous reported brain regions that are susceptible 
to hypoxia after cardiac arrest (Neumann et al. 2013). It is important to study how the compound 
distribute within different regions in the brain to see if the compounds reached desired 
concentration or exposure at the site of action. 
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To ensure the administered dose can achieve desired brain concentrations in pediatric 
cardiac arrest rats. PK and PD studies are required to be performed in injured animals to obtain 
information in clearance, volume of distribution, brain to plasma ratio, and brain 20-HETE 
inhibition. The PK parameters and PD endpoint and the relationship between dose and brain 20-
HETE could be used as a guide to support dose regimen that will be used in the following animal 
efficacy studies. Furthermore, the addition of the PK data under disease state can contribute to the 
development and refinement of animal popPK model, which can study whether disease, 
temperature, or gender would alter the PK of UPMP107. 
The experiment of great interest would be to test whether UPMP107 could produce 
neuroprotective effect in the pediatric cardiac arrest injury model. We are interested in evaluating 
the treatment effect on cortical perfusion, neuron viability, brain edema, BBB integrity, and 
functional outcomes in injured animals. The result of decreased brain 20-HETE concentrations 
without affecting EETs and DiHETs, improvement in the cortical perfusion, reduction in brain 
water content and lower neurological deficit score in the treated group will reaffirm the important 
role of CYP-derived eicosanoids in cerebral blood flow and neurodegeneration in cardiac arrest. 
It will also provide the first evidence of novel UPMP107 being effective in ameliorating secondary 
brain injury after cardiac arrest.  
To envision advancing to clinical development of the UPMP107, obtaining no observed 
adverse effect level (NOAEL) from nonclinical safety studies in the most appropriate animal 
species would inform the first-in-human dose. Due to the complexity of pathophysiological 
mechanisms of brain injury after cardiac arrest or other critical illness, single agent might not be 
adequate to achieve treatment success. The hope of improved neurological outcomes may lie in a 
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combination of the novel compound with other medications targeting at different mechanisms of 
the pathophysiology of secondary brain injury.  
6.3.3 Future work related to propofol model development 
It would be ideal to collect serial plasma samples to inform the model development. Using 
published plasma concentrations from literature could potentially help refine the model. Another 
approach is to adopt a PRIOR subroutine in NONMEM with parameter estimate from previous 
models. Development of a PD model that characterizes the level of sedation and establishment of 
a relationship between the PD and population PK model would be of great interest. The PD model 
could be developed using sedation scores such as Bispectral Index (BIS) or Richmond Agitation 
Sedation Scale (RASS). The observed or measured sedation scores could be modeled using a 
sigmoidal Emax model and link to effect site concentrations. If a population PK/PD could be 
developed, the model would potentially allow the exploration of the relationship between propofol 
exposure and sedation depth. Various dosing regimens could be simulated to evaluate if the dosing 
regimen might achieve a preset sedation level in this ICU population.  
6.4 Conclusions  
In this dissertation, we focused on two projects related to CNS drugs. First, we developed 
and validated several bioanalytical assays that are sensitive, accurate, and robust to facilitate the 
discovery, development, and evaluation of novel 20-HETE formation inhibitors. Next, we applied 
a multi-tiered approach to facilitate the evaluation of novel chemical entities. We identified 
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multiple novel molecules that are specific and selective 20-HETE formation inhibitors. Of these 
novel molecules, we selected UPMP107 as a preclinical candidate that is highly soluble, potent, 
selective, metabolically stable, brain penetrable, and did not show toxicity at 10 µM in in vitro 
Safetyscreen44Panel. Based on the favorable characteristics, UPMP107 was advanced to the 
preclinical in vivo evaluation in pediatric rats. We demonstrated for the first time that UPMP107 
crossed the blood-brain barrier, worked centrally to inhibit brain 20-HETE, and obtained plasma 
pharmacokinetics of UPMP107. In the second project, we used a modelling approach to 
characterize the PK of propofol, a widely used sedative in patients with brain injury, in an ICU 
population. A two-compartment model with zero-order infusion and linear elimination best 
described the sparse plasma concentrations. There was a large interindividual variability of 
propofol PK in this population. No significant covariate that explain the variability of PK 
parameters was found.  
To summarize, 20-HETE has been identified as an important modifiable mediator in 
various cerebrovascular disease. 20-HETE is a quantifiable biomarker that relates to compounds’ 
potency. 20-HETE is found to be associated with clinical outcomes in ischemic stroke and 
subarachnoid hemorrhage patients. Developing novel therapies targeting 20-HETE formation to 
ameliorate secondary brain injury is an interesting and exciting research direction which requires 
continuous and collaborative efforts from researchers and scientists across different fields.
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 Supplementary data for Chapter 3 - In vitro evaluation of 20-HETE formation 
inhibitors  
Appendix Table 1 CYP4 inhibition of analogs with single substituion on benzene in RLM 
 
a Data were obtained from screening results in RLM.  











010 - 13.5b 019 -  
027 4-OMe 31.8 031 4-OMe 25.9 
028 3-OMe 42.5 029 3-OMe 45.6 
041 2-OMe 0 042 2-OMe 0 
037 4-COOMe 3.60 038 4-COOMe 18.3 
039 3-COOMe 0 040 3-COOMe 43.0 
046 4-Me 0 047 4-Me 16.3 
081 3-Me 12.0 077 3-Me 44.0 
080 2-Me 0 078 2-Me 0 
049 4-ethylsulfonyl 0 048 4-ethylsulfonyl 13.4 








062 4-acetamide 38.0 072 4-acetamide 27.0 
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% of inhibition 
in RLM 
071 4-F 41.0 070 4-F 57.0 
074 3-F 0 075 3-F 31.0 
079 2-F 26.0 083 2-F 53.0 
085 4-Cl 0 086 4-Cl 21.3 
- - - 084 3-Cl 61.0 
 














076 3-F,4-OMe 27.0 068 3-F, 4-OMe 42.0 
082 2-F, 4-OMe 46.0 073 2-F, 4-OMe 63.0 
097 3-F, 5-OMe 61 096 3-F, 5-OMe 11.1 
098 3-OMe, 4-F 55 099 3-OMe, 4-F 61 
091 3-Cl, 4-OMe 30.2 088 3-Cl, 4-OMe 49.0 











Appendix Table 4 CYP4 inhibition in RLM for analogs with extended linker 
 
Compd R1 
% of inhibition 
in RLM 
Compd R2 
% of inhibition in 
RLM 
10 - 13.5 19 - - 
21 R1 = C 0 22 R3 = C 2.49 
12 R1 = O 0 43 R3 = O 0 
56 R1 = S 0 57 R3 = S 7.80 





















R1 =  
 072 
R1 =  
 
102 
R1 =  
0 101 
R1 =  
13.8 
106 
R1 = , 
R3 = F 
2.30 105 
R1 = , 
R3 = F 
19.3 
108 
R1 =  
42.7 107 
R1 =  
49.6 
120 
R1 =  
0 109 
R1 =  
0 
125 
R1 =  
48.7 124 
R1 =  
42.9 
136 R1 = ,  
R2 = F 
63.6 135 R1 = ,  
R2 = F 
62.7 
- - - 131 R1 = NH2 27.0 
- - - 113 
R1 =  
0 
138 
R1 =  
21.9 137 
R1 =   
22.3 
- - - 139 
R1 =  
24.3 
- - - 134 





- - - 126 




- - - 130 
R1 =  
36.0 
- - - 140 
R1 =  
26.7 
a Not all compounds with 4-phenyl-1-(1H-pyrazol-5-yl)piperidine core were synthesized. 
b R2 = H and R3 = H when R2 and R3 are not defined in the table.  
 
 















021 R1 = CH2 0 022 R3 = CH2 2.39 
- - - 103 
R3 = CH2, R4 = 4-
OMe 
4.00 
- - - 069 
R3 = CH2, R4 = 3-
OMe 
24.0 
- - - 142 




R1 = CH2, R2 = 3-
CH3 
0 118 
R3 = CH2, R4 = 3-
CH3 
13.5 
- - - 117 R3 = CH2, R4 = 4-Cl 64.3 
115 
R1 = CH2, R2 = 3-
Cl 
0 114 R3 = CH2, R4 = 3-Cl 20.8 
- - - 133 








- - - 100 R3 = S, R4 = 3-OMe 0 
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- - - 104 R3= S, R4 = 4-OMe 42.0 
- - - 094 R3 = S, R4 = 4-F 35.7 
- - - 116 R3= S, R4 = 2-F 0 
a Not all compounds with 4-phenyl-1-(1H-pyrazol-5-yl)piperidine core were synthesized. 
b R2 = H when R2 is not defined in the table.  
 
  
Appendix Figure 1 CYP4 homology model and docking of hit compound UPMP019 
The hit compound UPMP019 was positioned in CYP4F2 homology model assuming the 
coordination of pyrazole with the heme iron.  
  
Previously, a crystal structure with rabbit CYP4B1 - HET0016 complex was reported and 
the binding of HET0016 in CYP4B1 active site was proposed. With the cis orientation of the N-
hydroxyl group of HET0016, the nitrogen coordinates with ferric iron of the heme, the hydroxyl 
group binds with Thr-314 via hydrogen binding, and the long butyl chain fits in the active site 
cavity that could potentially increase the selectivity of ω-1 hydroxylation (Jennings et al. 2018). A 
CYP4 homology model was built in our collaborator Dr. David Koes’s lab (School of Medicine, 
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University of Pittsburgh) based on a published crystal structure of rabbit CYP4B1 complexed with 
octane. In our homology model, the hit compound UPMP019 was positioned in CYP4F2 
homology model assuming the pyrazole moiety coordinating with the heme (Appendix Figure 1). 
After optimization and validation of the CYP4F2 homology model, it could be applied to screen 
potential candidates as 20-HETE formation inhibitors, identify potential active binding site in the 
future to help discover new compounds.   
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 Supplementary data for Chapter 4 – PK and PD evaluation of UPMP107 in 
pediatric rats 
Appendix Table 7 Summary of structural model development process 
Model description AIC 
2cmt, additive RES, linear elimination - 
2cmt, proportional RES, linear elimination 1539.2 
2cmt, combined RES, linear elimination 1438.0 
1cmt, combined RES, linear elimination 1519.7 
1cmt, combined RES, saturated elimination 1506.2 
2cmt, combined RES, saturated elimination 1433.1 
Cmt: compartment; RES: residual error; “-”: model did not converge.  
The model selection was based on AIC values. A smaller AIC value supports the selection of the 
structural model.  
 
 
The control stream of UPMP107 popPK model:  
$PROBLEM    157 PK 
$INPUT      C ID TIME DV CONC=DROP LNDV=DROP DOSE WT AMT MDV EVID 
$DATA      107_NONMEM_exc.csv IGNORE=C 
$SUBROUTINE  ADVAN6 TRANS1 TOL = 6  
$MODEL  
NCOMP = 2 
COMP = (CENTRAL)  
COMP = (PERIPHERAL)  
$PK  
V1 = THETA(1)*EXP(ETA(1))  
KM = THETA(2)  
VMAX = THETA(3) 
Q = THETA(4)*EXP(ETA(2))  
V2 = THETA(5)  
S1 = V1/1000 ;S1 = V1/1000  ;DOSE in mg, CONC in ng/ml(ug/L)  
K12 = Q/V1  
K21 = Q/V2  
 
$ERROR  
IPRED = F  
W = SQRT(IPRED**2*SIGMA(1)+SIGMA(2)) 
IRES = DV- IPRED 
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Y = IPRED + IPRED* EPS(1) + EPS(2) 
IWRES = IRES/W 
$THETA   
 (0.00001,0.014,10) ; V1 in L 
 (0.00001, 47, 100000) ; Km  
 (0.00001,0.02,10) ; Vmax in L/min 
 (0.00001, 0.0056, 10) ;Q 
 (0.00001, 0.0171, 10) ;V2 
$OMEGA  
 0.1  ; V 
 0.5  ; Q 
$DES 
C1 = A(1)/S1  
DADT(1) = -K12*A(1) +K21*A(2) - (VMAX * A(1) /( KM*V1 + A(1) ) 
) 
DADT(2) =  K12*A(1) -K21*A(2)  
$SIGMA   
 0.3  ;   prop RV 
 300 ;  additive RV 
$COVARIANCE PRINT=E MATRIX=R 
$EST METHOD=1 INTER MAXEVAL=9999 NOABORT SIG=2 PRINT=1 POSTHOC 
$TABLE ID TIME DOSE MDV EVID PRED IPRED IRES IWRES CWRES CWRESI 
ONEHEADER NOPRINT FILE=sdtab15 






Appendix Figure 2 Observed concentrations versus individual predicted concentrations for 
each animal 
The blue dots represent the observed concentrations, the black line connects the individual 
predicted concentrations. Overall, there is good agreement in the predicted values and the observed 
values. 
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 Supplementary data for Chapter 5 - Propofol popPK model 
 
Appendix Table 8 Summary of structural model development process 




  CL V1 Q V2 IIV CL IIV V1 IIV Q IIV V2 prop add 
1cmt, CL~V, prop RES 3213.8 1 2   19 19   13  
1cmt, CL~V, additive RES 3454.2 18 27   26 27    7 
1cmt, CL~V, combined RES 3207.0 13 18   18 18   21 305 
            
2cmt, combined RES, no covariance 3162.9 35 156 18 27 10 5707 0 0 15 154 
2cmt, combined RES IIV V1 = 0, no 
covariance 3160.9 24 32 18 17 54  29 16 15 171 
2cmt, combined RES, IIV V1 =0, 
CL~Q 3161.2 20 53 21 18 26  43 17 15 101 
2cmt, combined RES, IIV V1 =0, 
CL~V2 3161.1 41 906 44 19 151  66 15 19 322 
2cmt, combined RES, IIV V1 =0, block 
(3) 3186.4 94 9807 517 299 82  372 238 17 281 
2cmt, combined RES, CL~V1, Q~V2 3166.6 30 102 51 18 58 503 162 14 15 33 
2cmt, combined RES, CL~Q, V1~V2 3165.2 23 62 19 20 47 272 82 18 17 110 
2cmt, combined RES, block(4) 3159.7 41 687 45 34 34 259 89 86 15 273 
RES: residual error;  
“~”: covariance between two parameters; 
IIV: interindividual variability; 
Block: block structure of the covariance matrix; 
Prop: proportional residual error  
Add: additive residual error
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Control stream of the final model:  
$PROBLEM    PROP PK 
$INPUT C ID DV LNDV=DROP DATE=DROP TIME TSFD TSLD DOSE MDV EVIDRATE 
DUR SEX AMT aDUR SEVL MILDL LIVER BIL MAP SFLV SFCV WT AGE HT BMI CR 
RACE SMOKE SFLVEN SFCVEN SFCNSEN SFRENALEN APACHE 
$DATA   df_covariates.csv IGNORE=C  
 
$SUBROUTINE  ADVAN3 TRANS4 
$PK  
CL = THETA(1)*EXP(ETA(1)) ;exponential model 
V1 = THETA(2)  
Q  = THETA(3)*EXP(ETA(2)) 
IF (SFLV.LE.3) TVV2 = THETA(4)   
IF (SFLV.GE.4) TVV2 = THETA(4)+THETA(5)*SFLV   
V2 = TVV2*EXP(ETA(3)) 
S1 = V1/1000  ;DOSE in mg, CONC in ng/ml(ug/L)  
$ERROR  
IPRED = F  
W = SQRT(IPRED**2*SIGMA(1)+SIGMA(2)) 
IRES = DV- IPRED 
Y = IPRED + IPRED* EPS(1) + EPS(2) 
IWRES = IRES/W 
$THETA   
 (0.001, 40, 1000) ;CL in L/h 
 (0.001, 20, 1000) ;V1 in L 
 (0.001, 300, 1000) ;Q in L/h 
 (0.001, 8500, 100000) ;V2 in L 
 (-10000, -200, 0) ;SOFA on V2 
$OMEGA BLOCK(2) 
 1.5 ; CL 
 0.5  1 ;Q 
$OMEGA 
 1.9; V2 
$SIGMA 
(0, 0.18,10) ;prop RV 
(0, 150,1000) ;add RV 
$COVARIANCE PRINT=E MATRIX=R 
$EST METHOD=1 INTER MAXEVAL=9999 NOABORT SIG=2 PRINT=1 POSTHOC 
$TABLE ID TIME DOSE MDV EVID RATE IPRED IWRES CWRES CWRESI ONEHEADER 
NOPRINT FILE=sdtab230 
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$TABLE ID WT AGE HT BMI CR BIL MAP ONEHEADER NOAPPEND NOPRINT 
FILE=cotab134 
$TABLE ID SEX SEVL MILDL LIVER SFLV SFCV RACE SMOKE SFLVEN SFCVEN 
SFCNSEN SFRENALEN APACHE ONEHEADER NOAPPEND NOPRINT FILE=catab134 





Appendix Figure 3 Individual plots of observed vs. predicted concentrations 
The open circles represent the observed concentrations, the red solid line connects the population 





Appendix Figure 4 Frequncy distribution histograms of parameter mean estimates from 
bootstrap analysis (n=1000) 
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